Document:

Term Loan Credit Agreement

 Exhibit 10.1 

 
  

 
  
 

 
 TERM LOAN CREDIT AGREEMENT 
 dated as of 
 June 22, 2012, 

among 
 WATSON
PHARMACEUTICALS, INC., 
 as Borrower, 
 THE LENDERS PARTY HERETO 
 and 

BANK OF AMERICA, N.A., 
 as Administrative Agent 
 WELLS FARGO BANK, N.A., 

as Syndication Agent 
 and 
 BARCLAYS BANK PLC, UNION BANK, N.A., 

MIZUHO CORPORATE BANK, LTD. and JPMORGAN CHASE BANK, N.A., 
 as Co-Documentation Agents 
  

 
 MERRILL LYNCH,
PIERCE, FENNER & SMITH INCORPORATED 
 and 
 WELLS FARGO SECURITIES, LLC, 
 as Joint Book Managers and Joint Lead Arrangers

 and 

BARCLAYS BANK PLC and J.P. MORGAN SECURITIES LLC 
 as Joint Lead Arrangers 
  

 
  

 

  
 Watson
Pharmaceuticals Term Loan Credit Agreement 

 TABLE OF CONTENTS 

 

							
	 Section
	  	Page	 
		  	ARTICLE I.	  			
		  	DEFINITIONS AND ACCOUNTING TERMS	  			
			
	 1.01
	  	Defined Terms	  	 	1	  
	 1.02
	  	Other Interpretive Provisions	  	 	23	  
	 1.03
	  	Accounting Terms	  	 	24	  
	 1.04
	  	Times of Day	  	 	25	  
	 1.05
	  	Rounding	  	 	25	  
	 1.06
	  	Schedules	  	 	25	  
			
		  	ARTICLE II.	  			
		  	THE COMMITMENTS AND BORROWINGS	  			
			
	 2.01
	  	Loans	  	 	25	  
	 2.02
	  	Borrowings, Conversions and Continuations of Loans	  	 	26	  
	 2.03
	  	[Reserved]	  	 	28	  
	 2.04
	  	[Reserved]	  	 	28	  
	 2.05
	  	[Reserved]	  	 	28	  
	 2.06
	  	Prepayments	  	 	28	  
	 2.07
	  	Termination or Reduction of Commitments	  	 	29	  
	 2.08
	  	Repayment of Loans	  	 	29	  
	 2.09
	  	Interest	  	 	29	  
	 2.10
	  	Fees	  	 	30	  
	 2.11
	  	Computation of Interest and Fees	  	 	30	  
	 2.12
	  	Evidence of Debt	  	 	31	  
	 2.13
	  	Payments Generally; Administrative Agent’s Clawback	  	 	31	  
	 2.14
	  	Sharing of Payments by Lenders	  	 	33	  
	 2.15
	  	[Reserved]	  	 	33	  
	 2.16
	  	[Reserved]	  	 	33	  
	 2.17
	  	Defaulting Lenders	  	 	33	  
			
		  	ARTICLE III.	  			
		  	TAXES, YIELD PROTECTION AND ILLEGALITY	  			
	 3.01
	  	Taxes	  	 	35	  
	 3.02
	  	Illegality	  	 	39	  
	 3.03
	  	Inability to Determine Rates	  	 	40	  
	 3.04
	  	Increased Costs; Additional Reserve Requirements	  	 	40	  
	 3.05
	  	Compensation for Losses	  	 	42	  
	 3.06
	  	Mitigation Obligations; Replacement of Lenders	  	 	43	  
	 3.07
	  	Survival	  	 	43	  

  

			
	i	  	Watson Pharmaceuticals Term Loan Credit Agreement

							
		  	ARTICLE IV.	  			
		  	CONDITIONS PRECEDENT	  			
			
	 4.01
	  	Conditions to Effectiveness	  	 	43	  
	 4.02
	  	Conditions to Borrowing	  	 	44	  
			
		  	ARTICLE V.	  			
		  	REPRESENTATIONS AND WARRANTIES	  			
			
	 5.01
	  	Existence, Qualification and Power	  	 	46	  
	 5.02
	  	Authorization; No Contravention	  	 	46	  
	 5.03
	  	Material Governmental Authorization; Other Material Consents	  	 	47	  
	 5.04
	  	Binding Effect	  	 	47	  
	 5.05
	  	Financial Statements	  	 	47	  
	 5.06
	  	Litigation; Absence of Injunction	  	 	47	  
	 5.07
	  	No Default	  	 	48	  
	 5.08
	  	Ownership of Property; Liens	  	 	48	  
	 5.09
	  	Environmental Compliance	  	 	48	  
	 5.10
	  	Solvency	  	 	48	  
	 5.11
	  	Insurance	  	 	48	  
	 5.12
	  	Taxes	  	 	48	  
	 5.13
	  	Patriot Act	  	 	48	  
	 5.14
	  	ERISA	  	 	48	  
	 5.15
	  	OFAC	  	 	49	  
	 5.16
	  	Subsidiaries; Equity Interests	  	 	49	  
	 5.17
	  	Margin Regulations; Investment Company Act	  	 	50	  
	 5.18
	  	Disclosure	  	 	50	  
	 5.19
	  	Compliance with Laws	  	 	50	  
	 5.20
	  	Intellectual Property; Licenses, Etc	  	 	50	  
			
		  	ARTICLE VI.	  			
		  	AFFIRMATIVE COVENANTS	  			
			
	 6.01
	  	Financial Statements	  	 	51	  
	 6.02
	  	Certificates; Other Information	  	 	52	  
	 6.03
	  	Notices	  	 	53	  
	 6.04
	  	Payment of Taxes	  	 	54	  
	 6.05
	  	Preservation of Existence, Etc	  	 	54	  
	 6.06
	  	Maintenance of Properties	  	 	54	  
	 6.07
	  	Maintenance of Insurance	  	 	54	  
	 6.08
	  	Compliance with Laws	  	 	54	  
	 6.09
	  	Books and Records	  	 	54	  
	 6.10
	  	Inspection Rights	  	 	54	  
	 6.11
	  	Use of Proceeds	  	 	55	  
	 6.12
	  	Covenant to Guarantee Obligations	  	 	55	  

  

			
	ii	  	Watson Pharmaceuticals Term Loan Credit Agreement

							
			
		  	ARTICLE VII.	  			
		  	NEGATIVE COVENANTS	  			
			
	 7.01
	  	Liens	  	 	55	  
	 7.02
	  	Subsidiary Indebtedness	  	 	56	  
	 7.03
	  	Fundamental Changes	  	 	57	  
	 7.04
	  	Change in Nature of Business	  	 	58	  
	 7.05
	  	Transactions with Affiliates	  	 	58	  
	 7.06
	  	Investments	  	 	58	  
	 7.07
	  	Restricted Payments	  	 	58	  
	 7.08
	  	Consolidated Leverage Ratio	  	 	58	  
	 7.09
	  	Net Worth	  	 	59	  
			
		  	ARTICLE VIII.	  			
		  	EVENTS OF DEFAULT AND REMEDIES	  			
			
	 8.01
	  	Events of Default	  	 	59	  
	 8.02
	  	Remedies Upon Event of Default	  	 	61	  
	 8.03
	  	Application of Funds	  	 	61	  
	 8.04
	  	Cleanup Period	  	 	62	  
			
		  	ARTICLE IX.	  			
		  	ADMINISTRATIVE AGENT	  			
			
	 9.01
	  	Appointment and Authority	  	 	62	  
	 9.02
	  	Rights as a Lender	  	 	62	  
	 9.03
	  	Exculpatory Provisions	  	 	62	  
	 9.04
	  	Reliance by Administrative Agent	  	 	63	  
	 9.05
	  	Delegation of Duties	  	 	64	  
	 9.06
	  	Resignation of Administrative Agent	  	 	64	  
	 9.07
	  	Non-Reliance on Administrative Agent and Other Lenders	  	 	64	  
	 9.08
	  	No Other Duties, Etc	  	 	65	  
	 9.09
	  	Administrative Agent May File Proofs of Claim	  	 	65	  
	 9.10
	  	Guaranty Matters	  	 	66	  
			
		  	ARTICLE X.	  			
		  	MISCELLANEOUS	  			
			
	 10.01
	  	Amendments, Etc	  	 	66	  
	 10.02
	  	Notices; Effectiveness; Electronic Communication	  	 	67	  
	 10.03
	  	No Waiver; Cumulative Remedies; Enforcement	  	 	69	  
	 10.04
	  	Expenses; Indemnity; Damage Waiver	  	 	70	  
	 10.05
	  	Payments Set Aside	  	 	71	  
	 10.06
	  	Successors and Assigns	  	 	72	  
	 10.07
	  	Treatment of Certain Information; Confidentiality	  	 	76	  
	 10.08
	  	Right of Setoff	  	 	77	  
	 10.09
	  	Interest Rate Limitation	  	 	77	  
	 10.10
	  	Counterparts; Integration; Effectiveness	  	 	77	  
	 10.11
	  	Survival of Representations and Warranties	  	 	78	  
	 10.12
	  	Severability	  	 	78	  
	 10.13
	  	Replacement of Lenders	  	 	78	  

  

			
	iii	  	Watson Pharmaceuticals Term Loan Credit Agreement

							
	 10.14
	  	Governing Law; Jurisdiction; Etc	  	 	79	  
	 10.15
	  	WAIVER OF JURY TRIAL	  	 	80	  
	 10.16
	  	USA PATRIOT Act	  	 	80	  
	 10.17
	  	No Advisory or Fiduciary Responsibility	  	 	81	  
	 10.18
	  	Electronic Execution of Assignments	  	 	81	  

 SCHEDULES 
  

			
	 2.01
	  	 Applicable Percentages; Commitments

	 5.06
	  	 Litigation

	 5.16
	  	 Subsidiaries; Other Equity Investments

	 7.01
	  	 Existing Liens

	 7.02
	  	 Existing Indebtedness

	 10.02
	  	 Administrative Agent’s Office; Certain Addresses for Notices

 EXHIBITS 
  

			
	     Form of

	 A
	  	 Administrative Questionnaire

	 B
	  	 Assignment and Assumption

	 C
	  	 Compliance Certificate

	 D
	  	 Loan Notice

	 E
	  	 Note

	 F
	  	 Subsidiary Guaranty

	 G
	  	 Officer’s Certificate

	 H-1
	  	 Opinion of Latham & Watkins LLP, special New York counsel to the Company

	 H-2
	  	 Opinion of Greenberg Traurig LLP, special Nevada counsel to the Company

	 I
	  	 Solvency Certificate

	 J-1
	  	 U.S. Tax Compliance Certificate (For Foreign Lenders that are not Partnerships)

	 J-2
	  	 U.S. Tax Compliance Certificate (For Foreign Participants that are not Partnerships)

	 J-3
	  	 U.S. Tax Compliance Certificate (For Foreign Participants that are Partnerships)

	 J-4
	  	 U.S. Tax Compliance Certificate (For Foreign Lenders that are Partnerships)

  

			
	iv	  	Watson Pharmaceuticals Term Loan Credit Agreement

 TERM LOAN CREDIT AGREEMENT 

This TERM LOAN CREDIT AGREEMENT is entered into as of June 22, 2012, among WATSON PHARMACEUTICALS, INC., a Nevada
corporation (the “Company”), each lender from time to time party hereto (collectively, the “Lenders” and, individually, a “Lender”), and BANK OF AMERICA, N.A., as Administrative Agent.

 The Company intends to acquire, directly or indirectly (the “Acquisition”), all of the outstanding Equity
Interests of Actavis Pharma Holding 4 ehf., a company incorporated in Iceland, Actavis Inc., a Delaware corporation, and Actavis S.à r.l., a company incorporated in the Grand Duchy of Luxembourg (collectively, the “Target
Companies”) from their respective equity holders (collectively, the “Sellers”) and certain debt claims owed by the Target Companies to the Sellers and other affiliates pursuant to that certain Sale and Purchase Agreement,
dated as of April 25, 2012, among the Company, Watson Pharma S.à r.l., the Sellers and the other persons party thereto (such agreement, together with all schedules and exhibits attached thereto, all Transaction Documents (as defined
therein) and all Documents in Agreed Form (as defined therein), the “Acquisition Agreement”). 
 To finance, in
part, the Acquisition, the Company has requested that the Lenders provide a senior unsecured term loan facility, and the Lenders are willing to do so on the terms and conditions set forth herein. 

In consideration of the mutual covenants and agreements herein contained, the parties hereto covenant and agree as follows: 

ARTICLE I. 

DEFINITIONS AND ACCOUNTING TERMS 
 1.01 Defined Terms. As used in this Agreement, the following terms will have the meanings set forth below: 
 “Acquisition” has the meaning specified in the recitals hereto. 

“Acquisition Agreement” has the meaning specified in the recitals hereto (subject to Section 1.02(a)).

 “Acquisition Agreement Representations” means representations made by or with respect to the Target
Companies in the Acquisition Agreement as are material to the interests of the Lenders, but only to the extent that the Company or any of its Affiliates has the right to terminate its (or their) obligations under the Acquisition Agreement, or to
decline to consummate the Acquisition pursuant to the Acquisition Agreement, as a result of a breach of such representations in the Acquisition Agreement. 
 “Acquisition Indebtedness” means any debt or equity securities (including, without limitation, any securities convertible or exchangeable into or exercisable for equity securities, other
equity-linked securities or hybrid debt-equity securities) of the Company or any of its Affiliates that have been issued for the purpose of financing, in part, the Acquisition (including refinancing all or a portion of the Bridge Facility).

  

			
	1	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Administrative Agent” means Bank of America in its capacity as
administrative agent under any of the Loan Documents, or any successor administrative agent. 
 “Administrative
Agent’s Office” means the Administrative Agent’s address and account as set forth on Schedule 10.02, or such other address or account as the Administrative Agent may from time to time notify to the Company and the Lenders.

 “Administrative Fee Letter” means that certain administrative fee letter, dated April 25, 2012, between
the Company and Bank of America. 
 “Administrative Questionnaire” means an Administrative Questionnaire
substantially in the form of Exhibit A. 
 “Affiliate” means, with respect to any Person, another Person that,
directly or indirectly through one or more intermediaries, Controls or is Controlled by or is under common Control with the Person specified. 
 “Aggregate Commitments” means the Commitments of all the Lenders. As of the Effective Date, the Aggregate Commitments are $1,800,000,000. 

“Agreement” means this Term Loan Credit Agreement, dated as of June 22, 2012. 

“Applicable Percentage” means with respect to any Lender at any time, the percentage (carried out to the ninth decimal
place) of (a) prior to the Closing Date, the Aggregate Commitments represented by such Lender’s Commitment at such time and (b) thereafter, the principal amount of all Loans outstanding at such time represented by such Lender’s
outstanding Loans at such time. If the Aggregate Commitments have expired, then the Applicable Percentage of each Lender will be determined based on the Applicable Percentage of such Lender most recently in effect, giving effect to any subsequent
assignments. The initial Applicable Percentage of each Lender as of the Effective Date is set forth opposite the name of such Lender on Schedule 2.01. 
 “Applicable Rate” means, from time to time, the following percentages per annum, based upon the Debt Rating as set forth below: 

 

							
	Pricing Level	 	 Debt Ratings S&P/ Moody’s
	 	 Eurodollar Rate Loans
	 	 Base Rate Loans

	I	 	> A-/A3	 	1.000%	 	0.000%
	II	 	BBB+/Baa1	 	1.250%	 	0.250%
	III	 	BBB/Baa2	 	1.500%	 	0.500%
	IV	 	BBB-/Baa3	 	1.750%	 	0.750%
	V	 	< BB+/Ba1	 	2.000%	 	1.000%

 “Debt Rating” means, as of any date of determination, the rating as determined by
S&P, and Moody’s (collectively, the “Debt Ratings”) of the Company’s non-credit-enhanced, senior unsecured long-term debt (or if such debt is not so rated, the issuer rating or corporate credit

  

			
	2	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
rating of the Company); provided that (i) if either Moody’s or S&P does not have in effect a Debt Rating, then the Debt Rating assigned by the other rating agency shall be
used; (ii) if neither Moody’s nor S&P has in effect a Debt Rating, Pricing Level V shall apply; and (iii) if the relevant Debt Ratings assigned by Moody’s and S&P fall within different Pricing Levels, the Applicable Rate
shall be based on the higher of the two Debt Ratings (with Pricing Level I being the highest and Pricing Level V being the lowest), unless one of the two Debt Ratings is two or more Pricing Levels lower than the other, in which case the Applicable
Rate shall be based on the Pricing Level corresponding to the Debt Rating that is the midpoint between the two Debt Ratings or, if there is no such midpoint, the Pricing Level that is one level lower than the Pricing Level corresponding to the
higher Debt Rating. 
 Initially, the Applicable Rate shall be based on Pricing Level III. If the relevant Debt Rating assigned
by Moody’s or S&P shall be changed (other than as a result of a change in the rating system of Moody’s or S&P), such change shall be effective as of the date on which it is first announced by the applicable rating agency. Each
change in the Applicable Rate shall apply during the period commencing on the effective date of such change and ending on the date immediately preceding the effective date of the next such change. If the rating system of Moody’s or S&P
shall change or if either such rating agency shall cease to be in the business of rating corporate debt obligations, the Company and the Lenders shall negotiate in good faith to amend this definition to reflect such changed rating system (including,
in such case, an amendment to replace Moody’s or S&P, as applicable, with another rating agency) or the unavailability of ratings from such rating agency, and, pending the effectiveness of any such amendment, the Applicable Rate shall be
determined by reference to the rating most recently in effect prior to such change or cessation. 
 “Approved
Fund” means any Fund that is administered or managed by (a) a Lender, (b) an Affiliate of a Lender or (c) an entity or an Affiliate of an entity that administers or manages a Lender. 

“Arrangers” means MLPF&S and WFS, in their capacities as joint lead arrangers and joint book managers. 

“Assignee Group” means two or more Eligible Assignees that are Affiliates of one another or two or more Approved Funds
managed by the same investment advisor. 
 “Assignment and Assumption” means an assignment and assumption
entered into by a Lender and an Eligible Assignee (with the consent of any party whose consent is required by Section 10.06(b)), and accepted by the Administrative Agent, in substantially the form of Exhibit B or any other form
approved by the Administrative Agent. 
 “Audited Financial Statements” means the audited consolidated balance
sheet of the Company and its Subsidiaries for the fiscal year ended December 31, 2011, and the related consolidated statements of income or operations, shareholders’ equity and cash flows for such fiscal year of the Company and its
Subsidiaries, including the notes thereto. 
 “Bank of America” means Bank of America, N.A. and its successors.

  

			
	3	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Base Rate” means, for any day, a fluctuating rate per annum equal to the
highest of (a) the Federal Funds Rate in effect on such day plus 1/2 of 1%, (b) the rate of interest in effect for such day as publicly announced from time to time by the Administrative Agent as its “prime rate,” and
(c) the Eurodollar Rate in effect on such day plus 1.00%. The “prime rate” is a rate set by the Administrative Agent based upon various factors including the Administrative Agent’s costs and desired return, general
economic conditions and other factors, and is used as a reference point for pricing some loans, which may be priced at, above, or below such announced rate. Any change in such prime rate announced by the Administrative Agent shall take effect at the
opening of business on the day specified in the public announcement of such change. Any change in the Federal Funds Rate or the Eurodollar Rate will take effect on the effective date of such change in the Federal Funds Rate or the Eurodollar Rate,
as applicable. 
 “Base Rate Loan” means a Loan that bears interest based on the Base Rate. 

“Borrowing” means a borrowing consisting of simultaneous Loans of the same Type and, in the case of Eurodollar Rate
Loans, having the same Interest Period made by each of the Lenders pursuant to Section 2.01. 
 “Bridge
Facility” means that certain senior unsecured bridge loan in aggregate principal amount of $6,000,000,000 committed to be made to the Company pursuant to the Commitment Letter. 

“Business Day” means any day other than a Saturday, Sunday or other day on which commercial banks are authorized to
close under the Laws of, or are in fact closed in, New York City, New York and, if such day relates to any interest rate settings, any fundings, disbursements, settlements and payments in respect of a Eurodollar Rate Loan, or any other dealings to
be carried out pursuant to this Agreement in respect of a Eurodollar Rate Loan, means any such day on which dealings in deposits in US Dollars are conducted by and between banks in the London interbank eurodollar market. 

“Capital Lease Obligations” of any Person shall mean the obligations of such Person to pay rent or other amounts under
any lease of (or other arrangement conveying the right to use) real or personal property, or a combination thereof, which obligations are required to be classified and accounted for as capital leases on a balance sheet of such Person under GAAP, and
the amount of such obligations shall be the capitalized amount thereof determined in accordance with GAAP. 
 “Change in
Law” means the occurrence, after the Effective Date, of any of the following: (a) the adoption or taking effect of any law, rule, regulation or treaty, (b) any change in any law, rule, regulation or treaty or in the
administration, interpretation, implementation or application thereof by any Governmental Authority or (c) the making or issuance of any request, rule, guideline or directive (whether or not having the force of law) by any Governmental
Authority; provided that notwithstanding anything herein to the contrary, (x) the Dodd-Frank Wall Street Reform and Consumer Protection Act and all requests, rules, guidelines or directives thereunder or issued in connection therewith
and (y) all requests, rules, guidelines or directives promulgated by the Bank for International Settlements, the Basel Committee on Banking Supervision (or any successor or similar authority) or the United States or foreign regulatory
authorities, in each case pursuant to Basel III, shall, in each case, be deemed to be a “Change in Law”, regardless of the date enacted, adopted or issued. 

  

			
	4	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Change of Control” means an event or series of events by which:

 (a) any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the
Securities Exchange Act, but excluding any employee benefit plan of such person or its subsidiaries, and any person or entity acting in its capacity as trustee, agent or other fiduciary or administrator of any such plan) is or becomes the
“beneficial owner” (as defined in Rules 13d-3 and 13d-5 under the Securities Exchange Act, except that a person or group shall be deemed to have “beneficial ownership” of all securities that such person or group has the right to
acquire, whether such right is exercisable immediately or only after the passage of time (such right, an “option right”)), directly or indirectly, of more than 35% of the total voting power of the Equity Interests in the Company on
a fully-diluted basis (and taking into account all such securities that such person or group has the right to acquire pursuant to any option right); 
 (b) for purposes of Section 7.03 only, during any period of 12 consecutive months, a majority of the members of the board of directors or other equivalent governing body of the Company
cease to be composed of individuals (i) who were members of that board or equivalent governing body on the first day of such period, (ii) whose election or nomination to that board or equivalent governing body was approved by individuals
referred to in clause (i) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body or (iii) whose election or nomination to that board or other equivalent governing body
was approved by individuals referred to in clauses (i) and (ii) above constituting at the time of such election or nomination at least a majority of that board or equivalent governing body (excluding, in the case of both clause
(ii) and clause (iii), any individual whose initial nomination for, or assumption of office as, a member of that board or equivalent governing body occurs as a result of an actual or threatened solicitation of proxies or consents for the
election or removal of one or more directors by any person or group other than a solicitation for the election of one or more directors by or on behalf of the board of directors); 

(c) any sale, lease, exchange or other transfer (in one transaction or a series of related transactions) of all, or
substantially all, the assets of the Company and its Subsidiaries taken as a whole to any “person” or “group” (as such terms are used in Sections 13(d) and 14(d) of the Securities Exchange Act) other than to any Wholly Owned
Subsidiary of the Company; or 
 (d) the adoption of a plan of liquidation of the Company. 

“Closing Date” means the first date all the conditions precedent in Section 4.02 are satisfied (or waived in
accordance with Section 10.01), and in any event no later than February 28, 2013. 
 “Code”
means the Internal Revenue Code of 1986, as amended. 

  

			
	5	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Co-Documentation Agents” means Barclays Bank PLC, Union Bank, N.A., Mizuho
Corporate Bank, Ltd., and JPMorgan Chase Bank, N.A., in their capacities as co-documentation agents. 

“Commitment” means, as to each Lender, its obligation to make a Loan to the Company pursuant to Section 2.01
in a principal amount not to exceed the amount set forth opposite such Lender’s name on Schedule 2.01 or in the Assignment and Assumption pursuant to which such Lender becomes a party hereto, as applicable, as such amount may be adjusted
from time to time in accordance with this Agreement. 
 “Commitment Letter” means that certain Commitment
Letter, dated April 25, 2012, among Bank of America, MLPF&S, Wells Fargo, WFS and the Company. 

“Company” has the meaning specified in the introductory paragraph hereto. 

“Company Materials” has the meaning specified in Section 6.02. 

“Company SEC Documents” means all reports, schedules, forms, proxy statements, prospectuses (including prospectus
supplements), registration statements and other information filed by the Company with the SEC or furnished by the Company to the SEC pursuant to the Securities Exchange Act. 
 “Compliance Certificate” means a certificate substantially in the form of Exhibit C. 
 “Consolidated EBITDA” means, for any period, for the Company and its Subsidiaries on a consolidated basis, an amount equal to Consolidated Net Income for such period plus, without
duplication and only to the extent such amount represents a charge or expense determined in accordance with GAAP and reflected in the consolidated earnings of the Company and regardless of classification within the Company’s statement of
income, the sum of (i) interest expense, (ii) income tax expense, (iii) depreciation and amortization expense, (iv) losses attributable to non-controlling interest, (v) stock compensation expense, (vi) asset impairment
charges or other charges associated with the revaluation of assets or liabilities, (vii) charges associated with the revaluation of acquisition related contingent liabilities that are based in whole or in part on future estimated cash flows,
(viii) business restructuring charges associated with the Company’s Global Supply Chain and Operational Excellence initiatives or other restructurings of a similar nature, (ix) costs and charges associated with the acquisition of
businesses and assets including, but not limited to, Milestone Payments and integration charges, (x) litigation charges and settlements, (xi) losses and expenses associated with the sale of assets and (xii) other unusual charges or
expenses minus, to the extent included in calculating such Consolidated Net Income, the sum of (1) interest income, (2) gains or income of a nature similar to items (i) through (xii) above. For the purposes of calculating
Consolidated EBITDA for any period of four consecutive fiscal quarters (each, a “Reference Period”), (i) if at any time during such Reference Period the Company or any Subsidiary shall have made any Material Disposition, the
Consolidated EBITDA for such Reference Period shall be reduced by an amount equal to the Consolidated EBITDA (if positive) attributable to the property that is the subject of such Material Disposition for such Reference Period or increased by an
amount equal to the Consolidated EBITDA (if negative) attributable thereto for such Reference Period, and (ii) if during such Reference Period 

  

			
	6	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
the Company or any Subsidiary shall have made a Material Acquisition, Consolidated EBITDA for such Reference Period shall be calculated after giving pro forma effect thereto in accordance with
Section 1.03(c) as if such Material Acquisition occurred on the first day of such Reference Period. 

“Consolidated Leverage Ratio” means, as of any date of determination, the ratio of (a) Consolidated Total Debt as
of such date to (b) Consolidated EBITDA for the period of the four fiscal quarters of the Company most recently ended. 
 “Consolidated Net Income” means, for any period, the consolidated net income (or loss) of the Company and its Subsidiaries for that period, determined on a consolidated basis in
accordance with GAAP. 
 “Consolidated Total Assets” means, at any time, the total assets of the Company and
its Subsidiaries, at such time, that would be reflected on a consolidated balance sheet of the Company and its Subsidiaries prepared in accordance with GAAP. 
 “Consolidated Total Debt” means, at any time, for the Company and its Subsidiaries on a consolidated basis, the aggregate amount of (a) all Indebtedness for borrowed money,
(b) all Receivables Facility Attributable Indebtedness, and (c) all Capital Lease Obligations and Synthetic Lease Obligations. 
 “Contractual Obligation” means, as to any Person, any provision of any security issued by such Person or of any agreement, instrument or other undertaking to which such Person is a party
or by which it or any of its property is bound. 
 “Control” means the possession, directly or indirectly, of
the power to direct or cause the direction of the management or policies of a Person, whether through the ability to exercise voting power, by contract or otherwise. “Controlling” and “Controlled” have meanings
correlative thereto. 
 “Debtor Relief Laws” means the Bankruptcy Code of the United States, and all other
liquidation, conservatorship, bankruptcy, assignment for the benefit of creditors, moratorium, rearrangement, receivership, insolvency, reorganization, or similar debtor relief Laws of the United States or other applicable jurisdictions from time to
time in effect and affecting the rights of creditors generally. 
 “Default” means any event or condition that
constitutes an Event of Default or that, with the giving of any notice, the passage of time, or both, would be an Event of Default. 
 “Default Rate” means an interest rate equal to the rate otherwise applicable to the relevant Loan pursuant to Section 2.09 plus 2.00% per annum. 

“Defaulting Lender” means, subject to Section 2.17(b), any Lender that, (a) has failed to (i) fund
all or any portion of its Loans within two Business Days of the date required to be funded by it hereunder unless such Lender notifies the Administrative Agent and the Company in writing that such failure is the result of such Lender’s good
faith determination that one or more conditions precedent to funding (each of which conditions precedent, together with any 

  

			
	7	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
applicable Default, shall be specifically identified and supported by reasonable background information provided by such Lender in such writing) has not been satisfied, or (ii) pay to the
Administrative Agent or any other Lender any other amount required to be paid by it hereunder within two Business Days of the date when due, (b) has notified the Company or the Administrative Agent in writing that it does not intend to comply
with its funding obligations hereunder, or has made a public statement to that effect (unless such writing or public statement relates to such Lender’s obligation to fund a Loan hereunder and states that such position is based on such
Lender’s good faith determination that a condition precedent to funding (which condition precedent, together with any applicable Default, shall be specifically identified and supported by reasonable background information provided by such
Lender in such writing or public statement) cannot be satisfied), (c) has failed, within three Business Days after request by the Administrative Agent or the Company, to confirm in writing to the Administrative Agent and the Company that it
will comply with its prospective funding obligations hereunder or (d) has, or has a direct or indirect parent company that has, (i) become the subject of a proceeding under any Debtor Relief Law, (ii) had appointed for it a receiver,
custodian, conservator, trustee, administrator, assignee for the benefit of creditors or similar Person charged with reorganization or liquidation of its business or assets, including the Federal Deposit Insurance Corporation or any other state or
federal regulatory authority acting in such a capacity; provided that a Lender shall not be a Defaulting Lender solely by virtue of the ownership or acquisition of any equity interest in that Lender or any direct or indirect parent company
thereof by a Governmental Authority so long as such ownership interest does not result in or provide such Lender with immunity from the jurisdiction of courts within the United States or from the enforcement of judgments or writs of attachment on
its assets or permit such Lender (or such Governmental Authority) to reject, repudiate, disavow or disaffirm any contracts or agreements made with such Lender. Any determination by the Administrative Agent or the Company, as applicable, that a
Lender is a Defaulting Lender under clauses (a) through (d) above shall be conclusive and binding absent manifest error, and such Lender shall be deemed to be a Defaulting Lender (subject to Section 2.17(b) upon delivery of
written notice of such determination to the Administrative Agent, the Company, and each Lender). 

“Disposition” or “Dispose” means the sale, transfer, license, lease or other disposition (including any
sale and leaseback transaction) of any property by any Person, including any sale, assignment, transfer or other disposal, with or without recourse, of any notes or accounts receivable or any rights and claims associated therewith. 

“Domestic Subsidiary” means any Subsidiary that was incorporated or organized under the laws of the United States, any
state thereof or the District of Columbia, other than (a) any such Subsidiary substantially all of whose assets consist of stock or securities of a Foreign Subsidiary (or Subsidiaries) or (b) any such Subsidiary that is wholly or partially
owned by a Foreign Subsidiary. 
 “Effective Date” means the date on which the conditions precedent set forth
in Section 4.01 shall have been satisfied, which date is June 22, 2012. 
 “Eligible Assignee”
means any Person that meets the requirements to be an assignee under Section 10.06(b)(iii) and (v), subject to such consents, if any, as may be required under Section 10.06(b)(iii). 

  

			
	8	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Eligible Pre-Closing Lenders” means Bank of America, N.A., Wells Fargo
Bank, National Association, Barclays Bank PLC, JPMorgan Chase Bank, N.A., Deutsche Bank AG New York Branch, Mizuho Corporate Bank, Ltd., The Bank of Tokyo-Mitsubishi UFJ, Ltd., DnB Bank ASA, Grand Cayman Branch, HSBC Bank USA, National Association,
the Royal Bank of Scotland plc, and U.S. Bank National Association. 
 “Environmental Laws” means any and all
federal, state, local, and foreign statutes, laws, regulations, ordinances, rules, judgments, orders, decrees, permits, concessions, grants, franchises, licenses, agreements or governmental restrictions relating to pollution and the protection of
the environment or the release of any materials into the environment, including those related to hazardous substances or wastes, air emissions and discharges to waste or public systems. 

“Environmental Liability” means any liability, contingent or otherwise (including any liability for damages, costs of
environmental remediation, fines, penalties or indemnities), of the Company or any of its respective Subsidiaries directly or indirectly resulting from or based upon (a) violation of any Environmental Law, (b) the generation, use,
handling, transportation, storage, treatment or disposal of any Hazardous Materials, (c) exposure to any Hazardous Materials, (d) the release or threatened release of any Hazardous Materials into the environment or (e) any contract,
agreement or other consensual arrangement pursuant to which liability is assumed or imposed with respect to any of the foregoing. 
 “Equity Interests” means, with respect to any Person, all of the shares of capital stock of (or other ownership or profit interests in) such Person, all of the warrants, options or other
rights for the purchase or acquisition from such Person of shares of capital stock of (or other ownership or profit interests in) such Person, all of the securities convertible into or exchangeable for shares of capital stock of (or other ownership
or profit interests in) such Person or warrants, rights or options for the purchase or acquisition from such Person of such shares (or such other interests), and all of the other ownership or profit interests in such Person (including partnership,
member or trust interests therein), whether voting or nonvoting, and whether or not such shares, warrants, options, rights or other interests are outstanding on any date of determination. 

“ERISA” means the Employee Retirement Income Security Act of 1974, as amended. 

“ERISA Affiliate” means any trade or business (whether or not incorporated) under common control with the Company within
the meaning of Section 414(b) or (c) of the Code (and Sections 414(m) and (o) of the Code for purposes of provisions relating to Section 412 of the Code). 
 “ERISA Event” means (a) a Reportable Event with respect to a Pension Plan or Multiemployer Plan; (b) a withdrawal by the Company or any ERISA Affiliate from a Pension Plan
subject to Section 4063 of ERISA during a plan year in which it was a substantial employer (as defined in Section 4001(a)(2) of ERISA) or a cessation of operations that is treated as such a withdrawal under Section 4062(e) of ERISA;
(c) a complete or partial withdrawal by the Company or any ERISA Affiliate from a Multiemployer Plan or notification that a Multiemployer Plan is in reorganization; (d) the filing of a notice of intent to terminate, the treatment of a
Pension Plan or Multiemployer Plan amendment as a termination under 

  

			
	9	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Sections 4041 or 4041A of ERISA, or the commencement of proceedings by the PBGC to terminate a Pension Plan or Multiemployer Plan; (e) an event or condition which constitutes grounds under
Section 4042 of ERISA for the termination of, or the appointment of a trustee to administer, any Pension Plan or Multiemployer Plan; (f) the imposition of any liability under Title IV of ERISA, other than for PBGC premiums due but not
delinquent under Section 4007 of ERISA, upon the Company or any ERISA Affiliate; or (g) the determination that any Pension Plan or Multiemployer Plan is considered an at-risk plan or a plan in endangered or critical status within the
meaning of Sections 430, 431 and 432 of the Code or Sections 303, 304 and 305 of ERISA. 
 “Eurodollar Rate”
means: 
 (a) for any Interest Period with respect to a Eurodollar Rate Loan, the rate per annum equal to
(i) the British Banker’s Association LIBOR Rate (“BBA LIBOR”), as published by Reuters (or other commercially available source providing quotations of BBA LIBOR as designated by the Administrative Agent from time to time)
at approximately 11:00 a.m., London time, two Business Days prior to the commencement of such Interest Period, for deposits in US Dollars (for delivery on the first day of such Interest Period) with a term equivalent to such Interest Period, or
(ii) if such rate referenced in the preceding clause (i) is not available at such time for any reason, then the “Eurodollar Rate” for such Interest Period will be the rate per annum determined by the Administrative Agent to be
the rate at which deposits in US Dollars for delivery on the first day of such Interest Period in Same Day Funds in the approximate amount of the Eurodollar Rate Loan being made, continued or converted by Bank of America and with a term equivalent
to such Interest Period would be offered by Bank of America’s London Branch (or other Bank of America branch or Affiliate) to major banks in the London interbank market for US Dollars at their request at approximately 11:00 a.m., London time,
two Business Days prior to the commencement of such Interest Period; and 
 (b) for any interest
calculation with respect to a Base Rate Loan on any date, the rate per annum equal to (i) BBA LIBOR, at approximately 11:00 a.m., London time determined two Business Days prior to such date for US Dollar deposits being delivered in the London
interbank market for a term of one month commencing that day or (ii) if such published rate is not available at such time for any reason, the rate per annum determined by the Administrative Agent to be the rate at which deposits in US Dollars
for delivery on the date of determination in Same Day Funds in the approximate amount of the Base Rate Loan being made or maintained and with a term equal to one month would be offered by Bank of America’s London Branch to major banks in the
London interbank Eurodollar market at their request at the date and time of determination. 
 “Eurodollar Rate
Loan” means a Loan that bears interest at a rate based on clause (a) of the definition of “Eurodollar Rate.” 
 “Event of Default” has the meaning specified in Section 8.01. 
 “Excluded Taxes” means, with respect to the Administrative Agent, any Lender or any other recipient of any payment to be made by or on account of any obligation of the Company

  

			
	10	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
hereunder or under any other Loan Document, (a) Taxes imposed on or measured by its overall net income (however denominated), and franchise Taxes imposed on it (in lieu of net income Taxes),
by the United States (or any political subdivision or taxing authority thereof or therein), or by the jurisdiction (or any political subdivision or taxing authority thereof or therein) under the laws of which such recipient is organized or in which
its principal office is located or, in the case of any Lender, in which its applicable Lending Office is located, or by any jurisdiction with which such recipient has a present or former connection (other than solely on account of the execution,
delivery, performance, filing, recording and enforcement of, and the other activities contemplated in, this Agreement), (b) any branch profits Taxes imposed by the United States or any similar Tax imposed by any other jurisdiction described in
clause (a) of this definition, (c) any backup withholding Tax that is required by the Code to be withheld from amounts payable to any recipient that has failed to comply with clause (A) of Section 3.01(e)(ii),
(d) in the case of a Foreign Lender (other than an assignee pursuant to a request by the Company under Section 10.13), any withholding Tax that is imposed on amounts payable to such Foreign Lender pursuant to any law in effect at
the time such Foreign Lender becomes a party hereto (or designates a new Lending Office) or is attributable to such Foreign Lender’s failure or inability to comply with Section 3.01(g) or clause (B) of
Section 3.01(e)(ii), except to the extent that such Foreign Lender (or its assignor, if any) was entitled, at the time of designation of a new Lending Office (or assignment), to receive additional amounts from the Company with respect to
such withholding Tax pursuant to Section 3.01(a), and (e) any United States federal withholding Taxes imposed pursuant to FATCA. 
 “FASB ASC” means the Accounting Standards Codification of the Financial Accounting Standards Board. 
 “FATCA” means Sections 1471 through 1474 of the Code as of the Effective Date (or any amendment or successor provisions that are substantively similar and not materially more onerous to
comply with), and any present or future regulations promulgated with respect thereto or official interpretations thereof. 
 “Federal Funds Rate” means, for any day, the rate per annum equal to the weighted average of the rates on overnight federal funds transactions with members of the Federal Reserve System
arranged by federal funds brokers on such day, as published by the Federal Reserve Bank of New York on the Business Day next succeeding such day; provided that (a) if such day is not a Business Day, the Federal Funds Rate for such day
will be such rate on such transactions on the next preceding Business Day as so published on the next succeeding Business Day, and (b) if no such rate is so published on such next succeeding Business Day, the Federal Funds Rate for such day
will be the average rate (rounded upward, if necessary, to a whole multiple of 1/100 of 1%) charged to Bank of America on such day on such transactions as determined by the Administrative Agent. 
 “Fee Letters” means each of the Administrative Fee Letter and the Joint Fee Letter, collectively, the “Fee Letters.” 

“Fiscal Year” means the fiscal year of the Company and its Subsidiaries ending on December 31st of each calendar
year. 

  

			
	11	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Foreign Lender” means any Administrative Agent or Lender that is not a
United States person, as such term is defined in Section 7701(a)(30) of the Code. 
 “Foreign Subsidiary”
means a Subsidiary that is not formed under the laws of the United States, any state thereof or the District of Columbia. 

“Fund” means any Person (other than a natural person) that is (or will be) engaged in making, purchasing, holding or
otherwise investing in commercial loans and similar extensions of credit in the ordinary course of its activities. 

“GAAP” means generally accepted accounting principles in the United States set forth in the opinions and pronouncements
of the Accounting Principles Board and the American Institute of Certified Public Accountants and statements and pronouncements of the Financial Accounting Standards Board or such other principles as may be approved by a significant segment of the
accounting profession in the United States, that are applicable to the circumstances as of the date of determination, consistently applied; provided that, notwithstanding anything in this Agreement to the contrary, leases will be accounted
for using accounting principles as in effect on the Effective Date. 
 “Governmental Authority” means the
government of the United States or any other nation, or of any political subdivision thereof, whether state or local, and any agency, authority, instrumentality, regulatory body, court, central bank or other entity exercising executive, legislative,
judicial, taxing, regulatory or administrative powers or functions of or pertaining to government (including any supra-national bodies such as the European Union or the European Central Bank). 

“Guarantee” means, as to any Person, (a) any obligation, contingent or otherwise, of such Person guaranteeing or
having the economic effect of guaranteeing any Indebtedness or other obligation payable or performable by another Person (the “primary obligor”) in any manner, whether directly or indirectly, and including any obligation of such Person,
direct or indirect, (i) to purchase or pay (or advance or supply funds for the purchase or payment of) such Indebtedness or other obligation, (ii) to purchase or lease property, securities or services for the purpose of assuring the
obligee in respect of such Indebtedness or other obligation of the payment or performance of such Indebtedness or other obligation, (iii) to maintain working capital, equity capital or any other financial statement condition or liquidity or
level of income or cash flow of the primary obligor so as to enable the primary obligor to pay such Indebtedness or other obligation, or (iv) entered into for the purpose of assuring in any other manner the obligee in respect of such
Indebtedness or other obligation of the payment or performance thereof or to protect such obligee against loss in respect thereof (in whole or in part), or (b) any Lien on any assets of such Person securing any Indebtedness or other obligation
of any other Person, whether or not such Indebtedness or other obligation is assumed by such Person (or any right, contingent or otherwise, of any holder of such Indebtedness to obtain any such Lien). The amount of any Guarantee will be deemed to be
an amount equal to the stated or determinable amount of the related primary obligation, or portion thereof, in respect of which such Guarantee is made or, if not stated or determinable, the maximum reasonably anticipated liability in respect thereof
as determined by the guaranteeing Person in good faith. The term “Guarantee” as a verb has a corresponding meaning. 

  

			
	12	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Hazardous Materials” means all explosive or radioactive substances or
wastes and all hazardous or toxic substances, wastes or other pollutants, including petroleum or petroleum distillates, asbestos or asbestos-containing materials, polychlorinated biphenyls, radon gas, infectious or medical wastes and all other
substances or wastes of any nature regulated pursuant to any Environmental Law. 
 “Indebtedness” means, as to
any Person at a particular time, without duplication, all of the following, whether or not included as indebtedness or liabilities in accordance with GAAP: 
 (a) all obligations of such Person for borrowed money and all obligations of such Person evidenced by bonds, debentures, notes, loan agreements or other similar instruments; 

(b) all direct or contingent obligations of such Person arising under letters of credit (including standby and
commercial), bankers’ acceptances, bank guaranties, surety bonds and similar instruments; 
 (c) net
obligations of such Person under any Swap Contract; 
 (d) all obligations of such Person to pay the
deferred purchase price of property or services (other than trade accounts payable in the ordinary course of business); 
 (e) indebtedness (excluding prepaid interest thereon) secured by a Lien on property owned or being purchased by such Person (including indebtedness arising under conditional sales or other title
retention agreements), whether or not such indebtedness will have been assumed by such Person or is limited in recourse; 
 (f) Capital Lease Obligations; 
 (g) Synthetic Lease
Obligations; 
 (h) Receivables Facility Attributable Indebtedness; and 

(i) all Guarantees of such Person in respect of any of the foregoing; provided that Indebtedness shall not
include any performance guarantee or any other guarantee that is not a guarantee of other Indebtedness. 
 For all purposes
hereof, the Indebtedness of any Person will include the Indebtedness of any partnership or joint venture (other than a joint venture that is itself a corporation or limited liability company) in which such Person is a general partner or a joint
venturer, unless such Indebtedness is expressly made non-recourse to such Person. The amount of any net obligation under any Swap Contract on any date will be deemed to be the Swap Termination Value thereof as of such date. 

“Indemnified Taxes” means (a) Taxes other than Excluded Taxes imposed on or with respect to any payment made by or
on account of any obligation of any Loan Party under any Loan Document and (b) to the extent not otherwise described in (a), Other Taxes. 

  

			
	13	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Indemnitees” has the meaning specified in Section 10.04(b).

 “Information” has the meaning specified in Section 10.07. 

“Interest Payment Date” means, (a) as to any Loan other than a Base Rate Loan, the last day of each Interest Period
applicable to such Loan and the Maturity Date; provided, however, that if any Interest Period for a Eurodollar Rate Loan exceeds three months, the respective dates that fall every three months after the beginning of such Interest
Period will also be Interest Payment Dates; and (b) as to any Base Rate Loan, the last Business Day of each March, June, September and December and the Maturity Date. 
 “Interest Period” means, as to each Eurodollar Rate Loan, the period commencing on the date such Eurodollar Rate Loan is disbursed or converted to or continued as a Eurodollar Rate Loan
and ending on the date one, two, three or six months thereafter (or, if agreed to by all Lenders, nine or twelve months or a period of shorter than one month), as selected by the Company in its Loan Notice; provided that: 

(i) any Interest Period that would otherwise end on a day that is not a Business Day shall be extended to the next
succeeding Business Day unless, in the case of a Eurodollar Rate Loan, such Business Day falls in another calendar month, in which case such Interest Period shall end on the next preceding Business Day; 

(ii) any Interest Period pertaining to a Eurodollar Rate Loan that begins on the last Business Day of a calendar
month (or on a day for which there is no numerically corresponding day in the calendar month at the end of such Interest Period) shall end on the last Business Day of the calendar month at the end of such Interest Period; and 

(iii) no Interest Period will extend beyond the Maturity Date. 

“Investment” means, as to any Person, any direct or indirect acquisition or investment by such Person, whether by means
of (a) the purchase or other acquisition of capital stock or other securities of another Person, (b) a loan, advance (other than prepaid expenses, extension of trade credit and advances to customers and suppliers, advances to employees and
similar items to the extent made in the ordinary course of business) or capital contribution to, Guarantee or assumption of debt of, or purchase or other acquisition of any other debt or equity participation or interest in, another Person, including
any partnership or joint venture interest in such other Person and any arrangement pursuant to which the investor Guarantees Indebtedness of such other Person, or (c) the purchase or other acquisition (in one transaction or a series of
transactions) of assets of another Person that constitute a business unit. For purposes of covenant compliance, the amount of any Investment shall be the amount actually invested, without adjustment for subsequent increases or decreases in the value
of such Investment. 
 “IP Rights” has the meaning specified in Section 5.20. 

“Joint Fee Letter” means that certain joint fee letter, dated April 25, 2012, among Bank of America, MLPF&S,
Wells Fargo, WFS and the Company. 

  

			
	14	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Laws” means, collectively, all international, foreign, federal, state and
local statutes, treaties, rules, guidelines, regulations, ordinances, codes and administrative or judicial precedents or authorities, including the interpretation or administration thereof by any Governmental Authority charged with the enforcement,
interpretation or administration thereof, and all applicable administrative orders, directed duties, requests, licenses, authorizations and permits of, and agreements with, any Governmental Authority, in each case whether or not having the force of
law. 
 “Lender” has the meaning specified in the introductory paragraph hereto. 

“Lending Office” means, as to any Lender, the office or offices of such Lender described as such in such Lender’s
Administrative Questionnaire, or such other office or offices as a Lender may from time to time notify the Company and the Administrative Agent. 
 “Lien” means any mortgage, pledge, hypothecation, assignment, deposit arrangement, encumbrance, lien (statutory or other), charge, or preference, priority or other security interest or
preferential arrangement in the nature of a security interest of any kind or nature whatsoever (including any conditional sale or other title retention agreement, any easement, right of way or other encumbrance on title to real property, and any
financing lease having substantially the same economic effect as any of the foregoing). 
 “Loan” has the
meaning specified in Section 2.01. 
 “Loan Documents” means this Agreement, each Note, the Fee
Letters and each Subsidiary Guaranty (if any). 
 “Loan Notice” means a notice of (a) a Borrowing,
(b) a conversion of Loans from one Type to the other, or (c) a continuation of Eurodollar Rate Loans, pursuant to Section 2.02(a), which, if in writing, will be substantially in the form of Exhibit D. 

“Loan Parties” means, collectively, the Company and the Subsidiary Guarantors (if any). 

“Major Default” means a Default that has occurred and is continuing under Section 8.01 (a), (b), (e), (f), (g),
(j) (solely with respect to this Agreement) or (k). 
 “Material Acquisition” means any acquisition
of property or series of related acquisitions of property that (a) constitutes (i) assets comprising all or substantially all or any significant portion of a business or operating unit of a business, division, product line (including
rights in respect of any drug or other pharmaceutical product) or line of business, or (ii) all or substantially all of the common stock or other Equity Interests of a Person, and (b) involves the payment of consideration (including the
aggregate principal amount of any Indebtedness that is assumed by the Company or any Subsidiary following such acquisition) by the Company and its Subsidiaries in excess of $200,000,000 (including the value of any Equity Interests of the Company or
any of its Subsidiaries used as consideration in any such transaction). 
 “Material Adverse Effect” means
(a) a material adverse change in, or a material adverse effect upon, the business, results of operations or financial condition of the Company and its Subsidiaries taken as a whole; (b) a material adverse effect on the ability of the
Company or any 

  

			
	15	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Subsidiary Guarantor, if any, to perform its payment obligations under any Loan Document to which it is a party; or (c) a material adverse effect on the legality, validity, binding effect or
enforceability against the Company or any Subsidiary Guarantor, if any, of any Loan Document to which it is a party. 

“Material Disposition” means any Disposition of property or series of Dispositions of property (other than any sale and
leaseback transaction or any Permitted Receivables Transfer, in each case to the extent the Indebtedness or Liens arising in connection therewith are permitted under Sections 7.01 and 7.02) that yield gross proceeds (including the
aggregate principal amount of any Indebtedness of the Company or any Subsidiary that is assumed by another Person following such Disposition) to the Company or any of its Subsidiaries in excess of $200,000,000. 

“Material Indebtedness” means Indebtedness (other than the Obligations) of any one or more of the Company and its
Subsidiaries in an aggregate principal amount exceeding $100,000,000. 
 “Material Subsidiary” means each
Subsidiary of the Company that meets any of the following tests: (a) its assets equal or exceed 5% of Consolidated Total Assets of the Company and its Subsidiaries, or (b) its revenues equal or exceed 5% of the total revenues of the
Company and its Subsidiaries on a consolidated basis as of the last day of the Company’s most recently ended fiscal quarter for the four consecutive fiscal quarters ending with such fiscal quarter; provided that if the Subsidiaries that meet
either of the tests in (a) or (b), when combined with revenues generated or assets owned directly by the Company (excluding any assets or revenues located or generated at the Subsidiary level), aggregate less than 90% of the Consolidated Total
Assets or total revenues of the Company and its Subsidiaries on a consolidated basis, the Company shall identify additional Subsidiaries to constitute Material Subsidiaries until such threshold is met. 

“Maturity Date” means the date that is the fifth anniversary of the Closing Date; provided, however, that
if such date is not a Business Day, the Maturity Date shall be the next preceding Business Day. 
 “Milestone
Payments” means payments made under contractual arrangements arising in connection with any acquisition (or licensing) of assets or Equity Interests by the Company or any Subsidiary to the sellers (or licensors) of the assets or Equity
Interests acquired (or licensed) under such contractual arrangements based on the achievement of specified revenue, profit or other performance targets (financial or otherwise). 

“MLPF&S” means Merrill Lynch, Pierce, Fenner & Smith Incorporated and its successors. 

“Moody’s” means Moody’s Investors Service, Inc. and any successor thereto. 

“Multiemployer Plan” means any employee benefit plan of the type described in Section 4001(a)(3) of ERISA, to which
the Company or any ERISA Affiliate makes or is obligated to make contributions, or during the preceding five plan years, has made or been obligated to make contributions. 

  

			
	16	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Net Worth” means, as at any time, the sum of Consolidated Total Assets of
the Company less all liabilities of the Company and its Subsidiary, at such time, calculated in accordance with GAAP on a consolidated basis. 
 “Note” means a promissory note made by the Company in favor of a Lender evidencing Loans made by such Lender to the Company, substantially in the form of Exhibit E. 

“Obligations” means all advances to, and debts, liabilities, obligations, covenants and duties of, any Loan Party
arising under any Loan Document or otherwise with respect to any Loan, whether direct or indirect (including those acquired by assumption), absolute or contingent, due or to become due, now existing or hereafter arising and including interest and
fees that accrue after the commencement by or against the Company or any other Loan Party of any proceeding under any Debtor Relief Laws naming such Person as the debtor in such proceeding, regardless of whether such interest and fees are allowed
claims in such proceeding. 
 “OFAC” has the meaning specified in Section 5.15. 

“OFAC Countries” has the meaning specified in Section 5.15. 

“OFAC Listed Person” has the meaning specified in Section 5.15. 

“Organization Documents” means, (a) with respect to any corporation, the certificate or articles of incorporation
and the bylaws; (b) with respect to any limited liability company, the certificate or articles of formation or organization and operating agreement; and (c) with respect to any partnership, joint venture, trust or other form of business
entity, the partnership, joint venture or other applicable agreement of formation or organization and any agreement, instrument, filing or notice with respect thereto filed in connection with its formation or organization with the applicable
Governmental Authority in the jurisdiction of its formation or organization and, if applicable, any certificate or articles of formation or organization of such entity. 
 “Originators” means the Company and/or any of its Subsidiaries in their respective capacities as parties to any Receivables Purchase Documents as sellers or transferors of any Receivables
and Related Security in connection with a Permitted Receivables Transfer. 
 “Other Taxes” means all present or
future stamp or documentary taxes or any other excise or property taxes, charges or similar levies arising from any payment made hereunder or under any other Loan Document or from the execution, delivery or enforcement of, or otherwise with respect
to, this Agreement or any other Loan Document. 
 “Overnight Rate” means, for any day, the greater of
(a) the Federal Funds Rate and (b) an overnight rate determined by the Administrative Agent in accordance with banking industry rules on interbank compensation. 
 “Participant” has the meaning specified in Section 10.06(e). 
 “Participant Register” has the meaning specified in Section 10.06(e). 

  

			
	17	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Patriot Act” means the USA PATRIOT Act (Title III of Pub. L. 107-56
(signed into law October 26, 2001)). 
 “PBGC” means the Pension Benefit Guaranty Corporation.
“Pension Act” means the Pension Protection Act of 2006. 
 “Pension Funding Rules” means the rules of
the Code and ERISA regarding minimum required contributions (including any installment payment thereof) to Pension Plans and set forth in, with respect to plan years ending prior to the effective date of the Pension Act, Section 412 of the Code
and Section 302 of ERISA, each as in effect prior to the Pension Act and, thereafter, Section 412, 430, 431, 432 and 436 of the Code and Sections 302, 303, 304 and 305 of ERISA. 

“Pension Plan” means any “employee pension benefit plan” (as such term is defined in Section 3(2) of
ERISA), other than a Multiemployer Plan, that is subject to Title IV of ERISA and is sponsored or maintained by the Company or any ERISA Affiliate or to which the Company or any ERISA Affiliate contributes or has an obligation to contribute, or in
the case of a multiple employer or other plan described in Section 4064(a) of ERISA, has made contributions at any time during the immediately preceding five plan years. 
 “Permitted Receivables Transfer” means (a) a sale or other transfer by an Originator to an SPV or any other Person of Receivables and Related Security for fair market value and
without recourse (except for limited recourse typical of such structured finance transactions), and/or (b) a sale or other transfer by an Originator or an SPV to (i) purchasers of or other investors in such Receivables and Related Security
or (ii) any other Person (including an SPV) in a transaction in which purchasers or other investors purchase or are otherwise transferred such Receivables and Related Security, in each case pursuant to and in accordance with the terms of the
applicable Receivables Purchase Documents. 
 “Person” means any natural person, corporation, limited liability
company, trust, joint venture, association, company, partnership, Governmental Authority or other entity. 

“Plan” means any “employee benefit plan” within the meaning of Section 3(3) of ERISA (including a Pension
Plan), maintained for employees of the Company or any ERISA Affiliate or any such Plan to which the Company or any ERISA Affiliate is required to contribute on behalf of any of its employees. 

“Platform” has the meaning specified in Section 6.02. 

“Pre-Advanced Funds” has the meaning specified in Section 2.02(d). 

“Pre-Funding Compensation Amount” has the meaning specified in Section 2.02(d). 

“Pre-Funding Date” has the meaning specified in Section 2.02(c). 

“Pro Forma Financial Statements” has the meaning specified in Section 4.02(a)(vi). 

“Public Lender” has the meaning specified in Section 6.02. 

  

			
	18	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Quarterly Financial Statements” has the meaning specified in
Section 4.02(a)(vi). 
 “Receivables” means, with respect to any Originator or SPV, such
Originator’s or SPV’s presently existing and hereafter arising or acquired accounts, accounts receivable, and all present and future rights of such Originator or SPV to payment for goods sold or leased or for services rendered (except
those evidenced by instruments or chattel paper), whether or not they have been earned by performance, and all rights in any merchandise or goods which any of the same may represent, and all rights, title, security and guaranties with respect to
each of the foregoing, including, without limitation, any right of stoppage in transit. 
 “Receivables and Related
Security” means the Receivables and the related security and collections with respect thereto which are sold or transferred by any Originator or SPV in connection with any Permitted Receivables Transfer. 

“Receivables Facility Attributable Indebtedness” means the amount of obligations outstanding under a Receivables
Purchase Facility on any date of determination that would be characterized as principal if such facility were structured as a secured lending transaction rather than as a purchase. 

“Receivables Purchase Documents” means any series of receivables purchase or sale agreements generally consistent with
terms contained in comparable structured finance transactions pursuant to which one or more Originators sell or transfer to one or more SPVs all of their respective rights, title and interests in and to certain Receivables and Related Security for
further sale or transfer to other purchasers of or investors in such assets (and the other documents, instruments and agreements executed in connection therewith), as any such agreements may be amended, restated, supplemented, refinanced, replaced
or otherwise modified from time to time. 
 “Receivables Purchase Facility” means the securitization facility
made available to the Company, pursuant to which the Receivables and Related Security of the Originators are transferred to one or more SPVs, and thereafter to certain investors, pursuant to the terms and conditions of the Receivables Purchase
Documents. 
 “Register” has the meaning specified in Section 10.06(d). 

“Related Parties” means, with respect to any Person, such Person’s Affiliates and the directors, officers,
employees and agents of such Person and of such Person’s Affiliates. 
 “Reportable Event” means any of
the events set forth in Section 4043(c) of ERISA, other than events for which the 30 day notice period has been waived under current law. 
 “Required Lenders” means, as of any date of determination, Lenders having more than 50% of the Aggregate Commitments or, if the Commitment of each Lender to make Loans has been fulfilled
pursuant to Section 2.01, Lenders holding in the aggregate more than 50% of the aggregate principal amount of the Loans then outstanding; provided that the Commitment of any Defaulting Lender will be excluded for purposes of
making a determination of Required Lenders. 

  

			
	19	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Responsible Officer” means the chief executive officer, the chief
financial officer, the vice president and treasurer, or the vice president and controller of the Company, or any other Loan Party, as applicable. Any document delivered hereunder that is signed by a Responsible Officer of the Company, or any other
Loan Party, as applicable, will be conclusively presumed to have been authorized by all necessary corporate, partnership and/or other action on the part of the Company or such Loan Party, as applicable, and such Responsible Officer will be
conclusively presumed to have acted on behalf of the Company, or such Loan Party, as applicable. 
 “Restricted
Payment” means any dividend or other distribution (whether in cash, securities or other property) with respect to any capital stock or other Equity Interest of the Company or any Material Subsidiary, or any payment (whether in cash,
securities or other property), including any sinking fund or similar deposit, on account of the purchase, redemption, retirement, acquisition, cancellation or termination of any such capital stock or other Equity Interest, or on account of any
return of capital to the Company’s stockholders, partners or members (or the equivalent Person thereof). 

“S&P” means Standard & Poor’s Financial Services LLC, a subsidiary of The McGraw-Hill Companies, Inc.
and any successor thereto. 
 “Same Day Funds” means immediately available funds. 

“SEC” means the Securities and Exchange Commission, or any Governmental Authority succeeding to any of its principal
functions. 
 “Securities Exchange Act” means the Securities Exchange Act of 1934, as amended from time to
time, and any successor statute. 
 “Sellers” has the meaning specified in the recitals hereto. 

“Solvent” and “Solvency” mean, with respect to any Person on a particular date, that on such date
(a) the fair value of the property of such Person (including, for the avoidance of doubt, property consisting of the residual equity value of such Person’s subsidiaries) is greater than the total amount of liabilities, including contingent
liabilities, of such Person, (b) the present fair salable value of the assets of such Person (including, for the avoidance of doubt, property consisting of the residual equity value of such Person’s subsidiaries) is greater than the amount
that will be required to pay the probable liability of such Person on the sum of its debts and other liabilities, including contingent liabilities, (c) such Person has not, does not intend to, and does not believe (nor should it reasonably
believe) that it will, incur debts or liabilities beyond such Person’s ability to pay such debts and liabilities as they become due (whether at maturity or otherwise), (d) such Person does not have unreasonably small capital with which to
conduct the businesses in which it is engaged as such businesses are now conducted and are proposed to be conducted following the Closing Date, (e) such Person is able to pay its debts and liabilities, contingent obligations and other
commitments as they mature in the ordinary course of business, and (f) such Person is “solvent” within the meaning given to that term and similar terms under the Bankruptcy Code of the United States and applicable laws relating to
fraudulent transfers and conveyances. The amount of contingent liabilities at any time shall be computed as the amount that, in the light of all the facts and circumstances existing at such time, represents the amount that can reasonably be expected
to become an actual or matured liability. 

  

			
	20	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Specified Representations” means (x) the representations and
warranties of the Company (in each case, solely as they relate to the Company) contained in Sections 5.01(a), 5.01(b)(ii), 5.02(a), 5.02(c), 5.04, 5.13, 5.15 and 5.17 and (y) the
representations and warranties of the Company contained in Sections 5.06(b) and 5.10. 
 “Springing
Amount” means, for any period, the sum, without duplication and only to the extent such amount represents a charge or expense determined in accordance with GAAP and reflected in the consolidated earnings of the Company for such period and
regardless of classification within the Company’s statement of income, of (a) litigation charges and settlements to the extent paid in cash by the Company or its Subsidiaries plus (b) unusual cash charges or expenses to the
extent paid in cash by the Company or its Subsidiaries. For the twelve-month period ending as of the first month-end after the Closing Date, the Springing Amount is equal to $0.00. 

“SPV” means any special purpose entity established for the purpose of purchasing receivables in connection with a
receivables securitization transaction permitted under the terms of this Agreement. 
 “Subsidiary” means with
respect to any Person (herein referred to as the “parent”), a corporation, partnership, joint venture, limited liability company or other business entity (a) of which a majority of the shares of securities or other interests
having ordinary voting power for the election of directors or other governing body (other than securities or interests having such power only by reason of the happening of a contingency) are at the time beneficially owned, or (b) that is, at
the time any determination is made, otherwise Controlled by the parent or one or more subsidiaries of the parent or by the parent and one or more subsidiaries of the parent. Unless otherwise specified, all references herein to a
“Subsidiary” or to “Subsidiaries” will refer to a Subsidiary or Subsidiaries of the Company. 

“Subsidiary Guarantor” means each Domestic Subsidiary of the Company that becomes a party to the Subsidiary Guaranty
either at the election of the Company or as required by Section 6.12 (whether by original execution thereof or by executing and delivering to the Administrative Agent a joinder agreement thereto). As of the Effective Date, there are no
Subsidiary Guarantors. 
 “Subsidiary Guaranty” means the Subsidiary Guaranty (including any and all
supplements or joinder agreements thereto) to be entered into by the Subsidiary Guarantors in favor of the Administrative Agent, substantially in the form of Exhibit F. 
 “Swap Contract” means (a) any and all rate swap transactions, basis swaps, credit derivative transactions, forward rate transactions, commodity swaps, commodity options, forward
commodity contracts, equity or equity index swaps or options, bond or bond price or bond index swaps or options or forward bond or forward bond price or forward bond index transactions, interest rate options, forward foreign exchange transactions,
cap transactions, floor transactions, collar transactions, currency swap transactions, cross-currency rate swap 

  

			
	21	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
transactions, currency options, spot contracts, or any other similar transactions or any combination of any of the foregoing (including any options to enter into any of the foregoing), whether or
not any such transaction is governed by or subject to any master agreement, and (b) any and all transactions of any kind, and the related confirmations, which are subject to the terms and conditions of, or governed by, any form of master
agreement published by the International Swaps and Derivatives Association, Inc., any International Foreign Exchange Master Agreement, or any other master agreement (any such master agreement, together with any related schedules, a “Master
Agreement”), including any such obligations or liabilities under any Master Agreement. 
 “Swap Termination
Value” means, in respect of any one or more Swap Contracts, after taking into account the effect of any netting agreement relating to such Swap Contracts, (a) for any date on or after the date such Swap Contracts have been closed out
and termination value(s) determined in accordance therewith, such termination value(s), and (b) for any date prior to the date referenced in clause (a) of this definition, the amount(s) determined as the mark-to-market value(s) for
such Swap Contracts, as determined based upon one or more mid-market or other readily available quotations provided by any recognized dealer in such Swap Contracts (which may include a Lender or any Affiliate of a Lender) or any third party in the
business of determining such values acceptable to the Administrative Agent. 
 “Syndication Agent” means Wells
Fargo, in its capacity as syndication agent. 
 “Synthetic Lease Obligation” means the monetary obligation of a
Person under (a) a so-called synthetic, off-balance sheet or tax retention lease, or (b) an agreement for the use or possession of property creating obligations that do not appear on the balance sheet of such Person but which, upon the
insolvency or bankruptcy of such Person, would be characterized as the indebtedness of such Person (without regard to accounting treatment), and the amount of such obligation shall be the capitalized amount of the remaining lease payments under the
relevant lease that would appear on a balance sheet of such Person prepared as of such date in accordance with GAAP if such lease were accounted for as capital lease. 
 “Target Companies” has the meaning specified in the recitals hereto. 
 “Target Material Adverse Effect” means a matter, event, development, change or occurrence (a “Target Event”) either alone or in combination that occurs or materialises in
the period from the date the Acquisition Agreement was executed and delivered to the Closing Date and results in, or can be reasonably expected to result in, a material adverse effect on the business, results of operations or the financial condition
of the Group (as defined in the Acquisition Agreement) (taken as a whole); provided that no Target Event to the extent it arises out of, in connection with or resulting from an External Event (as defined in the Acquisition Agreement) shall be
deemed to constitute or contribute to a Target Material Adverse Effect. 
 “Taxes” means all present or future
taxes, levies, imposts, duties, deductions, withholdings (including backup withholding), assessments, fees or other similar charges imposed by any Governmental Authority, including any interest, additions to tax or penalties applicable thereto.

  

			
	22	  	Watson Pharmaceuticals Term Loan Credit Agreement

 “Ticking Fee” has the meaning specified in Section 2.10(a).

 “Transaction” means, collectively, (a) the consummation of the Acquisition, (b) the repayment or
redemption of certain existing indebtedness and preferred stock of the Target Companies, (c) the execution and delivery by the Company of this Agreement, the borrowing of Loans hereunder and the use of the proceeds thereof and (d) the
issuance by the Company of senior unsecured notes generating aggregate gross proceeds of up $4,500,000,000 and/or the borrowing of any loans under the Bridge Facility, as applicable. 

“Type” means, with respect to a Loan, its character as a Base Rate Loan or a Eurodollar Rate Loan. 

“United States” and “U.S.” mean the United States of America. 

“US Dollar” and “$” mean lawful money of the United States. 

“Wells Fargo” means Wells Fargo Bank, N.A. and its successors. 

“WFS” means Wells Fargo Securities, LLC and its successors. 

“Wholly Owned Subsidiary” means a Subsidiary of the Company all the Equity Interests of which (except for
directors’ qualifying shares) are, at the time any determination is being made, owned, Controlled or held by the Company or one or more wholly owned Subsidiaries of the Company or by the Company and one or more wholly owned Subsidiaries of the
Company. 
 1.02 Other Interpretive Provisions. With reference to this Agreement and each other Loan Document, unless
otherwise specified herein or in such other Loan Document: 
 (a) The definitions of terms herein will apply equally to the
singular and plural forms of the terms defined. Whenever the context may require, any pronoun will include the corresponding masculine, feminine and neuter forms. The words “include,” “includes” and
“including” will be deemed to be followed by the phrase “without limitation.” The word “will” will be construed to have the same meaning and effect as the word “shall.” Unless the
context requires otherwise, (i) any definition of or reference to any agreement, instrument or other document (including any Organization Document) will be construed as referring to such agreement, instrument or other document as from time to
time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein or in any other Loan Document), (ii) any reference herein to any Person will be construed to include
such Person’s successors and assigns, (iii) the words “herein,” “hereof” and “hereunder,” and words of similar import when used in any Loan Document, will be construed to refer to such
Loan Document in its entirety and not to any particular provision thereof, (iv) all references in a Loan Document to Articles, Sections, Exhibits and Schedules will be construed to refer to Articles and Sections of, and Exhibits and Schedules
to, the Loan Document in which such references appear, (v) any reference to any law will include all statutory and regulatory provisions consolidating, amending, replacing or interpreting such law and any reference to any law or regulation
will, unless otherwise specified, refer to such law or regulation as amended, modified or supplemented from time to time, and (vi) the words “asset” and “property” will be construed to have the same meaning and
effect and to refer to any and all tangible and intangible assets and properties, including cash, securities, accounts and contract rights. 

  

			
	23	  	Watson Pharmaceuticals Term Loan Credit Agreement

 Notwithstanding the foregoing, any reference to the Acquisition Agreement shall be a
reference to the copy of the Acquisition Agreement delivered to the Arrangers on April 25, 2012 at 5:02 P.M. and include any modifications thereto approved by the Arrangers in accordance with the terms of the Commitment Letter. 

(b) In the computation of periods of time from a specified date to a later specified date, the word “from” means
“from and including;” the words “to” and “until” each mean “to but excluding;” and the word “through” means “to and including.” 

(c) Section headings herein and in the other Loan Documents are included for convenience of reference only and will not affect the
interpretation of this Agreement or any other Loan Document. 
 1.03 Accounting Terms. (a) Generally. All
accounting terms not specifically or completely defined herein shall be construed in conformity with, and all financial data (including financial ratios and other financial calculations) required to be submitted pursuant to this Agreement shall be
prepared in conformity with, GAAP applied on a consistent basis, as in effect from time to time, applied in a manner consistent with that used in preparing the Audited Financial Statements, except as otherwise specifically prescribed herein.
Notwithstanding the foregoing, for purposes of determining compliance with any covenant (including the computation of any financial covenant) contained herein, Indebtedness of the Company and its Subsidiaries shall be deemed to be carried at 100% of
the outstanding principal amount thereof, and the effects of FASB ASC 825 and FASB ASC 470-20 on financial liabilities shall be disregarded. 
 (b) Changes in GAAP. If at any time any change in GAAP would affect the computation of any financial ratio or requirement set forth in any Loan Document, and either the Company or the Required
Lenders shall so request, the Administrative Agent, the Lenders and the Company shall negotiate in good faith to amend such ratio or requirement to preserve the original intent thereof in light of such change in GAAP (subject to the approval of the
Required Lenders); provided that, until so amended, (i) such ratio or requirement shall continue to be computed in accordance with GAAP prior to such change therein and (ii) the Company shall provide to the Administrative
Agent and the Lenders financial statements and other documents required under this Agreement or as reasonably requested hereunder setting forth a reconciliation between calculations of such ratio or requirement made before and after giving effect to
such change in GAAP. For the avoidance of doubt, all calculations, ratios and computations with respect to leases contained in this Agreement will be computed with respect to each lease in conformity with GAAP as in effect on the Effective Date.

 (c) Pro Forma Calculations. All pro forma computations required to be made hereunder giving effect to any Material
Acquisition or Material Disposition shall be calculated after giving pro forma effect thereto immediately after giving effect to such acquisition or disposition (and to any other such transaction consummated since the first day of the period for
which such pro forma computation is being made and on or prior to the date of such 

  

			
	24	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
computation) as if such transaction had occurred on the first day of the period of four consecutive fiscal quarters ending with the most recent fiscal quarter for which financial statements shall
have been delivered pursuant to Sections 6.01(a) or 6.01(b), and, to the extent applicable, the historical earnings and cash flows associated with the assets acquired or disposed of, any related incurrence or reduction of Indebtedness and any
related cost savings, operating expense reductions and synergies which, in the case of reductions in cost, (i) are calculated on a basis that is consistent with Article 11 of Regulation S-X under the Securities Act of 1933, as amended or
(ii) are implemented, committed to be implemented, the commencement of implementation of which has begun or reasonably expected to be implemented in good faith by the business that was the subject of any such asset acquisition, disposition or
operational change within twelve (12) months of the date of such asset acquisition, disposition or operational change and that are factually supportable and quantifiable and expected to have a continuing impact, as if, in the case of each of
clauses (i) and (ii), all such reductions in costs had been effected as of the beginning of such period, decreased by any non-one-time incremental expenses incurred or to be incurred during the prior twelve month period in order to achieve such
reduction in costs. If any Indebtedness bears a floating rate of interest and is being given pro forma effect, the interest on such Indebtedness shall be calculated as if the rate in effect on the date of determination had been the applicable rate
for the entire period (taking into account any Swap Contract applicable to such Indebtedness). 
 1.04 Times of Day.
Unless otherwise specified, all references herein to times of day will be references to Eastern time (daylight or standard, as applicable). 
 1.05 Rounding. Any financial ratios required to be maintained by the Company pursuant to this Agreement shall be calculated by dividing the appropriate component by the other component, carrying
the result to one place more than the number of places by which such ratio is expressed herein and rounding the result up or down to the nearest number (with a rounding-up if there is no nearest number). 

1.06 Schedules. Notwithstanding anything in this Agreement to the contrary, solely with respect to any changes relating to the
Group (as defined in the Acquisition Agreement) and only to the extent permitted by the Acquisition Agreement, to the extent any changes or updates occur between the Effective Date and the Closing Date which would make the contents of Schedules
7.01 and/or 7.02 incorrect or incomplete, the Company may deliver to the Administrative Agent an updated version of such Schedules on or prior to the Closing Date, which updated version shall replace the version of such Schedules
delivered on the Effective Date without any requirement for any amendment or any consent by the Administrative Agent, any Lender or the Company. For the avoidance of doubt, such Schedules may not be amended pursuant to this Section 1.06
after the Closing Date. 
 ARTICLE II. 
 THE COMMITMENTS AND BORROWINGS 
 2.01 Loans. Subject to the terms
and conditions set forth herein, each Lender severally agrees to make a term loan (each such loan, a “Loan”) to the Company in US Dollars on the Closing Date, in an aggregate amount not to exceed such Lender’s Commitment. The
Borrowing on the Closing Date shall consist of Loans made simultaneously by the Lenders in 

  

			
	25	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
accordance with their respective Applicable Percentages. Amounts borrowed under this Section 2.01 and repaid or prepaid may not be reborrowed. Loans may be Base Rate Loans or
Eurodollar Rate Loans, as further provided herein. 
 2.02 Borrowings, Conversions and Continuations of Loans.
(a) Each Borrowing, each conversion of Loans from one Type to the other, and each continuation of Eurodollar Rate Loans will be made upon the Company’s irrevocable notice to the Administrative Agent, which may be given by telephone (and
confirmed promptly by hand delivery, fax or email). Each such notice must be received by the Administrative Agent not later than (i) 12:00 noon three Business Days prior to the requested date of any Borrowing of, conversion to or continuation
of Eurodollar Rate Loans or of any conversion of Eurodollar Rate Loans to Base Rate Loans, and (ii) 10:00 a.m. on the requested date of any Borrowing of Base Rate Loans; provided, however, that if the Company wishes to request
Eurodollar Rate Loans having an Interest Period other than one, two, three or six months in duration as provided in the definition of “Interest Period”, the applicable notice must be received by the Administrative Agent not later than
12:00 noon four Business Days prior to the requested date of such Borrowing, conversion or continuation of Eurodollar Rate Loans, whereupon the Administrative Agent will give prompt notice to the Lenders of such request and determine whether the
requested Interest Period is acceptable to all of them. Not later than 12:00 noon, three Business Days before the requested date of such Borrowing, conversion or continuation of Eurodollar Rate Loans, the Administrative Agent will notify the Company
(which notice may be by telephone) whether or not the requested Interest Period has been consented to by all the Lenders. Each telephonic notice by the Company pursuant to this Section 2.02(a) must be confirmed promptly by hand delivery,
fax or e-mail to the Administrative Agent of a written Loan Notice, appropriately completed and signed by a Responsible Officer of the Company. Each Borrowing of, conversion to or continuation of Eurodollar Rate Loans will be in a principal amount
of $5,000,000 or a whole multiple of $1,000,000 in excess thereof. Each Borrowing of or conversion to Base Rate Loans will be in a principal amount of $500,000 or a whole multiple of $100,000 in excess thereof. Each Loan Notice (whether telephonic
or written) will specify (i) whether the Company is requesting a Borrowing, a conversion of Loans from one Type to the other, or a continuation of Eurodollar Rate Loans, (ii) the requested date of the Borrowing, conversion or continuation,
as the case may be (which will be a Business Day), and, if applicable, the requested Pre-Funding Date, (iii) the principal amount of Loans to be borrowed, converted or continued, (iv) the Type of Loans to be borrowed or to which existing
Loans are to be converted, and (v) if applicable, the duration of the Interest Period with respect thereto. If the Company fails to specify a Type of Loan in a Loan Notice, then the applicable Loans will be made as Base Rate Loans. If the
Company fails to give timely notice requesting a conversion or continuation of a Eurodollar Rate Loan, such Eurodollar Rate Loan will be continued with an Interest Period of one month. If the Company requests a Borrowing of, conversion to, or
continuation of Eurodollar Rate Loans in any such Loan Notice, but fails to specify an Interest Period, it will be deemed to have specified an Interest Period of one month. 
 (b) Following receipt of a Loan Notice, the Administrative Agent will promptly notify each Lender of the amount of its Applicable Percentage of the applicable Loans, as described in the preceding
subsection. In the case of a Borrowing, each Lender will make the amount of its Loan available to the Administrative Agent in Same Day Funds at the Administrative Agent’s Office not later than 1:00 p.m. on the Business Day specified in the

  

			
	26	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
applicable Loan Notice. Upon delivery of evidence reasonably satisfactory to the Administrative Agent of the satisfaction (or waiver) of the applicable conditions set forth in
Section 4.02 (the Administrative Agent shall be entitled to rely on the certificate detailed in Section 4.02(a)(ii) for evidence of the satisfaction of the conditions set forth in Sections 4.02(b), (c) and
(d)), the Administrative Agent will make all funds so received available to the Company in like and Same Day Funds as received by the Administrative Agent either by (i) crediting the account of such Company on the books of Bank of
America with the amount of such funds or (ii) wire transfer of such funds, in each case in accordance with instructions provided to (and reasonably acceptable to) the Administrative Agent by the Company. If a Pre-Funding Date has been
specified, the Administrative Agent shall make such funds available not later than 9:00 a.m. on the Business Day on which the Administrative Agent receives the evidence referred to above that the conditions in Section 4.02 are satisfied
(or waived). 
 (c) The Company may require that Lenders transfer funds to the Administrative Agent in advance of the
anticipated Closing Date set forth in the Loan Notice to hold in reserve pursuant to Section 2.02(d), by specifying, in the relevant Loan Notice, the date (the “Pre-Funding Date”) upon which Lenders shall deliver such
funds to the Administrative Agent to be held in reserve (which requested Pre-Funding Date may be no earlier than three Business Days prior to the anticipated Closing Date set forth in the Loan Notice). In the event the Company specifies a
Pre-Funding Date in a Loan Notice, then such Loan Notice shall be submitted not later than (i) 12:00 noon three Business Days prior to the Pre-Funding Date of any Borrowing of Eurodollar Rate Loans, and (ii) 10:00 a.m. on the Pre-Funding
Date of any Borrowing of Base Rate Loans. 
 (d) If a Pre-Funding Date is specified in a Loan Notice, on the requested
Pre-Funding Date, no later than 1:00 p.m., each Lender shall deliver to the Administrative Agent an amount equal to its Applicable Percentage of the Loans requested to be made on the Closing Date, by wire transfer of immediately available funds to
the account of the Administrative Agent designated by it for such purpose by notice to the Lenders and each Lender hereby irrevocably authorizes the Administrative Agent to release such funds (the “Pre-Advanced Funds”) and use them
to fund such Lender’s Applicable Percentage of the Loans on the Closing Date unless the Administrative Agent shall have received written notice from such Lender prior to 9:00 a.m. on the anticipated Closing Date set forth in the Loan Notice
that any one or more of the conditions precedent in Section 4.02 has not been satisfied specifying both the conditions precedent that have not been satisfied and its objection thereto. The Pre-Advanced Funds shall be held in reserve by
the Administrative Agent for the benefit of such Lender, upon the following terms: 
 (i) The
Administrative Agent shall release the Pre-Advanced Funds only as follows: (A) the Administrative Agent shall release the Pre-Advanced Funds of each Lender to fund such Lender’s Applicable Percentage of the Loans on the Closing Date,
without any further authorization from such Lender, or (B) if for any reason the Closing Date does not occur on or before 11:59 p.m. on the date that is two Business Days after the proposed Closing Date set forth in the Loan Notice, the
Administrative Agent shall promptly return to each Lender the portion of the Pre-Advanced Funds delivered by such Lender. In the event any Pre-Advanced Funds remain in reserve at the time of expiration of the Aggregate Commitments, the
Administrative Agent shall return to each Lender the portion of the Pre-Advanced Funds delivered by such Lender. 

  

			
	27	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (ii) The Administrative Agent shall hold the Pre-Advanced Funds in a
non-interest bearing account with Bank of America, N.A. 
 (iii) It is understood and agreed that, except as set
forth in Section 2.02(b), the Company shall have no right, title or interest in any Pre-Advanced Funds, and shall have no right to give directions to the Administrative Agent with regard to investment, application or release of such
funds or otherwise with respect to such funds. Whether or not the Closing Date occurs and whether or not Loans are made on the Closing Date, the Company agrees to pay to each Lender an amount (the “Pre-Funding Compensation Amount”)
that is equal to the amount of interest that would have accrued hereunder on its Pre-Advanced Funds (at the rate(s) requested by the Company in the Loan Notice) if such Pre-Advanced Funds had been used to fund Loans on the Pre-Funding Date (or, if
later, the date such funds were delivered to the Administrative Agent to be placed in reserve) and as if such Loans were outstanding for the period of time that such Pre-Advanced Funds remain in reserve. To the extent that a Lender’s
Pre-Advanced Funds are used to fund its Applicable Percentage of Loans made on the Closing Date, the Pre-Funding Compensation Amount shall be due and payable by the Company to such Lender on the first Interest Payment Date following the Closing
Date. To the extent that all or any part of a Lender’s Pre-Advanced Funds are returned to such Lender for any reason and are not used to fund Loans, the Pre-Funding Compensation Amount shall be due and payable by the Company to such Lender
within one Business Day after demand. 
 (e) Except as otherwise provided herein, a Eurodollar Rate Loan may be continued or
converted only on the last day of an Interest Period for such Eurodollar Rate Loan. During the existence of an Event of Default, no Loans may be converted to or continued as Eurodollar Rate Loans without the consent of the Required Lenders.

 (f) The Administrative Agent will promptly notify the Company and the Lenders of the interest rate applicable to any Interest
Period for Eurodollar Rate Loans upon determination of such interest rate. At any time that Base Rate Loans are outstanding, the Administrative Agent will notify the Company and the Lenders of any change in the prime rate used in determining the
Base Rate promptly following the public announcement of such change. 
 (g) After giving effect to all Borrowings, all
conversions of Loans from one Type to the other, and all continuations of Loans as the same Type, there will not be more than ten Interest Periods in effect with respect to Loans. 

2.03 [Reserved]. 
 2.04 [Reserved]. 
 2.05 [Reserved]. 

2.06 Prepayments. The Company may, upon notice from it to the Administrative Agent, at any time or from time to time voluntarily
prepay Loans in whole or in part without premium or penalty; provided that (i) such notice must be received by the Administrative Agent not later than 11:00 a.m. (A) three Business Days prior to any date of prepayment of Eurodollar
Rate Loans and (B) on the date of prepayment of Base Rate Loans; (ii) any prepayment of 

  

			
	28	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Eurodollar Rate Loans will be in a principal amount of $5,000,000 or a whole multiple of $1,000,000 in excess thereof; and (iii) any prepayment of Base Rate Loans will be in a principal
amount of $500,000 or a whole multiple of $100,000 in excess thereof or, in each case, if less, the entire principal amount thereof then outstanding. Each such notice will specify the date and amount of such prepayment and the Type(s) of Loans to be
prepaid and, if Eurodollar Rate Loans are to be prepaid, the Interest Period(s) of such Loans. The Administrative Agent will promptly notify each Lender of its receipt of each such notice, and of the amount of such Lender’s Applicable
Percentage of such prepayment. If such notice is given by the Company, it will make such prepayment and the payment amount specified in such notice will be due and payable on the date specified therein. Any prepayment of a Eurodollar Rate Loan will
be accompanied by all accrued interest on the amount prepaid, together with any additional amounts required pursuant to Section 3.05. Each such prepayment will be applied to the Loans of the Lenders in accordance with their respective
Applicable Percentages and to the installments thereof as directed by the Company, or, in the absence of such direction, in direct order of maturity. Subject to the Company’s obligations under Section 3.05, prior to such prepayment,
the Company may rescind any notice of termination under this Section 2.06 if such termination would have resulted from a refinancing of all or a portion of the Loans, which refinancing shall not be consummated or shall otherwise be
delayed. 
 2.07 Termination or Reduction of Commitments. The Company may, upon notice to the Administrative Agent prior
to the Closing Date, terminate the Aggregate Commitments, or from time to time permanently reduce the Aggregate Commitments; provided that (i) any such notice will be received by the Administrative Agent not later than 11:00 a.m. five
Business Days prior to the date of termination or reduction, and (ii) any such partial reduction will be in an aggregate amount of $10,000,000 or any whole multiple of $1,000,000 in excess thereof. The Administrative Agent will promptly notify
the Lenders of any such notice of termination or reduction of the Aggregate Commitments. Any reduction of the Aggregate Commitments will be applied to the Commitment of each Lender according to its Applicable Percentage. All fees accrued until the
effective date of any termination of the Aggregate Commitments will be paid on the effective date of such termination. The Aggregate Commitments shall terminate automatically on the earliest of (a) February 28, 2013, if the Closing Date
has not occurred on or prior to such date, (b) the closing of the Acquisition without the use of Loans or (c) the termination of the Acquisition Agreement in accordance with its terms. 

2.08 Repayment of Loans. The Company will repay to each Lender in equal consecutive quarterly installments, commencing on
March 31, 2013 and on the last Business Day of each June, September, December and March thereafter, an amount equal to 2.50% of the stated principal amount of the Loans funded by such Lender on the Closing Date (which amounts shall be reduced
as a result of the application of prepayments in accordance with Section 2.06), with the remaining balance thereof payable on the Maturity Date; provided, however, that the final principal repayment installment of the Loans
shall be repaid on the Maturity Date and in any event shall be in an amount equal to the aggregate principal amount of all Loans outstanding on such date. 
 2.09 Interest. (a) Subject to the provisions of subsection (b) below, (i) each Eurodollar Rate Loan will bear interest on the outstanding principal amount thereof for each
Interest Period at a rate per annum equal to the Eurodollar Rate for such Interest Period plus the 

  

			
	29	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Applicable Rate; and (ii) each Base Rate Loan will bear interest on the outstanding principal amount thereof from the applicable borrowing date at a rate per annum equal to the Base Rate
plus the Applicable Rate. 
 (b) If any amount of principal of any Loan is not paid when due (without regard to any
applicable grace periods), whether at stated maturity, by acceleration or otherwise, such amount shall thereafter bear interest at a fluctuating interest rate per annum at all times equal to the Default Rate to the fullest extent permitted by
applicable Laws, payable on demand. 
 (c) Accrued and unpaid interest on past due amounts (including interest on past due
interest) shall be due and payable upon demand. 
 (d) Interest on each Loan will be due and payable in arrears on each Interest
Payment Date applicable thereto and at such other times as may be specified herein. Interest hereunder will be due and payable in accordance with the terms hereof before and after judgment, and before and after the commencement of any proceeding
under any Debtor Relief Law. 
 2.10 Fees. (a) Ticking Fee. The Company shall pay to the Administrative Agent
for the account of each Lender (other than a Defaulting Lender) in accordance with its Applicable Percentage, a ticking fee (the “Ticking Fee”) in US Dollars equal to 0.20% times the actual daily amount of undrawn Aggregate
Commitments. The Ticking Fee shall accrue at all times (other than any period during which the Administrative Agent shall hold Pre-Advanced Funds), from the Effective Date until the earlier of (x) the Closing Date and (y) the termination
of the Aggregate Commitments under this Agreement and shall be due and payable in arrears on the earlier of (x) the Closing Date and (y) the date of termination of the Aggregate Commitments under this Agreement. 

(b) Other Fees. (i) The Company will pay to the Arrangers and the Administrative Agent for their own respective accounts, in
US Dollars, fees in the amounts and at the times specified in the Fee Letters. Such fees will be fully earned when paid and will not be refundable for any reason whatsoever. 

(ii) The Company will pay to the Lenders, in US Dollars, such fees as will have been separately agreed upon in writing in
the amounts and at the times so specified. Such fees will be fully earned when paid and will not be refundable for any reason whatsoever. 
 2.11 Computation of Interest and Fees. All computations of interest for Base Rate Loans will be made on the basis of a year of 365 or 366 days, as the case may be, and actual days elapsed. All
other computations of fees and interest will be made on the basis of a 360-day year and actual days elapsed (which results in more fees or interest, as applicable, being paid than if computed on the basis of a 365-day year). Interest will accrue on
each Loan for the day on which the Loan is made, and will not accrue on a Loan, or any portion thereof, for the day on which the Loan or such portion is paid, provided that any Loan that is repaid on the same day on which it is made will,
subject to Section 2.13(a), bear interest for one day. Each determination by the Administrative Agent of an interest rate or fee hereunder will be conclusive and binding for all purposes, absent manifest error. 

  

			
	30	  	Watson Pharmaceuticals Term Loan Credit Agreement

 2.12 Evidence of Debt. The Loans made by each Lender will be evidenced by one or more
accounts or records maintained by such Lender and by the Administrative Agent in the ordinary course of business. The accounts or records maintained by the Administrative Agent and each Lender will be conclusive absent manifest error of the amount
of the Loans made by the Lenders to the Company and the interest and payments thereon. Any failure to so record or any error in doing so will not, however, limit or otherwise affect the obligation of the Company hereunder to pay any amount owing
with respect to the Obligations. The Administrative Agent will provide to the Company, upon its request, a statement of Loans, payments and other transactions pursuant to this Agreement. Such statement will be deemed correct, accurate, and binding
on the Company (except for corrections and errors discovered by the Administrative Agent), unless the Company notifies the Administrative Agent in writing to the contrary within thirty (30) days after such statement is rendered. In the event a
timely written notice of objections is given by the Company, only the items to which exception is expressly made will be considered to be disputed by the Company. In the event of any conflict between the accounts and records maintained by any Lender
and the accounts and records of the Administrative Agent in respect of such matters, the accounts and records of the Administrative Agent will control in the absence of manifest error. Upon the request of any Lender to the Company made through the
Administrative Agent, the Company will execute and deliver to such Lender (through the Administrative Agent) a Note, which will evidence such Lender’s Loans to the Company in addition to such accounts or records. Each Lender may attach
schedules to a Note and endorse thereon the date, Type (if applicable), amount and maturity of its Loans and payments with respect thereto. 
 2.13 Payments Generally; Administrative Agent’s Clawback. (a) General. All payments to be made by the Company will be made without condition or deduction for any counterclaim,
defense, recoupment or setoff. Except as otherwise expressly provided herein, all payments by the Company hereunder will be made to the Administrative Agent, for the account of the respective Lenders to which such payment is owed, at the applicable
Administrative Agent’s Office in US Dollars and in Same Day Funds not later than 1:00 p.m. on the date specified herein. The Administrative Agent will promptly distribute to each Lender (which is not a Defaulting Lender) its Applicable
Percentage (or other applicable share as provided herein) of such payment in like funds as received by wire transfer to such Lender’s Lending Office. All payments received by the Administrative Agent after 1:00 p.m. will be deemed received on
the next succeeding Business Day and any applicable interest or fee will continue to accrue. If any payment to be made by the Company will come due on a day other than a Business Day, payment will be made on the next following Business Day, except
(i) as otherwise set forth in the definition of Interest Period, or (ii) that no payment will extend past the Maturity Date, and such extension of time will be reflected in computing interest or fees, as the case may be. 

(b) Funding by Lenders; Presumption by Administrative Agent. (i) Unless the Administrative Agent will have received notice
from a Lender prior to the proposed date of any Borrowing of Eurodollar Rate Loans (or, in the case of any Borrowing of Base Rate Loans, prior to 1:00 p.m. on the date of such Borrowing) that such Lender will not make available to the Administrative
Agent such Lender’s share of such Borrowing, the Administrative Agent may assume that such Lender has made such share available on such date in accordance with Section 2.02 (or, in the case of a Borrowing of Base Rate Loans, that such
Lender has made such 

  

			
	31	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
share available in accordance with and at the time required by Section 2.02) and may, in reliance upon such assumption, make available to the Company a corresponding amount. In such
event, if a Lender has not in fact made its share of the applicable Borrowing available to the Administrative Agent, then the applicable Lender and the Company severally agree to pay to the Administrative Agent forthwith on demand such corresponding
amount in Same Day Funds with interest thereon, for each day from and including the date such amount is made available to the Company to but excluding the date of payment to the Administrative Agent, at (A) in the case of a payment to be made
by such Lender, the Overnight Rate, plus any administrative, processing or similar fees customarily charged by the Administrative Agent in connection with the foregoing, and (B) in the case of a payment to be made by the Company, the interest
rate applicable to Base Rate Loans. If the Company and such Lender will pay such interest to the Administrative Agent for the same or an overlapping period, the Administrative Agent will promptly remit to the Company the amount of such interest paid
by the Company for such period. If such Lender pays its share of the applicable Borrowing to the Administrative Agent, then the amount so paid will constitute such Lender’s Loan included in such Borrowing. Any payment by the Company will be
without prejudice to any claim the Company may have against a Lender that will have failed to make such payment to the Administrative Agent. 
 (ii) Payments by the Company; Presumptions by Administrative Agent. Unless the Administrative Agent will have received notice from the Company prior to the date on which any payment is due to the
Administrative Agent for the account of the Lenders hereunder that the Company will not make such payment, the Administrative Agent may assume that the Company has made such payment on such date in accordance herewith and may, in reliance upon such
assumption, distribute to the Lenders the amount due. In such event, if the Company has not in fact made such payment, then each of the Lenders severally agrees to repay to the Administrative Agent forthwith on demand the amount so distributed to
such Lender in Same Day Funds with interest thereon, for each day from and including the date such amount is distributed to it to but excluding the date of payment to the Administrative Agent, at the Overnight Rate. 

A notice of the Administrative Agent to any Lender or the Company with respect to any amount owing under this subsection
(b) will be conclusive, absent manifest error. 
 (c) Failure to Satisfy Conditions Precedent. If any Lender
makes available to the Administrative Agent funds for any Loan to be made by such Lender to the Company as provided in the foregoing provisions of this Article II, and such funds are not made available to the Company by the Administrative
Agent because the conditions to the applicable Borrowing set forth in Section 4.02 are not satisfied or waived in accordance with the terms hereof, the Administrative Agent will return such funds (in like funds as received from such
Lender) to such Lender as set forth in Section 2.02(d). 
 (d) Obligations of Lenders Several. The
obligations of the Lenders hereunder to make Loans and to make payments pursuant to Section 10.04(c) are several and not joint. The failure of any Lender to make any Loan or to make any payment under Section 10.04(c) on any
date required hereunder will not relieve any other Lender of its corresponding obligation to do so on such date, and no Lender will be responsible for the failure of any other Lender to so make its Loan, to purchase its participation or to make its
payment under Section 10.04(c). 

  

			
	32	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (e) Funding Source. Nothing herein will be deemed to obligate any Lender to obtain
the funds for any Loan in any particular place or manner or to constitute a representation by any Lender that it has obtained or will obtain the funds for any Loan in any particular place or manner. 

2.14 Sharing of Payments by Lenders. If any Lender will, by exercising any right of setoff or counterclaim or otherwise, obtain
payment in respect of any principal of or interest on any of the Loans made by it, resulting in such Lender’s receiving payment of a proportion of the aggregate amount of such Loans and accrued interest thereon greater than its pro rata share
thereof as provided herein, then the Lender receiving such greater proportion will (a) notify the Administrative Agent of such fact, and (b) purchase (for cash at face value) participations in the Loans of the other Lenders, or make such
other adjustments as will be equitable, so that the benefit of all such payments will be shared by the Lenders ratably in accordance with the aggregate amount of principal of and accrued interest on their respective Loans and other amounts owing
them, provided that: 
 (i) if any such participations are purchased and all or any portion of the
payment giving rise thereto is recovered, such participations will be rescinded and the purchase price restored to the extent of such recovery, without interest; and 

(ii) the provisions of this Section will not be construed to apply to (x) any payment made by the Company
pursuant to and in accordance with the express terms of this Agreement (including the application of funds arising from the existence of a Defaulting Lender), or (y) any payment obtained by a Lender as consideration for the assignment of or
sale of a participation in any of its Loans to any assignee or participant. 
 For purposes of this Section 2.14,
any calculation of pro rata shares of Loans will be determined on the basis of the aggregate principal amount of all Loans then outstanding. 
 The Company consents to the foregoing and agrees, to the extent it may effectively do so under applicable law, that any Lender acquiring a participation pursuant to the foregoing arrangements may exercise
against the Company rights of setoff and counterclaim with respect to such participation as fully as if such Lender were a direct creditor of the Company in the amount of such participation. 

2.15 [Reserved]. 
 2.16 [Reserved]. 
 2.17 Defaulting Lenders. 

(a) Adjustments. Notwithstanding anything to the contrary contained in this Agreement, if any Lender becomes a Defaulting Lender,
then, until such time as that Lender is no longer a Defaulting Lender, to the extent permitted by applicable Law: 
 (i) Waivers and Amendments. That Defaulting Lender’s right to approve or disapprove any amendment, waiver or consent with respect to this Agreement shall be restricted as set forth in
Section 10.01. 

  

			
	33	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (ii) Reallocation of Payments. Any payment of principal, interest,
fees or other amounts received by the Administrative Agent for the account of that Defaulting Lender (whether voluntary or mandatory, at maturity, pursuant to Article VIII or otherwise, and including any amounts made available to the
Administrative Agent by that Defaulting Lender pursuant to Section 10.08), shall be applied at such time or times as may be determined by the Administrative Agent as follows: first, to the payment of any amounts owing by that
Defaulting Lender to the Administrative Agent hereunder; second, as the Company may request (so long as no Default exists), to the funding of any Loan in respect of which that Defaulting Lender has failed to fund its portion thereof as
required by this Agreement, as determined by the Administrative Agent; third, if so determined by the Administrative Agent and the Company, to be held in a non-interest bearing deposit account and released in order to satisfy obligations of
that Defaulting Lender to fund Loans under this Agreement; fourth, to the payment of any amounts owing to the Lenders, as a result of any judgment of a court of competent jurisdiction obtained by any Lender, against that Defaulting Lender as
a result of that Defaulting Lender’s breach of its obligations under this Agreement; fifth, so long as no Default exists, to the payment of any amounts owing to the Company as a result of any judgment of a court of competent jurisdiction
obtained by the Company against that Defaulting Lender as a result of that Defaulting Lender’s breach of its obligations under this Agreement; and sixth, to that Defaulting Lender or as otherwise directed by a court of competent
jurisdiction; provided that if (x) such payment is a payment of the principal amount of any Loans in respect of which that Defaulting Lender has not fully funded its appropriate share and (y) such Loans were made at a time when the
conditions set forth in Section 4.02 were satisfied or waived, such payment shall be applied solely to pay the Loans of all non-Defaulting Lenders on a pro rata basis prior to being applied to the payment of any Loans of that Defaulting
Lender. Any payments, prepayments or other amounts paid or payable to a Defaulting Lender that are applied (or held) to pay amounts owed by a Defaulting Lender pursuant to this Section 2.17(a)(ii) shall be deemed paid to and redirected
by that Defaulting Lender, and each Lender irrevocably consents hereto. 
 (iii) Certain Fees. That
Defaulting Lender shall not be entitled to receive any Ticking Fee pursuant to Section 2.10(a) (and the Company shall not be required to pay any Ticking Fee that otherwise would have been required to have been paid to that Defaulting
Lender (nor shall any Ticking Fee that otherwise would have accrued with respect to that Defaulting Lender accrue)) for any period during which that Lender is a Defaulting Lender. 

(iv) No Default. Operation of the allocations provided in clause (ii) above shall not be deemed to
result in a default of the Company’s or any other Loan Party’s obligations to a Defaulting Lender under this Agreement or any other Loan Document. 
 (b) Defaulting Lender Cure. If the Company and the Administrative Agent agree in writing in their sole discretion that a Defaulting Lender should no longer be deemed to be a Defaulting Lender,
the Administrative Agent will so notify the parties hereto, whereupon as of the date such confirmation is so received or the effective date specified in such notice (and subject to any conditions set forth therein), as applicable, that Lender will,
to the extent applicable, purchase that portion of outstanding Loans of the other Lenders or take such other 

  

			
	34	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
actions as the Administrative Agent may determine to be necessary to cause the Loans to be held on a pro rata basis by the Lenders in accordance with their Applicable Percentages, together with
any payments reasonably determined by the Administrative Agent to be necessary to compensate the non-Defaulting Lenders for any loss, cost or expense of the type described in Section 3.05 (all of which purchases are hereby consented to
by the Company and each Lender) whereupon that Lender will cease to be a Defaulting Lender; provided that no adjustments will be made retroactively with respect to fees accrued or payments made by or on behalf of the Company while that Lender
was a Defaulting Lender; and provided, further, that except to the extent otherwise expressly agreed by the affected parties, no change hereunder from Defaulting Lender to Lender will constitute a waiver or release of any claim of any
party hereunder arising from that Lender’s having been a Defaulting Lender. 
 ARTICLE III. 

TAXES, YIELD PROTECTION AND ILLEGALITY 
 3.01 Taxes. 
 (a) Payments Free of Taxes; Obligation to Withhold;
Payments on Account of Taxes. 
 (i) Any and all payments by or on account of any obligation of the
Company hereunder or under any other Loan Document shall to the extent permitted by applicable Laws be made free and clear of and without reduction or withholding for any Taxes. If, however, applicable Laws require the Company or the Administrative
Agent to withhold or deduct any Tax, such Tax shall be withheld or deducted in accordance with such Laws as determined by the Company or the Administrative Agent, as the case may be, upon the basis of the information and documentation to be
delivered pursuant to subsection (e) below. 
 (ii) If the Company or the Administrative Agent shall
be required by applicable Law to withhold or deduct any Taxes, including both United States federal backup withholding and withholding taxes, from any payment, then (A) the Administrative Agent shall withhold or make such deductions as are
determined by the Administrative Agent to be required based upon the information and documentation it has received pursuant to Subsection (e) below, (B) the Administrative Agent shall timely pay the full amount withheld or deducted
to the relevant Governmental Authority in accordance with applicable Law, and (C) to the extent that the withholding or deduction is made on account of Indemnified Taxes, the sum payable by the Company shall be increased as necessary so that
after any required withholding or the making of all required deductions (including withholding or deductions applicable to additional sums payable under this Section 3.01) the Administrative Agent or Lender, as the case may be, receives
an amount equal to the sum it would have received had no such withholding or deduction been made. 
 (b) Payment of Other
Taxes by the Company. Without limiting the provisions of subsection (a) above, the Company shall timely pay any Other Taxes to the relevant Governmental Authority in accordance with applicable Laws, except for Other Taxes resulting
from an assignment by any Lender pursuant to Section 10.06(b), which assignment is not at the request of the Company pursuant to Section 10.13. 

  

			
	35	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (c) Tax Indemnifications. (i) Without limiting the provisions of subsection
(a) or (b) above, the Company shall, and does hereby, indemnify the Administrative Agent and each Lender, and shall make payment in respect thereof within 20 days after demand therefor, for the full amount of any Indemnified Taxes
(including Indemnified Taxes imposed or asserted on or attributable to amounts payable under this Section 3.01) paid by the Administrative Agent or such Lender, as the case may be, and any penalties, interest and reasonable expenses
arising therefrom or with respect thereto, whether or not such Indemnified Taxes were correctly or legally imposed or asserted by the relevant Governmental Authority. Each Lender and the Administrative Agent agrees to give written notice to the
Company of the assertion of any claim against such Lender or the Administrative Agent, as the case may be, relating to such Indemnified Taxes no later than 180 days after the principal officer of such party responsible for administering this
Agreement obtains knowledge thereof. The Company shall also, and does hereby, indemnify the Administrative Agent, and shall make payment in respect thereof within 10 days after demand therefor, for any amount which a Lender for any reason fails to
pay indefeasibly to the Administrative Agent as required by clause (ii) of this subsection after the Administrative Agent has exercised such remedies provided in clause (ii) of this subsection as the Administrative Agent in
its good faith discretion determines to be appropriate. A certificate as to the amount of any such payment or liability delivered to the Company by a Lender (with a copy to the Administrative Agent), or by the Administrative Agent on its own behalf
or on behalf of a Lender, shall be conclusive absent manifest error. 
 (ii) Without limiting the provisions of
subsection (a) or (b) above, each Lender shall, and does hereby, indemnify the Company and the Administrative Agent, and shall make payment in respect thereof within 20 days after demand therefor, against any and all Taxes
and any and all related losses, claims, liabilities, penalties, interest and expenses (including the fees, charges and disbursements of any counsel for the Company or the Administrative Agent) incurred by or asserted against the Company or the
Administrative Agent by any Governmental Authority as a result of the failure by such Lender to deliver, or as a result of the inaccuracy, inadequacy or deficiency of, any documentation required to be delivered by such Lender to the Company or the
Administrative Agent pursuant to subsection (e). Each Lender hereby authorizes the Administrative Agent (on its own behalf or on behalf of such Lender) to set off and apply any and all amounts (including interest and fees) at any time owing
to such Lender under this Agreement or any other Loan Document against any amount due to the Administrative Agent under this clause (ii). The agreements in this clause (ii) shall survive the resignation and/or replacement of the
Administrative Agent, any assignment of rights by, or the replacement of, a Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all other Obligations. 

(d) Evidence of Payments. Upon request by the Company or the Administrative Agent, as the case may be, after any payment of
Taxes by the Company or by the Administrative Agent to a Governmental Authority as provided in this Section 3.01, the Company shall deliver to the Administrative Agent or the Administrative Agent shall deliver to the Company, as the case
may be, the original or a certified copy of a receipt issued by such Governmental Authority 

  

			
	36	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
evidencing such payment, a copy of any return required by Laws to report such payment or other evidence of such payment reasonably satisfactory to the Company or the Administrative Agent, as the
case may be. 
 (e) Status of Lenders; Tax Documentation. (i) Each Lender and the Administrative Agent shall deliver
to the Company and to the Administrative Agent (if applicable), at the time or times prescribed by applicable Laws or when reasonably requested by the Company or the Administrative Agent, such properly completed and executed documentation prescribed
by applicable Laws or by the taxing authorities of any jurisdiction and such other reasonably requested information as will permit the Company or the Administrative Agent, as the case may be, to determine (A) whether or not payments made by the
Company hereunder or under any other Loan Document are subject to Taxes, (B) if applicable, the required rate of withholding or deduction, and (C) the entitlement of such Lender or the Administrative Agent to any available exemption from,
or reduction of, applicable Taxes in respect of all payments to be made to such Person by the Company pursuant to this Agreement or otherwise to establish such Person’s status for withholding tax purposes in the applicable jurisdictions.
Notwithstanding anything to the contrary in this Section 3.01(e), the completion, execution and submission of the documentation referred to in this Section 3.01(e) (other than specific forms set forth in Sections
3.01(e)(ii)(A) and (B) below) shall not be required if in such Lender’s judgment such completion, execution or submission would subject such Lender to any material unreimbursed cost or expense or materially prejudice the legal
or commercial position of such Lender. 
 (ii) Without limiting the generality of the foregoing, 

(A) any Lender or Administrative Agent that is a “United States person” within the meaning of
Section 7701(a)(30) of the Code shall, on or prior to the date it becomes a party to this Agreement (and from time to time thereafter upon the expiration, obsolescence or invalidity of any form, documentation or information previously delivered
pursuant to this clause (A)), deliver to the Company and the Administrative Agent two properly completed and executed originals of Internal Revenue Service Form W-9 or such other documentation or information prescribed by applicable Laws or
reasonably requested by the Company or the Administrative Agent as will establish its exemption from backup withholding; and 
 (B) each Foreign Lender that is entitled under the Code or any applicable treaty to an exemption from or reduction of withholding tax with respect to payments hereunder or under any other Loan
Document shall deliver to the Company and the Administrative Agent on or prior to the date on which such Foreign Lender becomes a Foreign Lender under this Agreement (and from time to time thereafter upon the expiration, obsolescence or invalidity
of any form, documentation or information previously delivered pursuant to this clause (B), or upon the request of the Company or the Administrative Agent, but only if such Foreign Lender is legally entitled to do so), two of whichever of the
following is applicable: 

  

			
	37	  	Watson Pharmaceuticals Term Loan Credit Agreement

	 	(I)	properly completed and executed originals of Internal Revenue Service Form W-8BEN (or successor form) claiming eligibility for benefits of an income tax treaty to which
the United States is a party, 

  

	 	(II)	properly completed and executed originals of Internal Revenue Service Form W-8ECI or W-8EXP (or successor form), 

 

	 	(III)	to the extent a Foreign Lender is not the beneficial owner of such payments, properly completed and executed originals of IRS Form W-8IMY (or successor form),
accompanied by IRS Form W-8ECI, IRS Form W-8BEN, and all required supporting documentation, IRS Form W-9, and/or other certification documents from each beneficial owner, as applicable; provided that if the Foreign Lender is a partnership for
U.S. federal income tax purposes and one or more direct or indirect partners of such Foreign Lender are claiming the portfolio interest exemption, such Foreign Lender may provide certification documents on behalf of each such direct and indirect
partner, 

  

	 	(IV)	in the case of a Foreign Lender claiming the benefits of the exemption for portfolio interest under section 881(c) of the Code, (x) a certificate substantially in
the form of Exhibit J-1, J-2, J-3 or J-4, as applicable, and (y) properly completed and executed originals of Internal Revenue Service Form W-8BEN (or successor form), or 

 

	 	(V)	properly completed and executed originals of any other form prescribed by applicable Laws as a basis for claiming exemption from or a reduction in United States federal
withholding tax together with such supplementary documentation as may be prescribed by applicable Laws to permit the Company or the Administrative Agent to determine the withholding or deduction required to be made. 

(iii) Each Lender and the Administrative Agent shall promptly (A) notify the Company and the Administrative Agent (if
applicable) of any change in circumstances which would modify or render invalid any claimed exemption or reduction, and (B) take such steps as shall not be materially disadvantageous to it, in the reasonable judgment of such Person, and as may
be reasonably necessary (including, in the case of any Lender, the re-designation of its Lending Office) to avoid any requirement of applicable Laws of any jurisdiction that the Company or the Administrative Agent make any withholding or deduction
for taxes from amounts payable to such Person. 

  

			
	38	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (iv) The Company shall promptly deliver to the Administrative Agent or any
Lender, as the Administrative Agent or such Lender shall reasonably request, in a timely fashion after the Effective Date, such documents and forms required by any relevant taxing authorities under the Laws of any jurisdiction, duly executed and
completed by the Company, as are required to be furnished by such Lender or the Administrative Agent under such Laws in connection with any payment by the Administrative Agent or any Lender of Taxes or Other Taxes, or otherwise in connection with
the Loan Documents, with respect to such jurisdiction. 
 (f) Treatment of Certain Refunds. Unless required by applicable
Laws, at no time shall the Administrative Agent have any obligation to file for or otherwise pursue on behalf of a Lender, or have any obligation to pay to any Lender, any refund of Taxes withheld or deducted from funds paid for the account of such
Lender. If the Administrative Agent or any Lender determines, in its sole discretion reasonably exercised in good faith, that it has received a refund (including, for this purpose, a credit in lieu of a refund) of any Taxes or Other Taxes as to
which it has been indemnified by the Company or with respect to which the Company has paid additional amounts pursuant to this Section 3.01, it shall pay to the Company an amount equal to such refund (but only to the extent of indemnity
payments made, or additional amounts paid, by the Company under this Section 3.01 with respect to the Taxes or Other Taxes giving rise to such refund), net of all out-of-pocket expenses incurred by the Administrative Agent or such
Lender, as the case may be, and without interest (other than any interest paid by the relevant Governmental Authority with respect to such refund), provided that the Company, upon the request of the Administrative Agent or such Lender, agrees
to repay the amount paid over to the Company to the Administrative Agent or such Lender in the event the Administrative Agent or such Lender is required to repay such refund to such Governmental Authority. This subsection shall not be construed to
require the Administrative Agent or any Lender to make available its tax returns (or any other information relating to its taxes that it deems confidential) to the Company or any other Person. 

(g) Additional Withholding Documentation. If a payment made to a Lender under this Agreement may be subject to United States
federal withholding tax under FATCA, such Lender shall deliver to the Company and the Administrative Agent, at the time or times prescribed by applicable Law and at such time or times reasonably requested by the Company or the Administrative Agent,
such documentation prescribed by applicable Law and such additional documentation reasonably requested by the Company or the Administrative Agent to comply with its withholding obligations, to determine that such Lender has complied with such
Lender’s obligations under FATCA or to determine the amount to deduct and withhold from such payment. Solely for purposes of this subsection (g), “FATCA” shall include any amendments made to FATCA after the Effective Date. 

3.02 Illegality. If any Lender determines that any Law has made it unlawful, or that any Governmental Authority has asserted that
it is unlawful, for any Lender or its applicable Lending Office to make, maintain or fund Eurodollar Rate Loans in US Dollars or to determine or charge interest rates based upon the Eurodollar Rate, or any Governmental Authority has imposed material
restrictions on the authority of such Lender to purchase or sell, or to take deposits of, US Dollars in the London interbank market, then, on notice thereof by such Lender to the Company through the Administrative Agent, (i) any obligation of
such Lender to make or 

  

			
	39	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
continue Eurodollar Rate Loans or to convert Base Rate Loans to Eurodollar Rate Loans will be suspended, and (ii) if such notice asserts the illegality of such Lender making or maintaining
Base Rate Loans the interest rate on which is determined by reference to the Eurodollar Rate component of the Base Rate, the interest rate on which Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the
Administrative Agent without reference to the Eurodollar Rate component of the Base Rate, in each case until such Lender notifies the Administrative Agent and the Company that the circumstances giving rise to such determination no longer exist. Upon
receipt of such notice, (x) the Company will, upon demand from such Lender (with a copy to the Administrative Agent), prepay or, if applicable, convert all such Eurodollar Rate Loans of such Lender to Base Rate Loans (the interest rate on which
Base Rate Loans of such Lender shall, if necessary to avoid such illegality, be determined by the Administrative Agent without reference to the Eurodollar Rate component of the Base Rate), either on the last day of the Interest Period therefor, if
such Lender may lawfully continue to maintain such Eurodollar Rate Loans to such day, or immediately, if such Lender may not lawfully continue to maintain such Eurodollar Rate Loans and (y) if such notice asserts the illegality of such Lender
determining or charging interest rates based upon the Eurodollar Rate, the Administrative Agent shall during the period of such suspension compute the Base Rate applicable to such Lender without reference to the Eurodollar Rate component thereof
until the Administrative Agent is advised in writing by such Lender that it is no longer illegal for such Lender to determine or charge interest rates based upon the Eurodollar Rate. Upon any such prepayment or conversion, the Company will also pay
accrued interest on the amount so prepaid or converted. 
 3.03 Inability to Determine Rates. If the Required Lenders
determine that for any reason in connection with any request for a Eurodollar Rate Loan or a conversion to or continuation thereof that (a) US Dollar deposits are not being offered to banks in the London interbank market for the applicable
amount and Interest Period of such Eurodollar Rate Loan, (b) adequate and reasonable means do not exist for determining the Eurodollar Rate for any requested Interest Period with respect to a proposed Eurodollar Rate Loan or in connection with
an existing or proposed Base Rate Loan, or (c) the Eurodollar Rate for any requested Interest Period with respect to a proposed Eurodollar Rate Loan does not adequately and fairly reflect the cost to such Lenders of funding such Eurodollar Rate
Loan, the Administrative Agent will promptly so notify the Company and each Lender. Thereafter, (x) the obligation of the Lenders to make or maintain Eurodollar Rate Loans will be suspended and (y) in the event of a determination described
in the preceding sentence with respect to the Eurodollar Rate component of the Base Rate, the utilization of the Eurodollar Rate component in determining the Base Rate shall be suspended, in each case until the Administrative Agent (upon the
instruction of the Required Lenders) revokes such notice. Upon receipt of such notice, the Company may revoke any pending request for a Borrowing of, conversion to or continuation of Eurodollar Rate Loans or, failing that, will be deemed to have
converted such request into a request for a Borrowing of Base Rate Loans in the amount specified therein. 
 3.04 Increased
Costs; Additional Reserve Requirements. 
 (a) Increased Costs Generally. If any Change in Law will: (i) impose,
modify or deem applicable any reserve, special deposit, compulsory loan, insurance charge or similar requirement against assets of, deposits with or for the account of, or credit extended or participated in by, any Lender (except any reserve
requirement contemplated by Section 3.04(e)); 

  

			
	40	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (ii) subject any Lender to any tax of any kind whatsoever with respect
to this Agreement or any Loan made by it, or change the basis of taxation of payments to such Lender in respect thereof (except for Indemnified Taxes or Other Taxes covered by Section 3.01 and the imposition of, or any change in the rate
of, any Excluded Tax payable by such Lender); or 
 (iii) impose on any Lender or the London interbank
market any other condition, cost or expense affecting this Agreement or Loans made by such Lender; 
 and the result of any of the foregoing
will be to increase the cost to such Lender of making or maintaining any Loan (or of maintaining its obligation to make any such Loan), or to reduce the amount of any sum received or receivable by such Lender hereunder (whether of principal,
interest or any other amount) then, upon request of such Lender, the Company will pay to such Lender such additional amount or amounts as will compensate such Lender for such additional costs incurred or reduction suffered. 

(b) Capital Requirements. If any Lender determines that any Change in Law affecting such Lender or any Lending Office of such
Lender or such Lender’s holding company, if any, regarding capital requirements has or would have the effect of reducing the rate of return on such Lender’s capital or on the capital of such Lender’s holding company as a consequence
of this Agreement, the Commitments of such Lender or the Loans made by such Lender to a level below that which such Lender could have achieved but for such Change in Law (taking into consideration such Lender’s policies with respect to capital
adequacy), then from time to time the Company will pay to such Lender such additional amount or amounts as will compensate such Lender for any such reduction suffered. 
 (c) Certificates for Reimbursement. A certificate of a Lender setting forth the amount or amounts necessary to compensate such Lender or its holding company, as the case may be, as specified in
subsection (a) or (b) of this Section and delivered to the Company will be conclusive absent manifest error. The Company will pay such Lender the amount shown as due on any such certificate within 10 days after receipt
thereof. 
 (d) Delay in Requests. Failure or delay on the part of any Lender to demand compensation pursuant to the
foregoing provisions of this Section will not constitute a waiver of such Lender’s right to demand such compensation, provided that the Company will not be required to compensate a Lender pursuant to the foregoing provisions of this
Section for any increased costs incurred or reductions suffered more than three months prior to the date that such Lender notifies the Company of the Change in Law giving rise to such increased costs or reductions and of such Lender’s intention
to claim compensation therefor (except that, if the Change in Law giving rise to such increased costs or reductions is retroactive, then the three-month period referred to above will be extended to include the period of retroactive effect thereof).

  

			
	41	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (e) Additional Reserve Requirements. The Company shall pay to each Lender,
(i) as long as such Lender shall be required by a central banking or financial regulatory authority with regulatory authority over such Lender to maintain reserves with respect to liabilities or assets consisting of or including Eurodollar
funds or deposits (currently known as “Eurocurrency liabilities”), additional interest on the unpaid principal amount of each Eurodollar Rate Loan equal to the actual costs of such reserves allocable to such Loan by such Lender (as
determined by such Lender in good faith, which determination shall be conclusive absent manifest error), and (ii) as long as such Lender shall be required to comply with any reserve ratio requirement or analogous requirement of any other
central banking or financial regulatory authority imposed in respect of the maintenance of the Commitments or the funding of the Eurodollar Rate Loans, such additional costs (expressed as a percentage per annum and rounded upwards, if necessary, to
the nearest five decimal places) equal to the actual costs allocated to such Commitment or Loan by such Lender (as determined by such Lender in good faith, which determination shall be conclusive absent manifest error), which in each case shall be
due and payable on each date on which interest is payable on such Loan, provided, that the Company shall have received at least 10 days’ prior notice (with a copy to the Administrative Agent) of such additional interest or costs from
such Lender with a reasonably detailed explanation of the regulatory requirements imposing such costs and a calculation of the allocation of such costs to the relevant Loan or Commitment. If a Lender fails to give notice 10 days prior to the
relevant Interest Payment Date, such additional interest or costs shall be due and payable 10 days from receipt of a proper notice. Notwithstanding the foregoing, if any reserves described in this clause (e) are based upon the financial
strength or creditworthiness of a Lender, for the purposes of calculating the actual costs of a Lender with respect to such reserves, each such Lender shall be deemed to be in the highest applicable category of financial strength or
creditworthiness. 
 3.05 Compensation for Losses. Upon demand of any Lender (with a copy to the Administrative Agent)
from time to time, the Company will promptly compensate such Lender for and hold such Lender harmless from any loss, cost or expense incurred by it as a result of: 
 (a) any continuation, conversion, payment or prepayment of any Loan other than a Base Rate Loan on a day other than the last day of the Interest Period for such Loan (whether voluntary, mandatory,
automatic, by reason of acceleration, or otherwise); 
 (b) any failure by the Company (for a reason other than the failure of
such Lender to make a Loan) to prepay, borrow, continue or convert any Loan other than a Base Rate Loan on the date or in the amount notified by the Company; 
 (c) any assignment of a Eurodollar Rate Loan on a day other than the last day of the Interest Period therefor as a result of a request by the Company pursuant to Section 10.13; or 

(d) with respect to amounts due pursuant to subsection (a) or (b) of this Section as a result of any Change in
Law relating to the Dodd-Frank Wall Street Reform and Consumer Protection Act or Basel III, the claim for additional amounts shall be generally consistent with such Lender’s treatment of customers of such Lender that such Lender considers, in
its reasonable discretion, to be similarly situated as the Company and having generally similar provisions in their credit agreements with such Lender. 

  

			
	42	  	Watson Pharmaceuticals Term Loan Credit Agreement

 For purposes of calculating amounts payable by the Company to the Lenders under this
Section 3.05, each Lender will be deemed to have funded each Eurodollar Rate Loan made by it at the Eurodollar Rate for such Loan by a matching deposit or other borrowing in the London interbank market for a comparable amount and for a
comparable period, whether or not such Eurodollar Rate Loan was in fact so funded. 
 3.06 Mitigation Obligations;
Replacement of Lenders. 
 (a) Designation of a Different Lending Office. If any Lender requests compensation under
Section 3.04, or the Company is required to pay any additional amount to any Lender or any Governmental Authority for the account of any Lender pursuant to Section 3.01, or if any Lender gives a notice pursuant to
Section 3.02, then such Lender will use reasonable efforts to designate a different Lending Office for funding or booking its Loans hereunder or to assign its rights and obligations hereunder to another of its offices, branches or
affiliates, if, in the judgment of such Lender, such designation or assignment (i) would eliminate or reduce amounts payable pursuant to Section 3.01 or 3.04, as the case may be, in the future, or eliminate the need for the
notice pursuant to Section 3.02, as applicable, and (ii) in each case, would not subject such Lender to any unreimbursed cost or expense and would not otherwise be disadvantageous to such Lender. The Company hereby agrees to pay all
reasonable costs and expenses incurred by any Lender in connection with any such designation or assignment. 
 (b)
Replacement of Lenders. In the event (i) any Lender requests compensation under Section 3.04, (ii) the Company is required to pay any additional amount to any Lender or any Governmental Authority for the account of any
Lender pursuant to Section 3.01, (iii) any Lender becomes a Defaulting Lender or (iv) any Lender refuses to consent to any amendment, waiver or other modification of this Agreement or any other Loan Document requested by the
Company that requires the consent of a greater percentage of the Lenders than the Required Lenders and such amendment, waiver or other modification is consented to by the Required Lenders, then the Company may replace such Lender in accordance with
Section 10.13. Each Lender hereby grants to the Company an irrevocable power of attorney (which power is coupled with an interest) to execute and deliver, on behalf of such Lender, as assignor, any Assignment and Assumption necessary to
effectuate any assignment in full of such Lender’s interests hereunder (including, subject to Section 2.17(a)(iii), the payment of accrued Ticking Fees) solely in the event that such Lender becomes a Defaulting Lender prior to the
Closing Date. The Company shall notify the Administrative Agent in advance of any exercise of the power of attorney referenced in the preceding sentence. 
 3.07 Survival. All of the Company’s obligations under this Article III will survive termination of the Aggregate Commitments and repayment of all other Obligations hereunder.

 ARTICLE IV. 
 CONDITIONS PRECEDENT 
 4.01 Conditions to Effectiveness. The
effectiveness of this Agreement and the Commitment of each Lender hereunder is subject solely to the Administrative Agent’s receipt of executed counterparts of this Agreement, each of which may be delivered by facsimile or other electronic
transmission (including “pdf” and “tif”), each executed by a Responsible 

  

			
	43	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Officer of the Company and a duly authorized officer of each Lender. The Administrative Agent shall promptly notify the Company and the Lenders of the Effective Date in writing, and such notice
shall be conclusive and binding. 
 4.02 Conditions to Borrowing. The obligation of each Lender to make its Loans
hereunder on the Closing Date is subject solely to satisfaction (or waiver) of the following conditions precedent, and upon satisfaction (or waiver) of such conditions each Lender shall make its Loans hereunder on the Closing Date: 

(a) The Administrative Agent’s receipt of the following, each of which may be delivered by facsimile or other electronic
transmission (including “pdf” and “tif”), followed promptly after the Closing Date by originals unless otherwise specified, each properly executed by a Responsible Officer of the Company, and each dated the Closing Date (or, in
the case of certificates of governmental officials, a recent date before the Closing Date); provided that the delivery of any originals is not a condition precedent to the obligation of any Lender to make its Loans hereunder on the Closing
Date: 
 (i) Notes executed by the Company in favor of each Lender requesting a Note at least two Business
Days prior to the Closing Date; 
 (ii) a certificate signed by a Responsible Officer of the Company
(A) certifying and attaching the resolutions adopted by the Company authorizing the execution, delivery and performance of this Agreement and the Notes, (B) certifying as to the incumbency and specimen signature of each Responsible Officer
executing this Agreement and the Notes, (C) attaching a good standing certificate and a certificate of incorporation evidencing that the Company is validly existing and in good standing in the State of Nevada, (D) certifying and attaching
a true and complete copy of the by-laws of the Company, and (E) certifying that the conditions specified in Sections 4.02 (b), (c) and (d) have been satisfied on and as of the Closing Date, in the form attached as
Exhibit G hereto; 
 (iii) an executed legal opinion of (A) Latham & Watkins, LLP,
special New York counsel for the Company, addressed to the Administrative Agent and each Lender and dated the Closing Date, substantially in the form attached hereto as Exhibit H-1 and (B) Greenberg Traurig LLP, special Nevada counsel
for the Company, addressed to the Administrative Agent and each Lender and dated the Closing Date, substantially in the form attached hereto as Exhibit H-2; 

(iv) a certificate as to the financial condition and solvency of the Company and its Subsidiaries (on a consolidated
basis, after giving effect to the Transaction), in the form attached as Exhibit I hereto; 
 (v) the
receipt of a Loan Notice in accordance with the requirements hereof; and 
 (vi) (A) for each fiscal
quarter of the 2012 fiscal year ended 45 days or more prior to the Closing Date, unaudited balance sheets and related statements of operations and cash flows of the Company and the Target Companies for such fiscal quarter and for

  

			
	44	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
the elapsed period of the 2012 fiscal year and for the comparable periods of the prior fiscal year (the “Quarterly Financial Statements”); (B) any audited and unaudited
financial statements not otherwise provided hereunder that are included in the registration statement under the Securities Act relating to the “Notes” (as defined in the Commitment Letter) and (C) a pro forma balance sheet and related
statement of operations of the Company for fiscal year 2011 and for the latest four-quarter period ending with the latest fiscal quarter covered by the Quarterly Financial Statements (if the Closing Date occurs on or before December 31, 2012,
such latest fiscal quarter shall be deemed to be the fiscal quarter ending June 30, 2012), in each case after giving effect to the Transaction, promptly after the historical financial statements for such periods are available, all of which
financial statements shall meet the requirements of Regulation S-X under the Securities Act and all other accounting rules and regulations of the SEC promulgated thereunder applicable to a registration statement under the Securities Act on Form S-1
for the Company (the “Pro Forma Financial Statements”); provided that the Company may satisfy its obligations to deliver financial statements under this clause (vi) by filing such statements with the SEC.

 (b) There shall not have occurred a Target Material Adverse Effect. 

(c) The Acquisition shall have been or shall be, contemporaneously with the making of the Loans, consummated in accordance with the terms
of the Acquisition Agreement, without giving effect to any amendments, modifications, supplements, waivers or consents by the Company thereto that are materially adverse to the interests of the Lenders not approved by the Administrative Agent (which
approval shall not be unreasonably withheld, conditioned or delayed). It is understood and agreed that any reduction in the purchase price (which, for the avoidance of doubt, shall not include any adjustment or decrease to the purchase price
pursuant to clauses (i) through (vi) of Section 3.1(a) or Section 3.1(b) of the Acquisition Agreement) shall be deemed to be materially adverse to the interest of the Lenders; provided that a reduction in the purchase
price of ten percent (10%) or less shall not be deemed material as long as the amount of the reduction is applied to reduce, on a pro rata basis, (x) the Aggregate Commitments and (y) the Notes (as defined in the Commitment Letter)
or, if such Notes have not been issued on or prior to the Closing Date, the Bridge Facility. 
 (d) The Acquisition Agreement
Representations and the Specified Representations shall be true and correct. For the avoidance of doubt, if the conditions set forth in this Section 4.02 are satisfied, the absence of any Default shall not be a condition precedent to the
Borrowing hereunder. 
 (e) All fees due to the Administrative Agent, the Arrangers and the Lenders pursuant to the Fee Letters
and, to the extent invoiced at least two Business Days prior to the Closing Date, all reasonable and documented expenses to be paid or reimbursed to the Administrative Agent and the Arrangers on or prior to the Closing Date pursuant to the
Commitment Letter, shall have been paid through the closing proceeds. 
 (f) To the extent requested at least 10 days prior to
the Closing Date by the Administrative Agent, the Company shall have delivered the documentation and other information with respect to the Company to the Administrative Agent that is required by regulatory authorities under applicable
“know-your-customer” rules and regulations, including the Patriot Act, prior to the Closing Date. 

  

			
	45	  	Watson Pharmaceuticals Term Loan Credit Agreement

 Without limiting the generality of the provisions of Section 9.04, for purposes
of determining compliance with the conditions specified in this Section 4.02, each Lender will be deemed to have consented to, approved or accepted or to be satisfied with, each document or other matter required thereunder to be
consented to or approved by or acceptable or satisfactory to a Lender unless the Administrative Agent will have received notice from such Lender prior to the proposed Closing Date specifying its objection thereto. 

For the avoidance of doubt, the conditions in this Section 4.02 shall not be conditions to the funding of each Lender’s
Applicable Percentage of the Loans on the Pre-Funding Date. 
 ARTICLE V. 

REPRESENTATIONS AND WARRANTIES 
 The Company represents and warrants to the Administrative Agent and the Lenders on the Closing Date (or, in the case of any of the following that is made solely as of any specific date, such specific
date); provided that, to the extent the Company is unable to make any of the following representations or warranties due to the inaccuracy thereof, the Company shall be deemed to have made such representation or warranty for all purposes
hereunder and there shall be a Default hereunder, subject to Section 8.04 and the last sentence of Section 4.02(d): 
 5.01 Existence, Qualification and Power. The Company and each Material Subsidiary thereof (a) is duly organized or formed, validly existing and in good standing (or the local equivalent) under
the Laws of the jurisdiction of its incorporation or organization, (b) has all requisite power and authority and all requisite governmental licenses, authorizations, consents and approvals to (i) own or lease its assets and carry on its
business and (ii) execute, deliver and perform its obligations under the Loan Documents to which it is a party, and (c) is duly qualified and is licensed and in good standing (or the local equivalent) under the Laws of each jurisdiction
where its ownership, lease or operation of properties or the conduct of its business requires such qualification or license; except in the case referred to in clause (a) with respect to any non-Loan Party only and in each case referred
to in clause (b)(i) or (c), to the extent that failure to do so would not reasonably be expected to have a Material Adverse Effect. 
 5.02 Authorization; No Contravention. The execution, delivery and performance by each Loan Party of each Loan Document to which such Person is party, have been duly authorized by all necessary
corporate or other organizational action, and do not and will not (a) contravene in any material respects the terms of any such Person’s Organization Documents; (b) conflict with or result in any breach or contravention of, or the
creation of any Lien under, or require any payment to be made under (i) any Contractual Obligation to which such Person is a party or affecting such Person or the properties of such Person or any of its Material Subsidiaries or (ii) any
order, injunction, writ or decree of any Governmental Authority or any arbitral award to which such Person or its property is subject; or (c) violate in any material respects any material Law; except in each case referred to in clause
(b) or (c), to the extent that failure to do so would not reasonably be expected to have a Material Adverse Effect. 

  

			
	46	  	Watson Pharmaceuticals Term Loan Credit Agreement

 5.03 Material Governmental Authorization; Other Material Consents. Other than any
filings with the SEC, no approval, consent, exemption, authorization, or other action by, or notice to, or filing with, any Governmental Authority or any other Person is necessary or required in connection with the execution, delivery or performance
by, or enforcement against, any Loan Party of this Agreement or any other Loan Document to which it is a party. 
 5.04
Binding Effect. This Agreement has been, and each other Loan Document, when delivered hereunder, will have been, duly executed and delivered by each Loan Party that is party thereto. This Agreement constitutes, and each other Loan Document when
so delivered will constitute, a legal, valid and binding obligation of such Loan Party, enforceable against such Loan Party in accordance with its terms, subject to applicable Debtor Relief Laws and the effect of general principles of equity,
whether applied by a court of law or equity. 
 5.05 Financial Statements. (a) The Pro Forma Financial Statements
(i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein and (ii) fairly present in all material respects on a pro forma basis the estimated
financial position of the Company and its Subsidiaries as of the date thereof (as if the Transaction had been consummated on such date) and their estimated results of operations for the period covered thereby in accordance with GAAP consistently
applied throughout the period covered thereby (as if the Transaction had been consummated at the beginning of such period), except as otherwise expressly noted therein. 
 (b) The Quarterly Financial Statements (i) were prepared in accordance with GAAP consistently applied throughout the period covered thereby, except as otherwise expressly noted therein, and
(ii) fairly present in all material respects the financial condition of the Company and its Subsidiaries as of the date thereof and their results of operations for the period covered thereby, subject, in the case of clauses (i) and
(ii), to the absence of footnotes and to normal year-end audit adjustments. 
 (c) As of the Effective Date, since
December 31, 2011, except for events and circumstances disclosed in the Company SEC Documents filed or furnished after January 1, 2012 (other than disclosure in the Company SEC Documents referred to solely in the “Risk Factors”
and “Forward Looking Statements” sections thereof or similar statements included in such Company SEC Documents that are solely forward looking in nature) there has been no event or circumstance, either individually or in the aggregate,
that has had or would reasonably be expected to have a Material Adverse Effect. 
 5.06 Litigation; Absence of
Injunction. (a) There are no actions, suits, proceedings, claims or disputes pending or, to the knowledge of the Company, threatened in writing, at law, in equity, in arbitration or before any Governmental Authority, by or against the
Company or any of its Subsidiaries or against any of their respective properties that (i) purport to affect or pertain to this Agreement or any other Loan Document, or any of the transactions contemplated hereby, or (ii) except as
specifically disclosed in Company SEC Documents filed or furnished on or before the Effective Date or on Schedule 5.06, either individually or in the aggregate, if determined adversely, would reasonably be expected to have a Material Adverse
Effect. 

  

			
	47	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (b) There is no court order (by any court of competent jurisdiction) in effect on the
Closing Date enjoining the Lenders from making Loans hereunder. 
 5.07 No Default. Neither the Company nor any
Subsidiary is in default under or with respect to any Contractual Obligation that could, either individually or in the aggregate, reasonably be expected to have a Material Adverse Effect. 

5.08 Ownership of Property; Liens. Each of the Company and each Subsidiary has good record and marketable title in fee simple to,
or valid leasehold interests in, all real property necessary or used in the ordinary conduct of its business, except for such defects in title as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.

 5.09 Environmental Compliance. The Company and its Subsidiaries conduct in the ordinary course of business a review of
the effect of existing Environmental Laws and claims alleging potential liability or responsibility for violation of any Environmental Law on their respective businesses, operations and properties, and as a result thereof the Company has reasonably
concluded that such Environmental Laws and claims would not, except as specifically disclosed in Company SEC Documents filed or furnished on or before the Effective Date, individually or in the aggregate, reasonably be expected to have a Material
Adverse Effect. 
 5.10 Solvency. The Company and its Subsidiaries, on a consolidated basis, will be Solvent after giving
effect to the Transaction. 
 5.11 Insurance. The Company and its Material Subsidiaries are insured with financially
sound and reputable insurance companies, in such amounts (after giving effect to any self-insurance), with such deductibles and covering such risks as are customarily carried by companies engaged in similar businesses and owning similar properties
in localities where the Company or the applicable Material Subsidiary operates. 
 5.12 Taxes. The Company and its
Material Subsidiaries have filed or caused to be filed all material federal, state and other tax returns and reports required to be filed by them, and have paid all material federal, state and other taxes, assessments, fees and other governmental
charges levied or imposed upon them or their properties, income or assets otherwise due and payable, except (a) those which are being contested in good faith by appropriate proceedings diligently conducted and for which adequate reserves have
been provided in accordance with GAAP or (b) to the extent that the failure to do so would not reasonably be expected to result in a Material Adverse Effect. 
 5.13 Patriot Act. The condition specified in Section 4.02(f) has been satisfied.  
 5.14 ERISA. (a) Except as could not reasonably be expected to have a Material Adverse Effect, (i) each Plan is in compliance in all respects with the applicable provisions of ERISA, the
Code and other Federal or state laws and (ii) each Pension Plan that is intended to be a qualified plan under Section 401(a) of the Code has received a favorable determination letter from the Internal Revenue Service to the effect that the
form of such Plan is qualified under Section 401(a) of the Code and the trust related thereto has been determined by the 

  

			
	48	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Internal Revenue Service to be exempt from federal income tax under Section 501(a) of the Code, or an application for such a letter is currently being processed by the Internal Revenue
Service. To the best knowledge of the Company, nothing has occurred that would prevent or cause the loss of such tax-qualified status. 
 (b) There are no pending or, to the best knowledge of the Company, threatened claims, actions or lawsuits, or action by any Governmental Authority, with respect to any Plan that could reasonably be
expected to have a Material Adverse Effect. There has been no prohibited transaction or violation of the fiduciary responsibility rules with respect to any Plan that has resulted or could reasonably be expected to result in a Material Adverse
Effect. 
 (i) No ERISA Event has occurred or is reasonably expected to occur that, when taken together with all other such
ERISA Events for which liability is reasonably expected to occur, could reasonably be expected to result in a Material Adverse Effect; (ii) neither the Company nor any ERISA Affiliate has incurred any material liability to the PBGC other than
for the payment of premiums, and there are no premium payments which have become due that are unpaid; (iii) neither the Company nor any ERISA Affiliate has engaged in a transaction that could be subject to Section 4069 or
Section 4212(c) of ERISA; (iv) no Pension Plan or Multiemployer Plan has been terminated by the plan administrator thereof nor by the PBGC, and no event or circumstance has occurred or exists that could reasonably be expected to cause the
PBGC to institute proceedings under Title IV of ERISA to terminate any Pension Plan or Multiemployer Plan; and (v) the Company and each ERISA Affiliate has met all applicable requirements under the Pension Funding Rules in respect of each
Pension Plan, and no waiver of the minimum funding standards under the Pension Funding Rules has been applied for or obtained. 

5.15 OFAC. The Company is not (i) a Person whose name appears on the list of Specially Designated Nationals and Blocked
Persons published by the Office of Foreign Assets Control of the U.S. Department of Treasury (“OFAC”) (an “OFAC Listed Person”) or a Person sanctioned by the United States of America pursuant to any of the
regulations administered or enforced by OFAC (31 C.F.R., Subtitle B, Chapter V, as amended); or (ii) a department, agency or instrumentality of, or is otherwise controlled by or acting on behalf of, directly or indirectly, (x) any OFAC
Listed Person, or (y) the government of a country the subject of comprehensive U.S. economic sanctions administered by OFAC (collectively, “OFAC Countries”). 

The Company represents and covenants that no Loan, nor the proceeds from any Loan, has been or will be used, to lend, contribute, provide
or has otherwise been made or will otherwise be made available for the purpose of funding any activity or business in any OFAC Countries or for the purpose of funding any prohibited activity or business of any Person located, organized or residing
in any OFAC Country or who is an OFAC Listed Person or, to the Company’s knowledge, any person owned by or controlled by, or acting for or on behalf of an OFAC Listed Person, absent valid and effective licenses and permits issued by the
government of the United States or otherwise in accordance with applicable Laws, or in any other manner that will result in any violation by any Lender, any Arranger or the Administrative Agent of the sanctions administered or enforced by OFAC (31
C.F.R., Subtitle B, Chapter V, as amended). 
 5.16 Subsidiaries; Equity Interests. As of the Effective Date, the Company
has no Material Subsidiaries other than those specifically disclosed in Schedule 5.16, and all of the 

  

			
	49	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
outstanding Equity Interests in its Material Subsidiaries have been validly issued, are fully paid and nonassessable and are owned by the Company in the amounts specified on Schedule 5.16
free and clear of all Liens (other than any Liens permitted under Section 7.01). 
 5.17 Margin Regulations;
Investment Company Act. (a) The Company is not engaged nor will it engage, principally or as one of its important activities, in the business of purchasing or carrying margin stock (within the meaning of Regulation U issued by the Board of
Governors of the Federal Reserve System of the United States), or extending credit for the purpose of purchasing or carrying margin stock. 
 (b) None of the Company, any Person Controlling the Company, or any Subsidiary is required to be registered as an “investment company” under the Investment Company Act of 1940. 

5.18 Disclosure. All written information (other than projected financial information and information of a general economic or
general industry nature) that has been made available to the Arrangers or any of the Lenders by or on behalf of the Company or any of its representatives, taken as a whole, or by or on behalf of the Target Companies or any of their representatives,
taken as a whole, in connection with any aspect of the Transaction is, when taken as a whole, complete and correct in all material respects and does not contain any untrue statement of a material fact or omit to state a material fact necessary to
make the statements contained therein not misleading (in each case after giving effect to all supplements and updates provided thereto); provided that, with respect to projected financial information, the Company represents only that such
information was prepared in good faith based upon reasonable assumptions that are believed by the preparer thereof to be reasonable at the time made and at the time such projected financial information is delivered to the Arrangers or any of the
Lenders; it being understood and agreed that such projected financial information is not to be viewed as facts and that actual results during the period or periods covered by any such projected financial information may differ significantly from the
projected results, and no assurance can be given that the projected results will be realized. Solely as they relate to matters with respect to the Target Companies and their subsidiaries, the foregoing representations and warranties are made to the
best of the Company’s knowledge. 
 5.19 Compliance with Laws. Each of the Company and each Material Subsidiary is
in compliance in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its properties, except in such instances in which (a) such requirement of Law or order, writ,
injunction or decree is being contested in good faith by appropriate proceedings diligently conducted or (b) the failure to comply therewith, either individually or in the aggregate, would not reasonably be expected to have a Material Adverse
Effect. 
 5.20 Intellectual Property; Licenses, Etc. The Company and its Subsidiaries own, or possess the right to use,
without conflict with the rights of any other Person, all of the trademarks, service marks, trade names, copyrights, patents, patent rights, franchises, licenses and other intellectual property rights (collectively, “IP Rights”)
with respect to which the failure to possess or have the right to use or the presence of a conflict with the rights of any other Person (other than with respect to any litigation arising under Section 505(j)(3)(A)(vii)(iv) of

  

			
	50	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
the Federal Food, Drug and Cosmetic Act of 1938, as amended) would not reasonably be expected to have a Material Adverse Effect. To the best knowledge of the Company, no slogan or other
advertising device, product, process, method, substance, part or other material now employed, or now contemplated to be employed, by the Company or any Subsidiary infringes upon any rights held by any other Person, except where such infringement
would not reasonably be expected to have a Material Adverse Effect. No claim or litigation regarding any of the foregoing is pending or, to the best knowledge of the Company, threatened, which, either individually or in the aggregate, would
reasonably be expected to have a Material Adverse Effect. 
 ARTICLE VI. 

AFFIRMATIVE COVENANTS 
 So long as any Loan or other Obligation hereunder will remain unpaid or unsatisfied, then, from and after the Closing Date, the Company will, and will (except in the case of the covenants set forth in
Sections 6.01, 6.02, 6.03 and 6.11) cause each Material Subsidiary to:  
 6.01 Financial
Statements. Deliver to the Administrative Agent (who will distribute copies to each Lender): 
 (a) as soon as
available, but in any event within 90 days after the end of each Fiscal Year of the Company (commencing with the fiscal year ending December 31, 2012), a consolidated balance sheet of the Company and its Subsidiaries as of the end of such
Fiscal Year, and the related consolidated statements of income or operations and cash flows for such Fiscal Year, setting forth in each case in comparative form the figures for the previous Fiscal Year, all in reasonable detail and prepared in
accordance with GAAP, audited and accompanied by a report and opinion of PricewaterhouseCoopers LLP or another independent public accountant of recognized national standing as to whether such financial statements are free of material misstatement,
which report and opinion will be prepared in accordance with audit standards of the Public Company Accounting Oversight Board and will not be subject to any “going concern” or like qualification or exception or any qualification or
exception as to the scope of such audit or with respect to the absence of material misstatement; and 
 (b) as soon as
available, but in any event within 45 days after the end of each of the first three fiscal quarters of each Fiscal Year of the Company (commencing with the first fiscal quarter ending after the Closing Date), a consolidated balance sheet of the
Company and its Subsidiaries as of the end of such fiscal quarter, and the related consolidated statements of income or operations and cash flows for such fiscal quarter and for the portion of the Company’s Fiscal Year then ended, setting forth
in each case in comparative form the figures for the corresponding fiscal quarter of the previous Fiscal Year and the corresponding portion of the previous Fiscal Year, all in reasonable detail, certified by the chief financial officer or the vice
president and controller of the Company as fairly presenting the financial condition, results of operations and cash flows of the Company and its Subsidiaries in accordance with GAAP, subject only to normal year-end audit adjustments and the absence
of footnotes. 

  

			
	51	  	Watson Pharmaceuticals Term Loan Credit Agreement

 As to any information contained in materials furnished pursuant to
Section 6.02(b), the Company will not be separately required to furnish such information under clause (a) or (b) above, but the foregoing will not be in derogation of the obligation of the Company to furnish the
information and materials described in clauses (a) and (b) above at the times specified therein. 

6.02 Certificates; Other Information. Deliver to the Administrative Agent (who will distribute copies to the Lenders), in form and
detail reasonably satisfactory to the Administrative Agent: 
 (a) concurrently with the delivery of the financial
statements referred to in Sections 6.01(a) and (b), a duly completed Compliance Certificate signed by a Responsible Officer of the Company (which delivery may, unless the Administrative Agent requests executed originals, be by
electronic communication including fax or email and shall be deemed to be an original authentic counterpart thereof for all purposes); 
 (b) promptly, after the same are available, copies of each proxy statement sent to the shareholders of the Company and copies of all annual, regular, periodic and special reports and registration
statements which the Company may file or be required to file with the SEC under Section 13 or 15(d) of the Securities Exchange Act, and not otherwise required to be delivered to the Administrative Agent pursuant hereto; 

(c) promptly, and in any event within five Business Days after receipt thereof by the Company or any Subsidiary thereof, copies of
each notice or other correspondence received from the SEC (or comparable agency in any applicable non-U.S. jurisdiction) concerning any investigation or possible investigation or other inquiry by such agency regarding financial or other operational
results of the Company or any Subsidiary thereof to the extent that any such notice or other correspondence would be required to be disclosed in a Form 8-K filing with the SEC; and 

(d) promptly, such additional information regarding the business, financial or corporate affairs of the Company or any Subsidiary,
or compliance with the terms of the Loan Documents, as the Administrative Agent or any Lender through the Administrative Agent may from time to time reasonably request. 
 Documents required to be delivered pursuant to Section 6.01(a) or (b) or Section 6.02(b) or (c) (to the extent any such documents are included in materials
otherwise filed with the SEC) may be delivered electronically and if so delivered, will be deemed to have been delivered on the date (i) on which the Company posts such documents, or provides a link thereto on the Company’s website on the
Internet at the website address listed on Schedule 10.02; or (ii) on which such documents are posted on the Company’s behalf on an Internet or intranet website, if any, to which each Lender and the Administrative Agent have access
(whether a commercial, third-party website or whether sponsored by the Administrative Agent); provided that (i) the Company shall deliver paper copies of such documents to the Administrative Agent who will distribute copies to any Lender
that requests the Company to deliver such paper copies until a written request to cease delivering paper copies is given by the Administrative Agent or such Lender and (ii) the Company shall notify the Administrative Agent (by facsimile or
electronic mail) of the posting of any such documents. The Administrative Agent shall have no obligation to request the delivery or to maintain copies of the documents referred to above, and in any event

  

			
	52	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
shall have no responsibility to monitor compliance by the Company with any such request for delivery, and each Lender shall be solely responsible for requesting delivery to it or maintaining its
copies of such documents. 
 The Company hereby acknowledges that (a) the Administrative Agent and/or the Arrangers will
make available to the Lenders materials and/or information provided by or on behalf of the Company hereunder (including, for the avoidance of doubt, materials/and or information delivered pursuant to Section 4.02) (collectively,
“Company Materials”) by posting the Company Materials on IntraLinks or another similar electronic system (the “Platform”) and (b) certain of the Lenders (each, a “Public Lender”) may have
personnel who do not wish to receive material non-public information with respect to the Company or its Subsidiaries, or the respective securities of any of the foregoing, and who may be engaged in investment and other market-related activities with
respect to such Persons’ securities. The Company hereby agrees that (w) all Company Materials that are to be made available to Public Lenders will be clearly and conspicuously marked “PUBLIC” which, at a minimum, will mean that
the word “PUBLIC” will appear prominently on the first page thereof; (x) by marking Company Materials “PUBLIC”, the Company will be deemed to have authorized the Administrative Agent, the Arrangers and the Lenders to treat
such Company Materials as not containing any material non-public information with respect to the Company or its securities for purposes of United States federal and state securities laws (provided, however, that to the extent such
Company Materials constitute Information, they will be treated as set forth in Section 10.07); (y) all Company Materials marked “PUBLIC” are permitted to be made available through a portion of the Platform designated
“Public Side Information”; and (z) the Administrative Agent and the Arrangers will be entitled to treat any Company Materials that are not marked “PUBLIC” as being suitable only for posting outside the portion the Platform
designated “Public Side Information”. 
 6.03 Notices. Promptly notify the Administrative Agent (and each
Lender through the Administrative Agent) of the following, upon any such event becoming known to any Responsible Officer of the Company: 
 (a) of the occurrence of any Default; 
 (b) of any matter that has
resulted or would reasonably be expected to result in a Material Adverse Effect, including any such matter resulting from (i) breach or non-performance of, or any default under, a Contractual Obligation of the Company or any Subsidiary, or
(ii) the commencement of, or any material development in, any litigation or proceeding affecting the Company or any Subsidiary, including pursuant to any applicable Environmental Laws; 

(c) of the occurrence of any ERISA Event, that, alone or together with any other ERISA Events that have occurred, would reasonably
be expected to result in liability to the Company and its Subsidiaries in an aggregate amount exceeding $50,000,000; and 

(d) of any announcement by Moody’s or S&P of any change in a Debt Rating. 

Each notice pursuant to subsections (a) through (c) of this Section 6.03 will be accompanied by a
statement of a Responsible Officer of the Company setting forth details of the 

  

			
	53	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
occurrence referred to therein and stating what action the Company has taken and proposes to take with respect thereto. Each notice pursuant to Section 6.03(a) will describe with
particularity any and all provisions of this Agreement and any other Loan Document that have been breached. 
 6.04 Payment
of Taxes. Pay and discharge as the same will become due and payable, all its tax liabilities, assessments and governmental charges or levies upon it or its properties or assets, unless the same are being contested in good faith by appropriate
proceedings diligently conducted and adequate reserves in accordance with GAAP are being maintained by the Company or such Material Subsidiary, except to the extent that failure to do so would not reasonably be expected to have a Material Adverse
Effect. 
 6.05 Preservation of Existence, Etc. (a) Preserve, renew and maintain in full force and effect the legal
existence and good standing of the Company and its Material Subsidiaries under the Laws of the jurisdiction of its organization except in a transaction permitted by Section 7.03; (b) take all reasonable action to maintain all
rights, privileges, permits, licenses and franchises necessary or desirable in the normal conduct of its business, except to the extent that failure to do so would not reasonably be expected to have a Material Adverse Effect; and (c) preserve
or renew all of its registered patents, trademarks, trade names and service marks, the non-preservation of which would reasonably be expected to have a Material Adverse Effect. 

6.06 Maintenance of Properties. (a) Maintain, preserve and protect all of its material properties and equipment necessary in
the operation of its business in good working order and condition, ordinary wear and tear excepted and (b) make all necessary repairs thereto and renewals and replacements thereof except, in the case of clauses (a) and (b),
where the failure to do so would not reasonably be expected to have a Material Adverse Effect. 
 6.07 Maintenance of
Insurance. Maintain with financially sound and reputable insurance companies, insurance with respect to its properties and business against loss or damage of the kinds customarily insured against by Persons engaged in the same or similar
business, of such types and in such amounts (after giving effect to any self-insurance) as are customarily carried under similar circumstances by such other Persons. 
 6.08 Compliance with Laws. Comply in all material respects with the requirements of all Laws and all orders, writs, injunctions and decrees applicable to it or to its business or property, except
in such instances in which (a) such requirement of Law or order, writ, injunction or decree is being contested in good faith by appropriate proceedings diligently conducted; or (b) the failure to comply therewith, either individually or in
the aggregate, would not reasonably be expected to have a Material Adverse Effect. 
 6.09 Books and Records. Maintain
proper books of record and account, in which full, true and correct entries in conformity with GAAP consistently applied will be made of all financial transactions and matters involving the assets and business of the Company or such Material
Subsidiary, as the case may be. 
 6.10 Inspection Rights. Permit representatives and independent contractors of the
Administrative Agent to visit and inspect any of its properties, to examine its corporate, financial and operating records, and make copies thereof or abstracts therefrom, and to discuss 

  

			
	54	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
its affairs, finances and accounts with its officers having direct knowledge or responsibility of the subject matter, provided, however, that such visits, inspections or
examinations will be made at a reasonable time during normal business hours with due regard for, and minimal disruption of, the business of the Company and its Subsidiaries, and will not (a) be at the expense of the Company, (b) occur more
frequently than once in any 12-month period and (c) be made without five (5) Business Days’ prior written notice; provided further, however, that when an Event of Default exists, the Administrative Agent or any
Lender (or any of their respective representatives or independent contractors) may do any of the foregoing at the expense of the Company at any time during normal business hours and without advance notice. 

6.11 Use of Proceeds. Use the proceeds of the Loans to (a) finance, in part, the Acquisition, and (b) pay fees and
expenses incurred in connection with the Transaction. 
 6.12 Covenant to Guarantee Obligations. Within 30 days (or such
later time as may be reasonably requested in writing by the Company and accepted by the Administrative Agent) of the designation of any Domestic Subsidiary as a guarantor under any other Material Indebtedness of the Company after the Closing Date,
the Company shall (a) cause each such Domestic Subsidiary to deliver to the Administrative Agent, a duly executed copy of the Subsidiary Guaranty (or supplement or joinder thereto) pursuant to which such Domestic Subsidiary agrees to be bound
by the terms and provisions of the Subsidiary Guaranty, and such Subsidiary Guaranty (or supplement or joinder thereto) and (b) deliver to the Administrative Agent documents of the types referred to in Section 4.02(a)(ii) and
opinions of counsel to such Person (which shall cover, among other things, the legality, validity, binding effect and enforceability of the documentation referred to in clause (a)) in form and substance substantially similar to the opinions of
counsel attached hereto as Exhibit H, all in form, content and scope reasonably satisfactory to the Administrative Agent. 

ARTICLE VII. 
 NEGATIVE COVENANTS 
 So long as any Loan or other Obligation hereunder will
remain unpaid or unsatisfied, then, from and after the Closing Date, the Company in each section of this Article VII (other than Section 7.02), will not, nor will it permit or allow any Material Subsidiary in any section of this
Article VII or any Subsidiary in Sections 7.01 and 7.02 to, directly or indirectly:  
 7.01
Liens. Create, incur, assume or suffer to exist any Lien upon any of its property, assets or revenues, whether now owned or hereafter acquired, other than the following: 
 (a) Liens pursuant to any Loan Document; 
 (b) Liens existing on the
Closing Date and listed on Schedule 7.01 and any renewals or extensions thereof, provided that (i) the property covered thereby is not changed, (ii) the amount secured or benefited thereby is not increased (except as
contemplated by Section 7.02(b)), (iii) the direct or any contingent obligor with respect thereto is not changed, and (iv) any renewal or extension of the obligations secured or benefited thereby is permitted by
Section 7.02(b); 

  

			
	55	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (c) Liens for taxes not yet due or which are being contested in good faith and by
appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person in accordance with GAAP; 
 (d) carriers’, warehousemen’s, mechanics’, materialmen’s, repairmen’s or other like Liens arising in the ordinary course of business which are not overdue for a period of
more than 60 days or which are being contested in good faith and by appropriate proceedings diligently conducted, if adequate reserves with respect thereto are maintained on the books of the applicable Person; 

(e) pledges or deposits in the ordinary course of business in connection with workers’ compensation, unemployment insurance and
other social security legislation, other than any Lien imposed by ERISA; 
 (f) deposits to secure the performance of bids,
trade contracts and leases (other than Indebtedness), statutory obligations, surety and appeal bonds, performance bonds and other obligations of a like nature incurred in the ordinary course of business; 

(g) easements, rights-of-way, restrictions and other similar encumbrances affecting real property which, in the aggregate, are not
substantial in amount, and which do not in any case materially detract from the value of the property subject thereto or materially interfere with the ordinary conduct of the business of the applicable Person; 

(h) Liens securing judgments for the payment of money not constituting an Event of Default under Section 8.01(h);

 (i) Liens securing Indebtedness permitted under Section 7.02(f); and 

(j) other Liens securing other Indebtedness permitted by Section 7.02 or other liabilities of the Company and its
Subsidiaries in an aggregate amount not to exceed, at any time, the greater of $500,000,000 and 15% of the Net Worth of the Company (it being understood that any Lien permitted under any other clause in this Section 7.01 shall not be
included in the computation described in this clause (j)). 
 7.02 Subsidiary Indebtedness. Create, incur, assume
or suffer to exist any Indebtedness, except: 
 (a) Indebtedness under the Loan Documents; 

(b) Indebtedness outstanding on the Closing Date and listed on Schedule 7.02 and any refinancings, refundings, renewals or
extensions thereof; provided that (i) the amount of such Indebtedness is not increased at the time of such refinancing, refunding, renewal or extension except by an amount equal to a reasonable premium or other reasonable amount paid,
and fees and expenses reasonably incurred, in connection with such refinancing and by an amount equal to any existing commitments unutilized thereunder and (ii) the terms relating to principal amount, amortization, maturity, collateral (if any)
and subordination (if any), and other material terms taken as a whole, of any such refinancing, refunding, renewing or extending Indebtedness, and of any agreement entered into and of any instrument issued in connection

  

			
	56	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
therewith, are no less favorable in any material respect to the Loan Parties or the Lenders than the terms of any agreement or instrument governing the Indebtedness being refinanced, refunded,
renewed or extended; 
 (c) obligations (contingent or otherwise) of any Subsidiary existing or arising under any Swap
Contract; provided that (i) such obligations are (or were) entered into by such Person for the purpose of directly mitigating risks associated with liabilities, commitments, investments, assets, or property held or reasonably anticipated
by such Person, or changes in the value of securities issued by such Person, and not for purposes of speculation or taking a “market view;” and (ii) such Swap Contract does not contain any provision exonerating the non-defaulting
party from its obligation to make payments on outstanding transactions to the defaulting party; 
 (d) Indebtedness of any
Subsidiary Guarantor; 
 (e) Guarantees of any Subsidiary in respect of Indebtedness otherwise permitted hereunder of any
Subsidiary; 
 (f) Indebtedness of any Person that becomes a Subsidiary after the Closing Date; provided that
(i) such Indebtedness exists at the time such Person becomes a Subsidiary and is not created in contemplation of or in connection with such Person becoming a Subsidiary and (ii) the aggregate principal amount of all such Indebtedness
permitted by this Section 7.02(f) at any one time outstanding shall not exceed the greater of $500,000,000 and 15% of the Net Worth of the Company; 
 (g) Capital Lease Obligations, Synthetic Lease Obligations or Receivables Facility Attributable Indebtedness in an aggregate principal amount which, when added to all other Capital Lease Obligations,
Synthetic Lease Obligations and Receivables Facility Attributable Indebtedness created, incurred or assumed under this clause (g), do not to exceed the greater of $500,000,000 and 15% of the Net Worth of the Company at any time, subject in
the case of any such Indebtedness secured by a Lien, to the limitation set forth in Section 7.01(j); 

(h) additional secured or unsecured Indebtedness not otherwise permitted under this Section 7.02 in an aggregate
principal amount at any time outstanding which, when added to, without duplication, the aggregate principal amount of Indebtedness and other obligations that are secured by a Lien permitted by Section 7.01(j) at such time, do not exceed
the greater of $500,000,000 and 15% of the Net Worth of the Company; 
 (i) intercompany loans made between the Company and
a Subsidiary or any two Subsidiaries; and 
 (j) any Acquisition Indebtedness. 

7.03 Fundamental Changes. Merge, dissolve, liquidate, consolidate with or into another Person, or Dispose of (whether in one
transaction or in a series of transactions) all or substantially all of the assets (whether now owned or hereafter acquired) of the Company and the Material Subsidiaries, taken as a whole, unless (a) at the time thereof and immediately after
giving effect thereto no Event of Default shall have occurred and be continuing and (b) after giving effect to any such transaction, the business, taken as a whole, of the Company and the

  

			
	57	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Material Subsidiaries shall not have been altered such that the Company or its Material Subsidiaries are unable to comply with the restriction on the covenant governing any change in nature of
business in Section 7.04, provided that (i) if the Company is not the survivor of any such consolidation or merger involving the Company, (A) the Company, at the time thereof and immediately after giving effect thereto,
shall be in compliance on a pro forma basis with the financial covenants contained in Sections 7.08 and 7.09 as if such consolidation or merger had been consummated (and any related Indebtedness incurred, assumed or
repaid in connection therewith had been incurred, assumed or repaid, as the case may be) on the first day of the most recently completed four fiscal quarters of the Company for which financial statements have been delivered pursuant to
Section 6.01 (as demonstrated by delivery to the Administrative Agent of a certificate of a Responsible Officer to such effect showing such calculation in reasonable detail prior to or concurrently with such consolidation or merger),
(B) the surviving Person of such consolidation or merger shall expressly assume all of the Company’s rights and obligations under this Agreement and the other Loan Documents pursuant to documentation reasonably satisfactory to the
Administrative Agent and shall thereafter be deemed to be the Company for all purposes hereunder and (C) such consolidation or merger will not result in a Change of Control; and (ii) the Company shall not liquidate or dissolve. 

7.04 Change in Nature of Business. Engage in any material line of business substantially different from those lines of business
conducted by the Company and its Material Subsidiaries on the Closing Date or any business substantially related or incidental thereto. 
 7.05 Transactions with Affiliates. Enter into any transaction of any kind with any Affiliate of the Company that is a Material Subsidiary, whether or not in the ordinary course of business, other
than on fair and reasonable terms substantially as favorable to the Company or such Material Subsidiary as would be obtainable by the Company or such Material Subsidiary at the time in a comparable arm’s length transaction with a Person other
than an Affiliate, provided that the foregoing restriction will not apply to (i) transactions between or among (A) the Company and any of its Wholly Owned Subsidiaries, (B) Wholly Owned Subsidiaries of the Company or
(C) Subsidiary Guarantors, (ii) Permitted Receivables Transfers, or (iii) any transaction between the Company and an Affiliate of the Company resulting in a transfer to the Company of the proceeds of any Acquisition Indebtedness
issued by such Affiliate. 
 7.06 Investments. Make any Investment (other than Investments made in the ordinary course of
business and Investments required in connection with the Receivables Purchase Documents) if, immediately before and after giving effect to such Investment, an Event of Default shall have occurred and be continuing. 

7.07 Restricted Payments. Declare or make, directly or indirectly, any Restricted Payment, or incur any obligation (contingent or
otherwise) to do so (exclusive of stock dividends and cash dividends paid to the Company or any Subsidiary Guarantor); provided that the foregoing restriction will not apply if, immediately before and after giving effect to such transaction,
no Event of Default shall have occurred and be continuing. 
 7.08 Consolidated Leverage Ratio. Permit the Consolidated
Leverage Ratio as of the last day of any period of four consecutive fiscal quarters of the Company to exceed (i) 4.25:1.00 from the Closing Date through December 31, 2013, (ii) 4.00:1.00 from January 1, 2014 through
December 31, 2014, and (iii) 3.50:1.00 from January 1, 2015 through the Maturity Date. 

  

			
	58	  	Watson Pharmaceuticals Term Loan Credit Agreement

 7.09 Net Worth. In the event the Springing Amount for the prior twelve-month period
is greater than 7.50% of the Net Worth of the Company as of the last day of the most recently ended fiscal quarter of the Company, the Net Worth of the Company shall not be less than the sum of (x) 75% of the Net Worth of the Company as of
June 30, 2011 plus (y) 50% of the Consolidated Net Income of the Company for each fiscal quarter of the Company ending after June 30, 2011, provided that the Consolidated Net Income of the Company for any such fiscal
quarter shall only be taken into account for purposes of this calculation if it is positive. 
 ARTICLE VIII. 

EVENTS OF DEFAULT AND REMEDIES 
 8.01 Events of Default. Subject to Section 8.04, from and after the Closing Date, any of the following will constitute an Event of Default: 

(a) Non-Payment. The Company fails to pay (i) when and as required to be paid herein, and in the currency required
hereunder, any amount of principal of any Loan, or (ii) within five (5) days after the same becomes due, any interest on any Loan, any fee due hereunder, or any other amount payable hereunder or under any other Loan Document (other than an
amount specified in clause (i) above); 
 (b) Specific Covenants. The Company fails to perform or
observe any term, covenant or agreement contained in Section 6.03(a) or 6.05(a) (with respect to the Company’s existence) or Article VII; 
 (c) Other Defaults. Any Loan Party fails to perform or observe any other covenant or agreement (not specified in subsection (a) or (b) above) contained in any Loan
Document on its part to be performed or observed and such failure continues for thirty (30) days after notice thereof from the Administrative Agent (given at the request of any Lender) to the Company, unless such failure is not susceptible to
cure within thirty (30) days and, within such thirty (30) days, the Company has taken reasonable steps to effectuate a cure, continues to diligently pursue such cure, and actually effectuates such cure within sixty (60) days after
such notice to the Company; 
 (d) Representations and Warranties. Any representation and warranty made or deemed
made by or on behalf of the Company or any other Loan Party herein or in any other Loan Document is incorrect in any material respect when made or deemed made; 
 (e) Cross-Default. (i) The Company or any Material Subsidiary fails to make any payment of principal or interest in respect of any Material Indebtedness, when and as the same shall become
due and payable (after giving effect to any applicable grace periods), (ii) any event or condition occurs that results in any Material Indebtedness (A) becoming due prior to its scheduled maturity or (B) that enables or permits (after
giving effect to any applicable grace periods) the holder or holders of any Material Indebtedness, or any trustee or agent on its or their behalf, to cause any Material Indebtedness to become due, or to require the prepayment, repurchase, redemption
or defeasance thereof, prior to its scheduled maturity; provided that this 

  

			
	59	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
subsection (e)(ii) shall not apply to secured Indebtedness that becomes due as a result of the voluntary sale or transfer of the property or assets securing such Indebtedness if such
secured Indebtedness is paid when due, (iii) any termination event or event of like import occurs under any Receivables Purchase Facility having a principal amount or committed amount in excess of $100,000,000, that (1) terminates, or
permits the investors under any Receivables Purchase Facility to terminate, the reinvestment of collections or proceeds of Receivables and Related Security under any Receivables Purchase Document (other than a termination resulting solely from the
request of the Company or any of its Subsidiaries) or (2) causes the replacement of, or permits the investors under any Receivables Purchase Facility to replace, the Person then acting as servicer for such Receivables Purchase Facility, if the
Person then acting as servicer is a Loan Party or an Affiliate of a Loan Party or (iv) there occurs under any Swap Contract an early termination date resulting from (x) any event of default under such Swap Contract as to which the Company
or any Material Subsidiary is the defaulting party thereunder or (y) any termination event under such Swap Contract as to which the Company or any Material Subsidiary is an affected party thereunder and, in either event, the Swap Termination
Value owed by the Company or such Material Subsidiary as a result thereof is greater than $100,000,000; 

(f) Insolvency Proceedings, Etc. The Company or any of its Material Subsidiaries institutes or consents to the institution of
any proceeding under any Debtor Relief Law, or makes an assignment for the benefit of creditors; or applies for or consents to the appointment of any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer for it or
for all or any material part of its property; any receiver, trustee, custodian, conservator, liquidator, rehabilitator or similar officer is appointed without the application or consent of the Company or any of its Material Subsidiary and the
appointment continues undischarged or unstayed for sixty (60) calendar days; or any proceeding under any Debtor Relief Law relating to the Company or any of its Material Subsidiaries or to all or any material part of its property is instituted
without the consent of the Company or such Material Subsidiary and continues undismissed or unstayed for sixty (60) calendar days, or an order for relief is entered in any such proceeding; 

(g) Inability to Pay Debts; Attachment. (i) The Company or any Material Subsidiary becomes unable or admits in writing
its inability or fails generally to pay its debts as they become due, or (ii) any writ or warrant of attachment or execution or similar process is issued or levied against all or any material part of the property of the Company or such Material
Subsidiary and is not released, vacated or fully bonded within thirty (30) days after its issue or levy; 

(h) Judgments. There is entered against the Company or any Material Subsidiary a final judgment or order for the payment of
money in an aggregate amount exceeding $100,000,000 (to the extent not covered by independent third-party insurance as to which the insurer does not dispute coverage) and (A) enforcement proceedings are commenced by any creditor upon such
judgment or order and (B) there is a period of thirty consecutive days during which execution shall not have been effectively stayed, vacated or bonded pending appeal or otherwise; 

(i) ERISA. (i) An ERISA Event occurs with respect to a Pension Plan or Multiemployer Plan which has resulted or could
reasonably be expected to result in liability of the Company under Title IV of ERISA to the Pension Plan, Multiemployer Plan or the PBGC in 

  

			
	60	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
an aggregate amount in excess of $100,000,000 or (ii) the Company or any ERISA Affiliate fails to pay when due, after the expiration of any applicable grace period, any installment payment
with respect to its withdrawal liability under Section 4201 of ERISA under a Multiemployer Plan in an aggregate amount in excess of $100,000,000; 
 (j) Invalidity of Loan Documents. This Agreement, any Note or any material Guarantee under the Subsidiary Guaranty shall, for any reason, cease to be in full force and effect, or the Company
or any Subsidiary Guarantor shall contest in writing the validity or enforceability hereunder or under any Note or any Subsidiary Guaranty, in each case, other than in accordance with the terms hereof and thereof (including, in the case of a
Subsidiary Guarantor, as a result of the release of such Subsidiary Guarantor in accordance with Section 9.10); or 

(k) Change of Control. There occurs any Change of Control. 

8.02 Remedies Upon Event of Default. Subject to Section 8.04, if any Event of Default occurs and is continuing, the
Administrative Agent will, at the request of, or may, with the consent of, the Required Lenders, take any or all of the following actions from and after the Closing Date: 
 (a) declare the unpaid principal amount of all outstanding Loans, all interest accrued and unpaid thereon, and all other amounts owing or payable hereunder or under any other Loan Document to be
immediately due and payable, without presentment, demand, protest or other notice of any kind, all of which are hereby expressly waived by the Company; and 
 (b) exercise on behalf of itself and the Lenders all rights and remedies available to it and the Lenders under the Loan Documents; 
 provided, however, that upon the occurrence of an actual or deemed entry of an order for relief with respect to the Company under the Bankruptcy Code of the United States, the unpaid
principal amount of all outstanding Loans and all interest and other amounts as aforesaid will automatically become due and payable, in each case without further act of the Administrative Agent or any Lender. 

8.03 Application of Funds. After the exercise of remedies provided for in Section 8.02 (or after the Loans have
automatically become immediately due and payable as set forth in the proviso to Section 8.02), any amounts received on account of the Obligations will, subject to Section 2.17, be applied by the Administrative Agent in the
following order: 
 First, to payment of that portion of the Obligations constituting fees, indemnities, expenses and
other amounts (including fees, charges and disbursements of counsel to the Administrative Agent and amounts payable under Article III) payable to the Administrative Agent in its capacity as such; 

Second, to payment of that portion of the Obligations constituting fees, indemnities and other amounts payable to the Lenders
(including fees, charges and disbursements of counsel to the respective Lenders and amounts payable under Article III), ratably among them in proportion to the respective amounts described in this clause Second payable to them;

  

			
	61	  	Watson Pharmaceuticals Term Loan Credit Agreement

 Third, to payment of that portion of the Obligations constituting accrued and unpaid
interest on the Loans and other Obligations, ratably among the Lenders in proportion to the respective amounts described in this clause Third payable to them; 
 Fourth, to payment of that portion of the Obligations constituting unpaid principal of the Loans, ratably among the Lenders in proportion to the respective amounts described in this clause
Fourth held by them; and 
 Last, the balance, if any, after all of the Obligations have been indefeasibly paid in
full, to the Company or as otherwise required by Law. 
 8.04 Cleanup Period. Notwithstanding anything to the contrary,
if during the five-day period following the Closing Date a matter or circumstance exists which constitutes a Default, that matter or circumstance will not constitute a Default; provided that (i) the matter or circumstance does not
constitute (x) a Major Default or (y) a Default incapable of being cured, (ii) reasonable steps are being taken to cure that matter or circumstance and (iii) such Default is cured or otherwise ceases to exist within five days
following the Closing Date. For the avoidance of doubt, nothing in this section shall affect the conditions precedent set forth in Article IV. 
 ARTICLE IX. 
 ADMINISTRATIVE AGENT 

9.01 Appointment and Authority. Each of the Lenders hereby irrevocably appoints Bank of America to act on its behalf as the
Administrative Agent hereunder and under the other Loan Documents and authorizes the Administrative Agent to take such actions on its behalf and to exercise such powers as are delegated to the Administrative Agent by the terms hereof or thereof,
together with such actions and powers as are reasonably incidental thereto. The provisions of this Article are solely for the benefit of the Administrative Agent and the Lenders, and the Company will have no rights as a third party beneficiary of
any of such provisions. 
 9.02 Rights as a Lender. The Person serving as the Administrative Agent hereunder will have
the same rights and powers in its capacity as a Lender as any other Lender and may exercise the same as though it were not the Administrative Agent and the term “Lender” or “Lenders” will, unless otherwise expressly indicated or
unless the context otherwise requires, include the Person serving as the Administrative Agent hereunder in its individual capacity. Such Person and its Affiliates may accept deposits from, lend money to, act as the financial advisor or in any other
advisory capacity for and generally engage in any kind of business with the Company or any Subsidiary or other Affiliate thereof as if such Person were not the Administrative Agent hereunder and without any duty to account therefor to the Lenders.

 9.03 Exculpatory Provisions. The Administrative Agent will not have any duties or obligations except those expressly
set forth herein and in the other Loan Documents. Without limiting the generality of the foregoing, the Administrative Agent: 

(a) will not be subject to any fiduciary or other implied duties, regardless of whether a Default has occurred and is continuing;

  

			
	62	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (b) will not have any duty to take any discretionary action or exercise any discretionary
powers, except discretionary rights and powers expressly contemplated hereby or by the other Loan Documents that the Administrative Agent is required to exercise as directed in writing by the Required Lenders (or such other number or percentage of
the Lenders as will be expressly provided for herein or in the other Loan Documents); provided that the Administrative Agent will not be required to take any action that, in its opinion or the opinion of its counsel, may expose the
Administrative Agent to liability or that is contrary to any Loan Document or applicable law; and 
 (c) will not, except
as expressly set forth herein and in the other Loan Documents, have any duty to disclose, and will not be liable for the failure to disclose, any information relating to the Company or any of its respective Affiliates that is communicated to or
obtained by the Person serving as the Administrative Agent or any of its Affiliates in any capacity. 
 The Administrative Agent
will not be liable for any action taken or not taken by it (i) with the consent or at the request of the Required Lenders (or such other number or percentage of the Lenders as will be necessary, or as the Administrative Agent will believe in
good faith will be necessary, under the circumstances as provided in Sections 10.01 and 8.02) or (ii) in the absence of its own gross negligence or willful misconduct. The Administrative Agent will be deemed not to have knowledge
of any Default unless and until notice describing such Default is given to the Administrative Agent by the Company or a Lender. 

The Administrative Agent will not be responsible for or have any duty to ascertain or inquire into (i) any statement, warranty or
representation made in or in connection with this Agreement or any other Loan Document, (ii) the contents of any certificate, report or other document delivered hereunder or thereunder or in connection herewith or therewith, (iii) the
performance or observance of any of the covenants, agreements or other terms or conditions set forth herein or therein or the occurrence of any Default, (iv) the validity, enforceability, effectiveness or genuineness of this Agreement, any
other Loan Document or any other agreement, instrument or document or (v) the satisfaction (or waiver) of any condition set forth in Article IV or elsewhere herein, other than to confirm receipt of items expressly required to be delivered to
the Administrative Agent. 
 9.04 Reliance by Administrative Agent. The Administrative Agent will be entitled to rely
upon, and will not incur any liability for relying upon, any notice, request, certificate, consent, statement, instrument, document or other writing (including any electronic message, Internet or intranet website posting or other distribution)
believed by it to be genuine and to have been signed, sent or otherwise authenticated by the proper Person. The Administrative Agent also may rely upon any statement made to it orally or by telephone and believed by it to have been made by the
proper Person, and will not incur any liability for relying thereon. In determining compliance with any condition hereunder to the making of a Loan that by its terms must be fulfilled to the satisfaction of a Lender, the Administrative Agent may
presume that such condition is satisfactory to such Lender unless the Administrative Agent will have received notice to the contrary from such Lender prior to the making of such Loan. The Administrative Agent may consult with legal counsel (who may
be counsel for the Company), independent accountants and other experts selected by it, and will not be liable for any action taken or not taken by it in accordance with the advice of any such counsel, accountants or experts. 

  

			
	63	  	Watson Pharmaceuticals Term Loan Credit Agreement

 9.05 Delegation of Duties. The Administrative Agent may perform any and all of its
duties and exercise its rights and powers hereunder or under any other Loan Document by or through any one or more sub-agents appointed by the Administrative Agent. The Administrative Agent and any such sub-agent may perform any and all of its
duties and exercise its rights and powers by or through their respective Related Parties. The exculpatory provisions of this Article will apply to any such sub-agent and to the Related Parties of the Administrative Agent and any such sub-agent, and
will apply to their respective activities in connection with the syndication of the credit facilities provided for herein as well as activities as Administrative Agent. 
 9.06 Resignation of Administrative Agent. The Administrative Agent may at any time give notice of its resignation to the Lenders and the Company (provided that such notice given while the
Administrative Agent is holding Pre-Advanced Funds shall become effective immediately after distribution of such funds to the Lenders or the Company pursuant to Section 2.02). Upon receipt of any such notice of resignation, the Required
Lenders will have the right, in consultation with the Company, to appoint a successor, which will be a bank with an office in the United States, or an Affiliate of any such bank with an office in the United States. If no such successor will have
been so appointed by the Required Lenders and will have accepted such appointment within 30 days after the retiring Administrative Agent gives notice of its resignation, then the retiring Administrative Agent may on behalf of the Lenders appoint a
successor Administrative Agent meeting the qualifications set forth above; provided that if the Administrative Agent will notify the Company and the Lenders that no qualifying Person has accepted such appointment, then such resignation will
nonetheless become effective in accordance with such notice and (1) the retiring Administrative Agent will be discharged from its duties and obligations hereunder and under the other Loan Documents and (2) all payments, communications and
determinations provided to be made by, to or through the Administrative Agent will instead be made by or to each Lender directly, until such time as the Required Lenders appoint a successor Administrative Agent as provided for above in this Section.
Upon the acceptance of a successor’s appointment as Administrative Agent hereunder, such successor will succeed to and become vested with all of the rights, powers, privileges and duties of the retiring (or retired) Administrative Agent, and
the retiring Administrative Agent will be discharged from all of its duties and obligations hereunder or under the other Loan Documents (if not already discharged therefrom as provided above in this Section). The fees payable by the Company to a
successor Administrative Agent will be the same as those payable to its predecessor unless otherwise agreed between the Company and such successor. After the retiring Administrative Agent’s resignation hereunder and under the other Loan
Documents, the provisions of this Article and Section 10.04 will continue in effect for the benefit of such retiring Administrative Agent, its sub-agents and their respective Related Parties in respect of any actions taken or omitted to
be taken by any of them while the retiring Administrative Agent was acting as Administrative Agent. 
 9.07 Non-Reliance on
Administrative Agent and Other Lenders. Each Lender acknowledges that it has, independently and without reliance upon the Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information

  

			
	64	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
as it has deemed appropriate, made its own credit analysis and decision to enter into this Agreement. Each Lender also acknowledges that it will, independently and without reliance upon the
Administrative Agent or any other Lender or any of their Related Parties and based on such documents and information as it will from time to time deem appropriate, continue to make its own decisions in taking or not taking action under or based upon
this Agreement, any other Loan Document or any related agreement or any document furnished hereunder or thereunder. 
 9.08
No Other Duties, Etc. Anything herein to the contrary notwithstanding, none of the Arrangers, the Syndication Agent or the Co-Documentation Agents will have any powers, duties or responsibilities under this Agreement or any of the other Loan
Documents, except in its capacity, as applicable, as the Administrative Agent or a Lender hereunder. 
 9.09 Administrative
Agent May File Proofs of Claim. In case any receivership, insolvency, liquidation, bankruptcy, reorganization, arrangement, adjustment, composition or other judicial proceeding relative to any Loan Party is pending, the Administrative Agent
(irrespective of whether the principal of any Loan will then be due and payable as herein expressed or by declaration or otherwise and irrespective of whether the Administrative Agent will have made any demand on the Company) will be entitled and
empowered, by intervention in such proceeding or otherwise: 
 (a) to file and prove a claim for the whole amount of the
principal and interest owing and unpaid in respect of the Loans and all other Obligations that are owing and unpaid and to file such other documents as may be necessary or advisable in order to have the claims of the Lenders and the Administrative
Agent (including any claim for the reasonable compensation, expenses, disbursements and advances of the Lenders and the Administrative Agent and their respective agents and counsel and all other amounts due the Lenders and the Administrative Agent
under Sections 2.10 and 10.04) allowed in such judicial proceeding; and 
 (b) to collect and receive any monies or other
property payable or deliverable on any such claims and to distribute the same; 
 and any custodian, receiver, assignee, trustee, liquidator,
sequestrator or other similar official in any such judicial proceeding is hereby authorized by each Lender to make such payments to the Administrative Agent and, in the event that the Administrative Agent will consent to the making of such payments
directly to the Lenders, to pay to the Administrative Agent any amount due for the reasonable compensation, expenses, disbursements and advances of the Administrative Agent and its agents and counsel, and any other amounts due the Administrative
Agent under Sections 2.10 and 10.04. 
 Nothing contained herein will be deemed to authorize the Administrative
Agent to authorize or consent to or accept or adopt on behalf of any Lender any plan of reorganization, arrangement, adjustment or composition affecting the Obligations or the rights of any Lender to authorize the Administrative Agent to vote in
respect of the claim of any Lender in any such proceeding. 

  

			
	65	  	Watson Pharmaceuticals Term Loan Credit Agreement

 9.10 Guaranty Matters. The Lenders irrevocably authorize the Administrative Agent to
release any Subsidiary Guarantor from its obligations under the Subsidiary Guaranty if such Person (a) ceases to be a Subsidiary of the Company as a result of a transaction permitted hereunder, (b) ceases to be a guarantor under all other
Material Indebtedness of the Company or (c) was voluntarily designated by the Company as a Subsidiary Guarantor and the Company requests, in writing, that the Administrative Agent release it from the Subsidiary Guaranty and no Event of Default
would immediately result from such a release. Upon request by the Administrative Agent at any time, the Required Lenders will confirm in writing the Administrative Agent’s authority to release any Subsidiary Guarantor from its obligations under
the Subsidiary Guaranty pursuant to this Section 9.10. 
 ARTICLE X. 

MISCELLANEOUS 
 10.01 Amendments, Etc. No amendment or waiver of any provision of this Agreement or any other Loan Document, and no consent to any departure by the Company or any other Loan Party therefrom, will
be effective unless in writing signed by the Required Lenders and the Company or the applicable Loan Party, as the case may be, and acknowledged by the Administrative Agent (such acknowledgement not to be unreasonably withheld, conditioned or
delayed) and each such waiver or consent will be effective only in the specific instance and for the specific purpose for which given; provided, however, that no such amendment, waiver or consent will: 

(a) extend or increase the Commitment of any Lender without the written consent of such Lender; 

(b) postpone any date fixed by this Agreement or any other Loan Document for any payment of principal, interest, fees or other
amounts due to the Lenders (or any of them) hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby; 
 (c) reduce the principal of, or the rate of interest specified herein on, any Loan, or (subject to clause (ii) of the second proviso to this Section 10.01) any fees or other
amounts payable hereunder or under any other Loan Document without the written consent of each Lender directly affected thereby; provided, however, that only the consent of the Required Lenders will be necessary to amend the definition
of “Default Rate” or to waive any obligation of the Company to pay interest at the Default Rate; 
 (d) change
Section 8.03 in a manner that would alter the pro rata sharing of payments required thereby without the written consent of each Lender; 
 (e) release all of the Subsidiary Guarantors without the written consent of each Lender, except to the extent the release of all of the Subsidiary Guarantors is permitted pursuant to
Section 9.10 (in which case such release may be made by the Administrative Agent acting alone); or 

(f) change any provision of this Section or the definition of “Required Lenders” or any other provision hereof specifying
the number or percentage of Lenders required to amend, waive or otherwise modify any rights hereunder or make any determination or grant any consent hereunder without the written consent of each Lender; 

  

			
	66	  	Watson Pharmaceuticals Term Loan Credit Agreement

 and, provided further, that (i) no amendment, waiver or consent will, unless in writing
and signed by the Administrative Agent in addition to the Lenders required above, affect the rights or duties of the Administrative Agent under this Agreement or any other Loan Document; and (ii) the Fee Letters may be amended, or rights or
privileges thereunder waived, in a writing executed only by the parties thereto. Notwithstanding anything to the contrary herein, no Defaulting Lender shall have any right to approve or disapprove any amendment, waiver or consent hereunder (and any
amendment, waiver or consent which by its terms requires the consent of all Lenders or each affected Lender may be effected with the consent of the applicable Lenders other than Defaulting Lenders), except that (x) the Commitment of such Lender
may not be increased or extended without the consent of such Lender and (y) any waiver, amendment or modification requiring the consent of all Lenders or each affected Lender that by its terms affects any Defaulting Lender more adversely than
other affected Lenders shall require the consent of such Defaulting Lender. 
 10.02 Notices; Effectiveness; Electronic
Communication. 
 (a) Notices Generally. Except in the case of notices and other communications expressly permitted
to be given by telephone (and except as provided in subsection (b) below), all notices and other communications provided for herein will be in writing and will be delivered by hand or overnight courier service, mailed by certified or
registered mail or sent by telecopy or e-mail as follows, and all notices and other communications expressly permitted hereunder to be given by telephone will be made to the applicable telephone number, as follows: 

(i) if to the Company or the Administrative Agent, to the address, telecopy number, electronic mail address or
telephone number specified for such Person on Schedule 10.02; and 
 (ii) if to any other Lender, to
the address, telecopy number, electronic mail address or telephone number specified in its Administrative Questionnaire (including, as appropriate, notices delivered solely to the Person designated by a Lender on its Administrative Questionnaire
then in effect for the delivery of notices that may contain material non-public information relating to the Company). 
 Notices and other
communications sent by hand or overnight courier service, or mailed by certified or registered mail, will be deemed to have been given when received; notices and other communications sent by telecopy will be deemed to have been given when sent
(except that, if not given during normal business hours for the recipient, will be deemed to have been given at the opening of business on the next business day for the recipient). Notices and other communications delivered through electronic
communications to the extent provided in subsection (b) below, will be effective as provided in such subsection (b). 
 (b) Electronic Communications. Notices and other communications to the Lenders hereunder may be delivered or furnished by electronic communication (including e-mail and Internet or intranet
websites) pursuant to procedures approved by the Administrative Agent, provided that the foregoing will not apply to notices to any Lender pursuant to Article II if such 

  

			
	67	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Lender has notified the Administrative Agent that it is incapable of receiving notices under such Article by electronic communication. The Administrative Agent or the Company may, in its
discretion, agree to accept notices and other communications to it hereunder by electronic communications pursuant to procedures approved by it, provided that approval of such procedures may be limited to particular notices or communications.

 Unless the Administrative Agent otherwise prescribes, (i) notices and other communications sent to an e-mail address
will be deemed received upon the sender’s receipt of an acknowledgement from the intended recipient (such as by the “return receipt requested” function, as available, return e-mail or other written acknowledgement), provided
that if such notice or other communication is not sent during the normal business hours of the recipient, such notice or communication will be deemed to have been sent at the opening of business on the next business day for the recipient, and
(ii) notices or communications posted to an Internet or intranet website will be deemed received upon the deemed receipt by the intended recipient at its e-mail address as described in the foregoing clause (i) of notification that
such notice or communication is available and identifying the website address therefor. 
 (c) The Platform. THE PLATFORM
IS PROVIDED “AS IS” AND “AS AVAILABLE.” THE AGENT PARTIES (AS DEFINED BELOW) DO NOT WARRANT THE ACCURACY OR COMPLETENESS OF THE COMPANY MATERIALS OR THE ADEQUACY OF THE PLATFORM, AND EXPRESSLY DISCLAIM LIABILITY FOR ERRORS IN OR
OMISSIONS FROM THE COMPANY MATERIALS. NO WARRANTY OF ANY KIND, EXPRESS, IMPLIED OR STATUTORY, INCLUDING ANY WARRANTY OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THIRD PARTY RIGHTS OR FREEDOM FROM VIRUSES OR OTHER CODE
DEFECTS, IS MADE BY ANY AGENT PARTY IN CONNECTION WITH THE COMPANY MATERIALS OR THE PLATFORM. In no event will the Administrative Agent or any of its Related Parties (collectively, the “Agent Parties”) have any liability to the
Company, any Lender or any other Person for losses, claims, damages, liabilities or expenses of any kind (whether in tort, contract or otherwise) arising out of the Company’s or the Administrative Agent’s transmission of Company Materials
through the Internet, except to the extent that such losses, claims, damages, liabilities or expenses are determined by a court of competent jurisdiction by a final and nonappealable judgment to have resulted from the gross negligence or willful
misconduct of such Agent Party; provided, however, that in no event will any Agent Party have any liability to the Company, any Lender or any other Person for indirect, special, incidental, consequential or punitive damages (as opposed
to direct or actual damages). 
 (d) Change of Address, Etc. Each of the Company and the Administrative Agent may change
its address, telecopy, telephone number or electronic mail address for notices and other communications hereunder by notice to the other parties hereto. Each other Lender may change its address, telecopy, telephone number or electronic mail address
for notices and other communications hereunder by notice to the Company and the Administrative Agent. In addition, each Lender agrees to notify the Administrative Agent from time to time to ensure that the Administrative Agent has on record
(i) an effective address, contact name, telephone number, telecopy number and electronic mail address to which notices and other communications may be sent and (ii) accurate wire instructions for such Lender. Furthermore, each Public
Lender agrees to cause at least one individual at or on behalf of such Public Lender to at all times have selected 

  

			
	68	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
the “Private Side Information” or similar designation on the content declaration screen of the Platform in order to enable such Public Lender or its delegate, in accordance with such
Public Lender’s compliance procedures and applicable Law, including United States federal and state securities laws, to make reference to Company Materials, if any, that are not made available through the “Public Side Information”
portion of the Platform and that may contain material non-public information with respect to the Company or its securities for purposes of United States federal or state securities laws. 

(e) Reliance by Administrative Agent and Lenders. The Administrative Agent and the Lenders will be entitled to rely and act upon
any notices (including telephonic Loan Notices) purportedly given by or on behalf of the Company even if (i) such notices were not made in a manner specified herein, were incomplete or were not preceded or followed by any other form of notice
specified herein, or (ii) the terms thereof, as understood by the recipient, varied from any confirmation thereof. The Company will indemnify the Administrative Agent, each Lender and the Related Parties of each of them from all losses, costs,
expenses and liabilities resulting from the reliance by such Person on each notice purportedly given by or on behalf of the Company. All telephonic notices to and other telephonic communications with the Administrative Agent may be recorded by the
Administrative Agent, and each of the parties hereto hereby consents to such recording. 
 10.03 No Waiver; Cumulative
Remedies; Enforcement. No failure by any Lender or the Administrative Agent to exercise, and no delay by any such Person in exercising, any right, remedy, power or privilege hereunder will operate as a waiver thereof; nor will any single or
partial exercise of any right, remedy, power or privilege hereunder preclude any other or further exercise thereof or the exercise of any other right, remedy, power or privilege. The rights, remedies, powers and privileges herein provided are
cumulative and not exclusive of any rights, remedies, powers and privileges provided by law. 
 Notwithstanding anything to the
contrary contained herein or in any other Loan Document, the authority to enforce rights and remedies hereunder and under the other Loan Documents against the Loan Parties or any of them shall be vested exclusively in, and all actions and
proceedings at law in connection with such enforcement shall be instituted and maintained exclusively by, the Administrative Agent in accordance with Section 8.02 for the benefit of all the Lenders; provided, however, that
the foregoing shall not prohibit (a) the Administrative Agent from exercising on its own behalf the rights and remedies that inure to its benefit (solely in its capacity as Administrative Agent) hereunder and under the other Loan Documents,
(b) any Lender from exercising setoff rights in accordance with Section 10.08 (subject to the terms of Section 2.14), or (c) any Lender from filing proofs of claim or appearing and filing pleadings on its own behalf
during the pendency of a proceeding relative to any Loan Party under any Debtor Relief Law; and provided, further, that if at any time there is no Person acting as Administrative Agent hereunder and under the other Loan Documents, then
(i) the Required Lenders shall have the rights otherwise ascribed to the Administrative Agent pursuant to Section 8.02 and (ii) in addition to the matters set forth in clauses (b) and (c) of the
preceding proviso and subject to Section 2.14, any Lender may, with the consent of the Required Lenders, enforce any rights and remedies available to it and as authorized by the Required Lenders. 

  

			
	69	  	Watson Pharmaceuticals Term Loan Credit Agreement

 10.04 Expenses; Indemnity; Damage Waiver. 

(a) Costs and Expenses. The Company will pay (i) all reasonable and documented out of pocket expenses incurred by the
Administrative Agent (including the reasonable fees, charges and disbursements of counsel for the Administrative Agent, which shall be limited to Shearman & Sterling LLP), in connection with the preparation, negotiation, execution, delivery
and administration of this Agreement and the other Loan Documents or any amendments, modifications or waivers of the provisions hereof or thereof; provided that the out of pocket expenses of the Administrative Agent and its Affiliates and
their counsel with respect to the preparation, negotiation, execution and delivery of the Loan Documents in connection with the Transaction shall be limited as set forth in the Commitment Letter and (ii) all reasonable and documented out of
pocket expenses incurred by the Administrative Agent and the Lenders (including the reasonable fees, disbursements and other charges of counsel, which shall be limited to one counsel, and if necessary, one local counsel in each appropriate
jurisdiction and, solely in the case of a conflict of interest, one special conflicts counsel to all affected Indemnitees, taken as a whole) in connection with the enforcement or protection of their respective rights in connection with this
Agreement and the other Loan Documents, including its rights under this Section. 
 (b) Indemnification by the Company.
Subject to Section 10.04(a), the Company will indemnify the Administrative Agent (and any sub-agent thereof), each Arranger, the Syndication Agent, each Co-Documentation Agent, each Lender, and each Related Party of any of the foregoing
Persons (each an “Indemnitee”) against, and hold each Indemnitee harmless from, any and all losses, claims, damages, liabilities and related expenses (including the fees, charges and disbursements of any counsel for any Indemnitee)
arising out of, in connection with, or as a result of (i) the execution or delivery of this Agreement, any other Loan Document or any agreement or instrument contemplated hereby or thereby, the performance by the parties hereto of their
respective obligations hereunder or thereunder, the consummation of the transactions contemplated hereby or thereby, or, in the case of the Administrative Agent (and any sub-agent thereof) and its Related Parties only, the administration of this
Agreement and the other Loan Documents, (ii) any Loan or the use or proposed use of the proceeds therefrom (including the financing, in part, of the Acquisition with the proceeds of the Loans), (iii) any actual or alleged presence or
release of Hazardous Materials on or from any property owned or operated by the Company or any of its Subsidiaries, or any Environmental Liability related in any way to the Company or any of its Subsidiaries, or (iv) any actual or prospective
claim, litigation, investigation or proceeding relating to any of the foregoing, whether based on contract, tort or any other theory, whether brought by a third party or by the Company, and regardless of whether any Indemnitee is a party thereto;
provided that such indemnity will not, as to any Indemnitee, be available to the extent that such losses, claims, damages, liabilities or related expenses (x) are determined by a court of competent jurisdiction by final and nonappealable
judgment to have resulted from the gross negligence, willful misconduct or bad faith of such Indemnitee (or its respective affiliates and their respective officers, directors, employees or agents), (y) result from a claim brought by the Company
against an Indemnitee for a material breach in bad faith of such Indemnitee’s obligations hereunder or under any other Loan Document, if the Company has obtained a final and nonappealable judgment in its favor on such claim as determined by a
court of competent jurisdiction or (z) result from a claim of any Indemnitee solely against one or more Indemnitees (and not by one or more Indemnitees against the Administrative Agent, any Arranger, the Syndication Agent or any
Co-Documentation Agent to the extent acting in their capacity as such and to the extent otherwise entitled to be indemnified hereunder) that have not 

  

			
	70	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
resulted from the action or inaction of the Company or its Subsidiaries or any of their respective officers, directors, employees or agents. Notwithstanding any of the foregoing provisions to the
contrary, this Section 10.04(b) shall not apply with respect to Taxes, other than any Taxes that represent losses or damages arising from a non-Tax claim. 
 (c) Reimbursement by Lenders. To the extent that the Company for any reason fails to indefeasibly pay any amount required under subsection (a) or (b) of this Section to be
paid by it to the Administrative Agent (or any sub-agent thereof) or any Related Party of any of the foregoing, each Lender severally agrees to pay to the Administrative Agent (or any such sub-agent) or such Related Party, as the case may be, such
Lender’s Applicable Percentage (determined as of the time that the applicable unreimbursed expense or indemnity payment is sought) of such unpaid amount, provided that the unreimbursed expense or indemnified loss, claim, damage,
liability or related expense, as the case may be, was incurred by or asserted against the Administrative Agent (or any such sub-agent) in its capacity as such, or against any Related Party of any of the foregoing acting for the Administrative Agent
(or any such sub-agent) in connection with such capacity. The obligations of the Lenders under this subsection (c) are subject to the provisions of Section 2.13(d). 

(d) Waiver of Consequential Damages, Etc. To the fullest extent permitted by applicable law, none of the parties to this Agreement
shall assert, and each party hereto hereby waives, any claim against any Indemnitee, on any theory of liability, for special, indirect, consequential or punitive damages (as opposed to direct or actual damages) arising out of, in connection with, or
as a result of, this Agreement, any other Loan Document or any agreement or instrument contemplated hereby, the transactions contemplated hereby or thereby, any Loan or the use of the proceeds thereof. No Indemnitee referred to in subsection
(b) above shall be liable for any damages arising from the use by unintended recipients (excluding any Indemnitee) of any information or other materials distributed to such unintended recipients by such Indemnitee through
telecommunications, electronic or other information transmission systems in connection with this Agreement or the other Loan Documents or the transactions contemplated hereby or thereby other than for direct or actual damages resulting from the
gross negligence, willful misconduct or bad faith of such Indemnitee as determined by a final and nonappealable judgment of a court of competent jurisdiction. The indemnities in this Section 10.04(b) shall not abrogate, modify or
diminish the obligations of the Administrative Agent and the Lenders to keep certain information confidential in the manner and to the extent provided in Section 10.07. 

(e) Payments. All amounts due under this Section will be payable not later than ten Business Days after demand therefor.

 (f) Survival. The agreements in this Section will survive the resignation of the Administrative Agent, the replacement
of any Lender, the termination of the Aggregate Commitments and the repayment, satisfaction or discharge of all the other Obligations. 
 10.05 Payments Set Aside. To the extent that any payment by or on behalf of the Company is made to the Administrative Agent or any Lender, or the Administrative Agent or any Lender exercises its
right of setoff, and such payment or the proceeds of such setoff or any part thereof is subsequently invalidated, declared to be fraudulent or preferential, set aside or required (including pursuant to any settlement entered into by the
Administrative Agent or such 

  

			
	71	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
Lender in its discretion) to be repaid to a trustee, receiver or any other party, in connection with any proceeding under any Debtor Relief Law or otherwise, then (a) to the extent of such
recovery, the obligation or part thereof originally intended to be satisfied will be revived and continued in full force and effect as if such payment had not been made or such setoff had not occurred, and (b) each Lender severally agrees to
pay to the Administrative Agent upon demand its applicable share (without duplication) of any amount so recovered from or repaid by the Administrative Agent, plus interest thereon from the date of such demand to the date such payment is made at a
rate per annum equal to the applicable Overnight Rate from time to time in effect. The obligations of the Lenders under clause (b) of the preceding sentence will survive the payment in full of the Obligations and the termination of this
Agreement. 
 10.06 Successors and Assigns. (a) Successors and Assigns Generally. The provisions of this
Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors and assigns permitted hereby, except that no Loan Party may assign or otherwise transfer any of its rights or obligations hereunder
without the prior written consent of the Administrative Agent and each Lender (except in connection with a transaction permitted under Section 7.03 in accordance with the terms thereof) and no Lender may assign or otherwise transfer any
of its rights or obligations hereunder except (i) to an assignee in accordance with the provisions of subsection (b) of this Section, (ii) by way of participation in accordance with the provisions of subsection
(e) of this Section, or (iii) by way of pledge or assignment of a security interest subject to the restrictions of subsection (g) of this Section (and any other attempted assignment or transfer by any party hereto shall be
null and void). Nothing in this Agreement, expressed or implied, shall be construed to confer upon any Person (other than the parties hereto, their respective successors and assigns permitted hereby, Participants to the extent provided in
subsection (e) of this Section and, to the extent expressly contemplated hereby, the Related Parties of each of the Administrative Agent and the Lenders) any legal or equitable right, remedy or claim under or by reason of this Agreement.

 (b) Assignments by Lenders. Any Lender may at any time assign to one or more assignees all or a portion of its rights
and obligations under this Agreement (including all or a portion of its Commitment and the Loans at the time owing to it); provided that any such assignment shall be subject to the following conditions: 

(i) Minimum Amounts. 
 (A) in the case of an assignment of the entire remaining amount of the assigning Lender’s Commitment and the Loans at the time owing to it or in the case of an assignment to a Lender, an Affiliate of
a Lender or an Approved Fund, no minimum amount need be assigned; and 
 (B) in any case not described in
subsection (b)(i)(A) of this Section, the aggregate amount of the Commitment (which for this purpose includes Loans outstanding thereunder) or, if the Commitment is not then in effect, the principal outstanding balance of the Loans of the
assigning Lender subject to each such assignment, determined as of the date the Assignment and Assumption with respect to such assignment is delivered to the Administrative Agent or, if “Trade Date” is specified in the Assignment and
Assumption, as of the Trade Date, shall 

  

			
	72	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
not be less than $5,000,000 unless each of the Administrative Agent and, so long as no Event of Default has occurred and is continuing, the Company otherwise consents (each such consent not to be
unreasonably withheld or delayed); provided, however, that concurrent assignments to members of an Assignee Group and concurrent assignments from members of an Assignee Group to a single Eligible Assignee (or to an Eligible Assignee
and members of its Assignee Group) will be treated as a single assignment for purposes of determining whether such minimum amount has been met. 
 (ii) Proportionate Amounts. Each partial assignment shall be made as an assignment of a proportionate part of all the assigning Lender’s rights and obligations under this Agreement with
respect to the Loans or the Commitment so assigned; 
 (iii) Required Consents. No consent shall be
required for any assignment except to the extent required by subsection (b)(i)(B) of this Section and, in addition: 
 (A) the consent of the Company (such consent not to be unreasonably withheld) shall be required unless (1) an Event of Default has occurred and is continuing at the time of such assignment or
(2) such assignment is to a Lender, an Affiliate of a Lender or an Approved Fund; provided that the Company shall be deemed to have consented to any such assignment unless it shall object thereto by written notice to the Administrative
Agent within ten Business Days after having received notice thereof; and 
 (B) the consent of the
Administrative Agent (such consent not to be unreasonably withheld, conditioned or delayed) shall be required if such assignment is to a Person that is not a Lender, an Affiliate of such Lender or an Approved Fund with respect to such Lender.

 (iv) Assignment and Assumption. The parties to each assignment shall execute and deliver to the
Administrative Agent an Assignment and Assumption, together with a processing and recordation fee in the amount of $3,500; provided, however, that the Administrative Agent may, in its sole discretion, elect to waive such processing and
recordation fee in the case of any assignment. The assignee, if it is not a Lender, shall deliver to the Administrative Agent an Administrative Questionnaire. 
 (v) No Assignment to Certain Persons. No such assignment shall be made (A) to the Company or any of the Company’s Affiliates or Subsidiaries, (B) to any Defaulting Lender or any of
its Subsidiaries, or any Person who, upon becoming a Lender hereunder, would constitute any of the foregoing Persons described in this clause (B), or (C) to a natural person. No such assignment of Commitments shall be made at any time prior to
the initial funding of the Loans hereunder on the Closing Date to any Person that is not an Eligible Pre-Closing Lender. 
 Subject to
acceptance and recording thereof by the Administrative Agent pursuant to subsection (d) of this Section, from and after the effective date specified in each Assignment and Assumption, the assignee thereunder shall be a party to this
Agreement and shall, to the extent of 

  

			
	73	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
the interest assigned by such Assignment and Assumption, have the rights and obligations of a Lender under this Agreement, and the assigning Lender thereunder shall, to the extent of the interest
assigned by such Assignment and Assumption, be released from its obligations under this Agreement (and, in the case of an Assignment and Assumption covering all of the assigning Lender’s rights and obligations under this Agreement, such Lender
shall cease to be a party hereto) but shall continue to be entitled to the benefits of Sections 3.01, 3.04, 3.05 and 10.04 with respect to facts and circumstances occurring prior to the effective date of such assignment.
Upon request, the Company (at its expense) shall execute and deliver a Note to the assignee Lender. Any assignment or transfer by a Lender of rights or obligations under this Agreement that does not comply with this subsection shall be treated for
purposes of this Agreement as a sale by such Lender of a participation in such rights and obligations in accordance with subsection (e) of this Section. 
 (c) Certain Additional Payments. In connection with any assignment of rights and obligations of any Defaulting Lender hereunder, no such assignment shall be effective unless and until, in addition
to the other conditions thereto set forth herein, the parties to the assignment shall make such additional payments to the Administrative Agent in an aggregate amount sufficient, upon distribution thereof as appropriate (which may be outright
payment, purchases by the assignee of participations or subparticipations, or other compensating actions, including funding, with the consent of the Company and the Administrative Agent, the applicable pro rata share of Loans previously requested
but not funded by the Defaulting Lender, to each of which the applicable assignee and assignor hereby irrevocably consent), to (x) pay and satisfy in full all payment liabilities then owed by such Defaulting Lender to the Administrative Agent
or any Lender hereunder (and interest accrued thereon) and (y) acquire (and fund as appropriate) its full pro rata share of all Loans in accordance with its Applicable Percentage. Notwithstanding the foregoing, in the event that any assignment
of rights and obligations of any Defaulting Lender hereunder shall become effective under applicable Law without compliance with the provisions of this subsection (c), then the assignee of such interest shall be deemed to be a Defaulting
Lender for all purposes of this Agreement until such compliance occurs. 
 (d) Register. The Administrative Agent, acting
solely for this purpose as an agent of the Company (and such agency being solely for tax purposes), shall maintain at the Administrative Agent’s Office a copy of each Assignment and Assumption delivered to it and a register for the recordation
of the names and addresses of the Lenders, and the Commitments of, and principal amounts of the Loans owing to, each Lender pursuant to the terms hereof from time to time (the “Register”). The entries in the Register shall be
conclusive, and the Company, the Administrative Agent and the Lenders may treat each Person whose name is recorded in the Register pursuant to the terms hereof as a Lender hereunder for all purposes of this Agreement, notwithstanding notice to the
contrary. In addition, the Administrative Agent shall maintain on the Register information regarding the designation, and revocation of designation, of any Lender as a Defaulting Lender. The Register shall be available for inspection by the Company
and, solely with respect to the Commitments of, and principal amounts of the Loans owing to, any Lender, such Lender, in each case at any reasonable time and from time to time upon reasonable prior notice. 

(e) Participations. Any Lender may at any time, without the consent of, or notice to, the Company or the Administrative Agent,
sell participations to any Person (other than a natural 

  

			
	74	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
person, a Defaulting Lender or the Company or any of the Company’s Affiliates or Subsidiaries) (each, a “Participant”) in all or a portion of such Lender’s rights
and/or obligations under this Agreement (including all or a portion of its Commitment and/or the Loans owing to it); provided that (i) such Lender’s obligations under this Agreement shall remain unchanged, (ii) such Lender
shall remain solely responsible to the other parties hereto for the performance of such obligations and (iii) the Company, the Administrative Agent, and the Lenders shall continue to deal solely and directly with such Lender in connection with
such Lender’s rights and obligations under this Agreement. Each Lender that sells a participation shall, acting solely for this purpose as a non-fiduciary agent of the Company, maintain a register on which it enters the name and address of each
Participant and the principal amounts (and stated interest) of each Participant’s interest in the Loans or other obligations under the Loan Documents (the “Participant Register”); provided that no Lender shall have any
obligation to disclose all or any portion of the Participant Register (including the identity of any Participant or any information relating to a Participant’s interest in any Commitments, Loans or its other obligations under this Agreement) to
any Person except to the extent that such disclosure is necessary to establish that such Commitment, Loan or other obligation is in registered form under Section 5f.103-1(c) of the United States Treasury Regulations. For the avoidance of doubt,
the Administrative Agent (in its capacity as Administrative Agent) shall have no responsibility for maintaining a Participant Register. The entries in the Participant Register shall be conclusive absent manifest error, and such Lender shall treat
each Person whose name is recorded in the Participant Register as the owner of such participation for all purposes of this Agreement notwithstanding any notice to the contrary. 

Any agreement or instrument pursuant to which a Lender sells such a participation shall provide that such Lender shall retain the sole
right to enforce this Agreement and to approve any amendment, modification or waiver of any provision of this Agreement; provided that such agreement or instrument may provide that such Lender will not, without the consent of the Participant,
agree to any amendment, waiver or other modification described in the first proviso to Section 10.01 that affects such Participant. Subject to subsection (f) of this Section, the Company agrees that each Participant shall be
entitled to the benefits of Sections 3.01, 3.04 and 3.05 to the same extent as if it were a Lender and had acquired its interest by assignment pursuant to subsection (b) of this Section; provided that such Participant
agrees to be subject to the provisions of Section 3.06 as if it were a Lender. To the extent permitted by law, each Participant also shall be entitled to the benefits of Section 10.08 as though it were a Lender, provided such
Participant agrees to be subject to Section 2.14 as though it were a Lender. 
 (f) Limitations upon Participant
Rights. A Participant shall not be entitled to receive any greater payment under Section 3.01 or 3.04 than the applicable Lender would have been entitled to receive with respect to the participation sold to such Participant,
unless the sale of the participation to such Participant is made with the Company’s prior written consent. A Participant shall not be entitled to the benefits of Section 3.01 unless the Company is notified of the participation sold
to such Participant and such Participant agrees, for the benefit of the Company, to comply with Section 3.01(e) as though it were a Lender. 
 (g) Certain Pledges. Any Lender may at any time pledge or assign a security interest in all or any portion of its rights under this Agreement (including under its Note(s), if any) to secure
obligations of such Lender, including any pledge or assignment to secure obligations to a Federal Reserve Bank; provided that no such pledge or assignment shall release such Lender from any of its obligations hereunder or substitute any such
pledgee or assignee for such Lender as a party hereto. 

  

			
	75	  	Watson Pharmaceuticals Term Loan Credit Agreement

 10.07 Treatment of Certain Information; Confidentiality. Each of the Administrative
Agent and the Lenders agrees to maintain the confidentiality of the Information (as defined below), except that Information may be disclosed (a) to its Affiliates and to its and its Affiliates’ respective partners, directors, officers,
employees, agents, advisors and representatives (it being understood that the Persons to whom such disclosure is made will be informed of the confidential nature of such Information and instructed to keep such Information confidential), (b) to
the extent requested by any regulatory authority purporting to have jurisdiction over it or its Affiliates (including any self-regulatory authority, such as the National Association of Insurance Commissioners), (c) to the extent required by
applicable laws or regulations or by any subpoena or similar legal process, (d) to any other party hereto, (e) in connection with the exercise of any remedies hereunder or under any other Loan Document or any action or proceeding relating
to this Agreement or any other Loan Document or the enforcement of rights hereunder or thereunder, (f) subject to an agreement containing provisions substantially the same as those of this Section, to (i) any assignee of or Participant in,
or any prospective assignee of or Participant in, any of its rights or obligations under this Agreement or (ii) any actual or prospective counterparty (or its advisors) to any swap or derivative transaction relating to the Company and its
obligations, (g) with the consent of the Company or (h) to the extent such Information (x) becomes publicly available other than as a result of a breach of this Section or (y) becomes available to the Administrative Agent, any
Lender or any of their respective Affiliates on a nonconfidential basis from a source other than the Company. 
 For purposes of
this Section, “Information” means all information received from the Company or any Subsidiary relating to the Company or any Subsidiary or any of their respective businesses, other than any such information that is available to the
Administrative Agent or any Lender on a nonconfidential basis prior to disclosure by the Company or any Subsidiary, provided that, in the case of information received from the Company or any Subsidiary after the Closing Date, such information
is clearly identified at the time of delivery as confidential. Any Person required to maintain the confidentiality of Information as provided in this Section will be considered to have complied with its obligation to do so if such Person has
exercised the same degree of care to maintain the confidentiality of such Information as such Person would accord to its own confidential information. 
 Each of the Administrative Agent and the Lenders acknowledges that (a) the Information may include material non-public information concerning the Company or a Subsidiary, as the case may be,
(b) it has developed compliance procedures regarding the use of material non-public information and (c) it will handle such material non-public information in accordance with applicable Law, including United States federal and state
securities laws. 
 Subject to any applicable requirements of United State federal, state or local laws or regulations,
including securities laws or regulations, neither the Administrative Agent nor any Lender will make or cause to be made, whether orally, in writing or otherwise, any public announcement or statement that is intended for the general public and not
targeted primarily to reach audiences in the banking industry and the banking industry’s customers with respect to the 

  

			
	76	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
transactions contemplated by this Agreement, or any of the provisions of this Agreement, without the prior written approval of the Company as to the form, content and timing of such announcement
or disclosure, which approval may be given or withheld in the Company’s sole discretion. 
 10.08 Right of Setoff.
If an Event of Default will have occurred and be continuing, each Lender and each of their respective Affiliates is hereby authorized at any time and from time to time, to the fullest extent permitted by applicable law, to set off and apply any and
all deposits (general or special, time or demand, provisional or final, in whatever currency) at any time held and other obligations at any time owing by such Lender or any such Affiliate to or for the credit or the account of the Company against
any and all of its obligations now or hereafter existing under this Agreement or any other Loan Document to such Lender, irrespective of whether or not such Lender will have made any demand under this Agreement or any other Loan Document and
although such obligations of the Company may be contingent or unmatured or are owed to a branch or office of such Lender different from the branch or office holding such deposit or obligated on such indebtedness; provided, that in the event
that any Defaulting Lender shall exercise any such right of setoff, (x) all amounts so set off shall be paid over immediately to the Administrative Agent for further application in accordance with the provisions of Section 2.17 and,
pending such payment, shall be segregated by such Defaulting Lender from its other funds and deemed held in trust for the benefit of the Administrative Agent and the Lenders, and (y) the Defaulting Lender shall provide promptly to the
Administrative Agent a statement describing in reasonable detail the Obligations owing to such Defaulting Lender as to which it exercised such right of setoff. The rights of each Lender and their respective Affiliates under this Section are in
addition to other rights and remedies (including other rights of setoff) that such Lender or their respective Affiliates may have. Each Lender agrees to notify the Company and the Administrative Agent promptly after any such setoff and application,
provided that the failure to give such notice will not affect the validity of such setoff and application. Notwithstanding the provisions of this Section 10.08, if at any time any Lender or any of their respective Affiliates
maintains one or more deposit accounts for the Company or any other Loan Party into which Medicare and/or Medicaid receivables are deposited, such Person shall waive the right of setoff set forth herein. 

10.09 Interest Rate Limitation. Notwithstanding anything to the contrary contained in any Loan Document, the interest paid or
agreed to be paid under the Loan Documents will not exceed the maximum rate of non-usurious interest permitted by applicable Law (the “Maximum Rate”). If the Administrative Agent or any Lender will receive interest in an amount that
exceeds the Maximum Rate, the excess interest will be applied to the principal of the Loans or, if it exceeds such unpaid principal, refunded to the Company. In determining whether the interest contracted for, charged, or received by the
Administrative Agent or a Lender exceeds the Maximum Rate, such Person may, to the extent permitted by applicable Law, (a) characterize any payment that is not principal as an expense, fee, or premium rather than interest, (b) exclude
voluntary prepayments and the effects thereof, and (c) amortize, prorate, allocate, and spread in equal or unequal parts the total amount of interest throughout the contemplated term of the Obligations hereunder. 

10.10 Counterparts; Integration; Effectiveness. This Agreement and the other Loan Documents may be executed in counterparts (and
by different parties hereto in different 

  

			
	77	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
counterparts), each of which will constitute an original, but all of which when taken together will constitute a single contract. This Agreement and the other Loan Documents constitute the entire
contract among the parties relating to the subject matter hereof and supersede any and all previous agreements and understandings, oral or written, relating to the subject matter hereof. This Agreement will become effective when it will have been
executed by the Administrative Agent and when the Administrative Agent will have received counterparts hereof that, when taken together, bear the signatures of each of the other parties hereto. Delivery of an executed counterpart of a signature page
of this Agreement and any other Loan Document by telecopy or other electronic transmission (including “pdf” or “tif”) will be effective as delivery of a manually executed counterpart of this Agreement and the other Loan
Documents. 
 10.11 Survival of Representations and Warranties. All representations and warranties made hereunder and in
any other Loan Document or other document delivered pursuant hereto or thereto or in connection herewith or therewith will survive the execution and delivery hereof and thereof. Such representations and warranties have been or will be relied upon by
the Administrative Agent and each Lender, regardless of any investigation made by the Administrative Agent or any Lender or on their behalf and notwithstanding that the Administrative Agent or any Lender may have had notice or knowledge of any
Default at the time of any Borrowing, and will continue in full force and effect as long as any Loan or any other Obligation hereunder will remain unpaid or unsatisfied. 
 10.12 Severability. If any provision of this Agreement or the other Loan Documents is held to be illegal, invalid or unenforceable, (a) the legality, validity and enforceability of the
remaining provisions of this Agreement and the other Loan Documents will not be affected or impaired thereby and (b) the parties will endeavor in good faith negotiations to replace the illegal, invalid or unenforceable provisions with valid
provisions the economic effect of which comes as close as possible to that of the illegal, invalid or unenforceable provisions. The invalidity of a provision in a particular jurisdiction will not invalidate or render unenforceable such provision in
any other jurisdiction. Without limiting the foregoing provisions of this Section 10.12, if and to the extent that the enforceability of any provisions in this Agreement relating to Defaulting Lenders shall be limited by Debtor Relief
Laws, as applicable, then such provisions shall be deemed to be in effect only to the extent not so limited. 
 10.13
Replacement of Lenders. In the event (i) any Lender requests compensation under Section 3.04, (ii) the Company is required to pay any additional amount to any Lender or any Governmental Authority for the account of any
Lender pursuant to Section 3.01, (iii) any Lender becomes a Defaulting Lender, (iv) any Lender refuses to consent to any amendment, waiver or other modification of this Agreement or any other Loan Document requested by the
Company that requires the consent of a greater percentage of the Lenders than the Required Lenders and such amendment, waiver or other modification is consented to by the Required Lenders, or (v) any other circumstance exists hereunder that
gives the Company the right to replace a Lender as a party hereto, then the Company may, at its sole expense and effort, upon notice to such Lender and the Administrative Agent, require such Lender to assign and delegate, without recourse (in
accordance with and subject to the restrictions contained in, and consents required by, Section 10.06), all of its interests, rights and obligations under this Agreement and the related Loan Documents to an assignee that will assume such
obligations (which assignee may be another Lender, if a Lender accepts such assignment), provided that: 

  

			
	78	  	Watson Pharmaceuticals Term Loan Credit Agreement

 (a) the Company will have paid to the Administrative Agent the assignment fee specified in
Section 10.06(b); 
 (b) such Lender will have received payment of an amount equal to 100% of the outstanding
principal of its Loans, accrued interest thereon, accrued fees and all other amounts payable to it hereunder and under the other Loan Documents (including any amounts under Section 3.05) from the assignee (to the extent of such
outstanding principal and accrued interest and fees) or the Company (in the case of all other amounts); 
 (c) in the case
of any such assignment resulting from a claim for compensation under Section 3.04 or payments required to be made pursuant to Section 3.01, such assignment will result in a reduction in such compensation or payments
thereafter; and 
 (d) such assignment does not conflict with applicable Laws. 

A Lender will not be required to make any such assignment or delegation if, prior thereto, as a result of a waiver by such Lender or
otherwise, the circumstances entitling the Company to require such assignment and delegation cease to apply. 
 10.14
Governing Law; Jurisdiction; Etc. 
 (a) GOVERNING LAW. THIS AGREEMENT WILL BE GOVERNED BY, AND CONSTRUED IN
ACCORDANCE WITH, THE LAW OF THE STATE OF NEW YORK; PROVIDED THAT (I) THE INTERPRETATION OF THE DEFINITION OF TARGET MATERIAL ADVERSE EFFECT AND WHETHER OR NOT A TARGET MATERIAL ADVERSE EFFECT HAS OCCURRED, (II) THE DETERMINATION OF THE
ACCURACY OF ANY ACQUISITION AGREEMENT REPRESENTATIONS AND WHETHER AS A RESULT OF ANY INACCURACY THEREOF THE COMPANY (OR ITS AFFILIATES) HAVE THE RIGHT TO TERMINATE ITS (OR THEIR) OBLIGATIONS UNDER THE ACQUISITION AGREEMENT, OR TO DECLINE TO
CONSUMMATE THE ACQUISITION PURSUANT TO THE ACQUISITION AGREEMENT AND (III) THE DETERMINATION OF WHETHER THE ACQUISITION HAS BEEN CONSUMMATED IN ACCORDANCE WITH THE TERMS OF THE ACQUISITION, IN EACH CASE, SHALL BE GOVERNED BY, AND CONSTRUED AND
INTERPRETED SOLELY IN ACCORDANCE WITH, THE LAWS OF ENGLAND AND WALES, WITHOUT REGARD TO ANY OTHER PRINCIPLES OF CONFLICTS OF LAW. 
 (b) SUBMISSION TO JURISDICTION. THE COMPANY IRREVOCABLY AND UNCONDITIONALLY SUBMITS, FOR ITSELF AND ITS PROPERTY, TO THE EXCLUSIVE JURISDICTION OF THE COURTS OF THE STATE OF NEW YORK SITTING IN NEW
YORK COUNTY AND OF THE UNITED STATES DISTRICT COURT OF THE SOUTHERN DISTRICT OF NEW YORK, AND ANY APPELLATE COURT FROM ANY THEREOF, IN ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT, OR FOR
RECOGNITION OR ENFORCEMENT OF ANY JUDGMENT, AND EACH OF THE PARTIES HERETO IRREVOCABLY AND UNCONDITIONALLY AGREES THAT ALL CLAIMS IN RESPECT OF ANY SUCH ACTION OR PROCEEDING MAY BE HEARD AND DETERMINED IN

  

			
	79	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
SUCH NEW YORK STATE COURT OR, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, IN SUCH FEDERAL COURT. EACH OF THE PARTIES HERETO AGREES THAT A FINAL JUDGMENT IN ANY SUCH ACTION OR PROCEEDING
WILL BE CONCLUSIVE AND MAY BE ENFORCED IN OTHER JURISDICTIONS BY SUIT ON THE JUDGMENT OR IN ANY OTHER MANNER PROVIDED BY LAW. NOTHING IN THIS AGREEMENT OR IN ANY OTHER LOAN DOCUMENT WILL AFFECT ANY RIGHT THAT THE ADMINISTRATIVE AGENT OR ANY LENDER
MAY OTHERWISE HAVE TO BRING ANY ACTION OR PROCEEDING RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT AGAINST THE COMPANY OR ITS PROPERTIES IN THE COURTS OF ANY JURISDICTION. 

(c) WAIVER OF VENUE. THE COMPANY IRREVOCABLY AND UNCONDITIONALLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY
OBJECTION THAT IT MAY NOW OR HEREAFTER HAVE TO THE LAYING OF VENUE OF ANY ACTION OR PROCEEDING ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT IN ANY COURT REFERRED TO IN PARAGRAPH (B) OF THIS SECTION. EACH OF THE
PARTIES HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, THE DEFENSE OF AN INCONVENIENT FORUM TO THE MAINTENANCE OF SUCH ACTION OR PROCEEDING IN ANY SUCH COURT. 

(d) SERVICE OF PROCESS. EACH PARTY HERETO IRREVOCABLY CONSENTS TO SERVICE OF PROCESS IN THE MANNER PROVIDED FOR NOTICES IN
SECTION 10.02. NOTHING IN THIS AGREEMENT WILL AFFECT THE RIGHT OF ANY PARTY HERETO TO SERVE PROCESS IN ANY OTHER MANNER PERMITTED BY APPLICABLE LAW. 
 10.15 WAIVER OF JURY TRIAL. EACH PARTY HERETO HEREBY IRREVOCABLY WAIVES, TO THE FULLEST EXTENT PERMITTED BY APPLICABLE LAW, ANY RIGHT IT MAY HAVE TO A TRIAL BY JURY IN ANY LEGAL PROCEEDING DIRECTLY
OR INDIRECTLY ARISING OUT OF OR RELATING TO THIS AGREEMENT OR ANY OTHER LOAN DOCUMENT OR THE TRANSACTIONS CONTEMPLATED HEREBY OR THEREBY (WHETHER BASED ON CONTRACT, TORT OR ANY OTHER THEORY). EACH PARTY HERETO (A) CERTIFIES THAT NO
REPRESENTATIVE, AGENT OR ATTORNEY OF ANY OTHER PERSON HAS REPRESENTED, EXPRESSLY OR OTHERWISE, THAT SUCH OTHER PERSON WOULD NOT, IN THE EVENT OF LITIGATION, SEEK TO ENFORCE THE FOREGOING WAIVER AND (B) ACKNOWLEDGES THAT IT AND THE OTHER PARTIES
HERETO HAVE BEEN INDUCED TO ENTER INTO THIS AGREEMENT AND THE OTHER LOAN DOCUMENTS BY, AMONG OTHER THINGS, THE MUTUAL WAIVERS AND CERTIFICATIONS IN THIS SECTION. 
 10.16 USA PATRIOT Act. Each Lender that is subject to the Patriot Act and the Administrative Agent (for itself and not on behalf of any Lender) hereby notifies the Company that pursuant to the
requirements of the Patriot Act, it is required to obtain, verify and record information that identifies the Company, which information includes the name and address of the Company and other information that will allow such Lender or the
Administrative Agent, as 

  

			
	80	  	Watson Pharmaceuticals Term Loan Credit Agreement

 
applicable, to identify the Company in accordance with the Patriot Act. The Company shall, promptly following a request by the Administrative Agent or any Lender, provide all documentation and
other information that the Administrative Agent or such Lender requests in order to comply with its ongoing obligations under applicable “know your customer” and anti-money laundering rules and regulations, including the Patriot Act.

 10.17 No Advisory or Fiduciary Responsibility. In connection with all aspects of each transaction contemplated hereby
(including in connection with any amendment, waiver or other modification hereof or of any other Loan Document), the Company acknowledges and agrees that: (i) (A) the arranging and other services regarding this Agreement provided by the
Administrative Agent, the Lenders and the Arrangers are arm’s-length commercial transactions between the Company, on the one hand, and the Administrative Agent, the Lenders and the Arrangers, on the other hand, (B) the Company has
consulted its own legal, accounting, regulatory and tax advisors to the extent it has deemed appropriate, and (C) the Company is capable of evaluating, and understands and accepts, the terms, risks and conditions of the transactions
contemplated hereby and by the other Loan Documents; (ii) (A) each of the Administrative Agent, the Lenders and the Arrangers is and has been acting solely as a principal and, except as expressly agreed in writing by the relevant parties,
has not been, is not, and will not be acting as an advisor, agent or fiduciary for the Company or any other Person and (B) neither the Administrative Agent nor any Lender nor any Arranger has any obligation to the Company with respect to the
transactions contemplated hereby, except those obligations expressly set forth herein and in the other Loan Documents; and (iii) the Administrative Agent, the Lenders and the Arrangers and their respective Affiliates may be engaged in a broad
range of transactions that involve interests that differ from those of the Company, and neither the Administrative Agent nor any Lender nor any Arranger has any obligation to disclose any of such interests to the Company. To the fullest extent
permitted by law, the Company hereby waives and releases any claims that it may have against the Administrative Agent, the Lenders and any Arranger with respect to any breach or alleged breach of agency or fiduciary duty in connection with any
aspect of any transaction contemplated hereby. 
 10.18 Electronic Execution of Assignments. The words
“execution,” “signed,” “signature,” and words of like import in any Assignment and Assumption shall be deemed to include electronic signatures or the keeping of records in electronic form, each of which shall be of the
same legal effect, validity or enforceability as a manually executed signature or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures
in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act. 
 [Remainder of page intentionally left blank]  

  

			
	81	  	Watson Pharmaceuticals Term Loan Credit Agreement

 IN WITNESS WHEREOF, the parties hereto have caused this Agreement to be duly executed
as of the date first above written. 
  

			
	WATSON PHARMACEUTICALS, INC.
		
	By:	 	/s/ R. Todd Joyce
		 	Name: R. Todd Joyce
		 	Title: Chief Financial Officer-Global

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 BANK OF AMERICA, N.A., as Administrative
 Agent

		
	By:	 	/s/ Darleen R Parmelee
		 	Name: Darleen R Parmelee
		 	Title: Assistant Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	BANK OF AMERICA, N.A., as Lender
		
	By:	 	/s/ Robert LaPorte
		 	Name: Robert LaPorte
		 	Title: Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 WELLS FARGO BANK, NATIONAL
 ASSOCIATION

		
	By:	 	/s/ Kirk Tesch
		 	Name: Kirk Tesch
		 	Title: Director

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	BARCLAYS BANK PLC
		
	By:	 	/s/ Michael Mozer
		 	Name: Michael Mozer
		 	Title: Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	JPMORGAN CHASE BANK, N.A.
		
	By:	 	/s/ Philip Mousin
		 	Name: Philip Mousin
		 	Title: Credit Executive

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	DEUTSCHE BANK AG NEW YORK BRANCH
		
	By:	 	/s/ Ming K. Chu
		 	Name: Ming K. Chu
		 	Title: Vice President
		
	By:	 	/s/ Hans-Josef Thiele
		 	Name: Hans-Josef Thiele
		 	Title: Director

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	MIZUHO CORPORATE BANK, LTD.
		
	By:	 	/s/ Bertram H. Tang
		 	Name: Bertram H. Tang
		 	Title: Authorized Signatory

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 THE BANK OF TOKYO-MITSUBISHI UFJ,
 LTD

		
	By:	 	/s/ Lillian Kim
		 	Name: Lillian Kim
		 	Title: Director

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 AUSTRALIA AND NEW ZEALAND
 BANKING GROUP LIMITED

		
	By:	 	/s/ Robert Grillo
		 	Name: Robert Grillo
		 	Title: Director

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 SUMITOMO MITSUI BANKING
 CORPORATION

		
	By:	 	/s/ David W. Kee
		 	Name: David W. Kee
		 	Title: Managing Director

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	TD BANK, N.A.
		
	By:	 	/s/ Todd Antico
		 	Name: Todd Antico
		 	Title: Senior Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 DNB BANK ASA, GRAND CAYMAN
 BRANCH

		
	 By:
	 	/s/ Kristie Li
		 	Name: Kristie Li
		 	Title: First Vice President
		
	 By:
	 	/s/ Thomas Tangen
		 	Name: Thomas Tangen
		 	Title: Senior Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 HSBC BANK USA, NATIONAL
 ASSOCIATION

		
	By:	 	/s/ Robert Moravec
		 	Name: Robert Moravec
		 	Title: Senior Relationship Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	THE ROYAL BANK OF SCOTLAND PLC
		
	By:	 	/s/ Bhavin Shah
		 	Name: Bhavin Shah
		 	Title: Managing Director

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	U.S. BANK NATIONAL ASSOCIATION
		
	By:	 	/s/ Michael West
		 	Name: Michael West
		 	Title: Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	LLOYDS TSB BANK PLC, as a Lender
		
	By:	 	/s/ Candi Obrentz
		 	Name: Candi Obrentz
		 	Title: Vice President—O013
	
	LLOYDS TSB BANK PLC, as a Lender
		
	By:	 	/s/ Julia R. Franklin
		 	Name: Julia R. Franklin
		 	Title: Vice President—F014

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	SOVEREIGN BANK, N.A.
		
	By:	 	/s/ JOHN W. DEEGAN
		 	Name: JOHN W. DEEGAN
		 	Title: SVP—CORPORATE BANKING

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 LAND BANK OF TAIWAN LOS ANGELES
 BRANCH

		
	By:	 	/s/ Juifu Chien
		 	Name: Juifu Chien
		 	Title: Vice President and General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 TAIWAN COOPERATIVE BANK LOS
 ANGELES BRANCH

		
	By:	 	/s/ Li-Hua Huang
		 	Name: Li-Hua Huang
		 	Title: VP & General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 CHANG HWA COMMERCIAL BANK, LTD.,
 NEW YORK BRANCH

		
	By:	 	/s/ Eric Y.S. Tsai
		 	Name: Eric Y.S. Tsai
		 	Title: V.P. & General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	BANK LEUMI USA
		
	By:	 	/s/ Joung Hee Hong
		 	Name: Joung Hee Hong
		 	Title: First Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 BANK OF COMMUNICATION CO. LTD.,
 NEW YORK BRANCH

		
	By:	 	/s/ Shelley He
		 	Name: Shelley He
		 	Title: Deputy General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	CITY NATIONAL BANK, NA
		
	By:	 	/s/ Charles Hill
		 	Name: Charles Hill
		 	Title: Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 HUA NAN COMMERCIAL BANK, LTD. NEW
 YORK AGENCY

		
	By:	 	/s/ Henry Hsieh
		 	Name: Henry Hsieh
		 	Title: Assistant Vice President

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 BANK OF TAIWAN, LOS ANGELES
 BRANCH

		
	By:	 	/s/ Chwan-Ming Ho
		 	Name: Chwan-Ming Ho
		 	Title: Vice President & General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 MEGA INTERNATIONAL COMMERCIAL
 BANK CO, LOS ANGELES BRANCH

		
	By:	 	/s/ Hsiao-Ho Huang
		 	Name: Hsiao-Ho Huang
		 	Title: SVP & GM

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 MEGA INTERNATIONAL COMMERCIAL
 BANK CO, NEW YORK BRANCH

		
	By:	 	/s/ Priscilla Hsing
		 	Name: Priscilla Hsing
		 	Title: VP & DGM

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 CHINATRUST COMMERCIAL BANK NEW
 YORK BRANCH

		
	By:	 	/s/ Amy Fong
		 	Name: Amy Fong
		 	Title: SVP & General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	CATHAY UNITED BANK, LTD.
		
	By:	 	/s/ Alexander Wu
		 	Name: Alexander Wu
		 	Title: SVP & General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement] 

 
			
	 THE CHIBA BANK, LTD., NEW YORK
 BRANCH

		
	By:	 	/s/ Yukihito Inamura
		 	Name: Yukihito Inamura
		 	Title: General Manager

  
 [Signature
Page to Watson Pharmaceuticals Term Loan Agreement]Offer Letter

 Exhibit 10.1 
 May 22, 2012 
 Leone Patterson 
 Private address 
 Dear Leone: 

I am pleased to offer you a position with Transcept Pharmaceuticals (the “Company”) as Vice President, Chief Financial Officer.
The position will be based out of our offices located at 1003 W. Cutting Blvd., Suite 110, Pt. Richmond, California. If you decide to join us you will receive a monthly salary of $26,250 less required deductions and withholdings, which will be paid
semi-monthly in accordance with the Company’s normal payroll procedures. 
 You will also be eligible to participate in the
executive bonus program with a target bonus of up to 35% of your base salary. At Transcept our salary merit increases and potential bonus amounts, if any, are based upon the assumption that an employee has provided services to the Company for the
entire calendar year. Therefore, if you join Transcept at any time between January 1 and November 1 of any calendar year, your potential salary merit increase and potential bonus, if either is awarded, will be pro-rated for the actual
amount of service you provide during that calendar year. If you leave at any time during a year, you will not be eligible for any pro-rata amount of your unearned target bonus for that year. Bonus payments will be subject to required deductions and
withholdings. The Company shall have the sole discretion to determine whether you have earned any bonus set forth in this paragraph and, if so, the amount of any such bonus. 
 As an employee, you are also eligible to receive certain employee benefits that currently include health, dental, life and vision insurance as well as a 401(k) plan pursuant to the terms of these benefit
plans. You should note that the Company may modify compensation and benefits from time to time as it deems necessary. The Company will also reimburse you for business expenses consistent with Company practices and policies, continuing education
expenses and fees required to maintain good standing as a Certified Public Accountant. 
 In addition, if you decide to join us,
it will be recommended to the Company’s Compensation Committee at the first meeting of the Compensation Committee following your start date, that the Company grant you an option to purchase 90,000 shares of the Company’s Common Stock at a
price per share equal to the fair market value per share of the Common Stock on the date of grant, as determined by the closing price. If granted, 25% of the shares subject to the option shall vest 12 months after the date your vesting begins (and,
except as provided in your Change of Control and Severance Benefit Agreement), no shares shall vest before such date and no rights to any vesting shall be earned or accrued prior to such date) and the remaining shares subject to the option shall
vest monthly over the next 36 months in equal monthly amounts subject to your continuing employment with the Company. This option grant shall be subject to the terms and conditions of the Company’s Stock Option Plan and Stock Option Agreement.
Over time, additional performance-based stock option grants may be made available in the sole discretion of the Company. 

 The Company also will enter into a Change of Control and Severance Benefits Agreement (the
“Severance Agreement”) with you. 
 Any successor in interest to the Company shall be bound by the terms of this
Agreement. 
 The Company is excited about the prospect of having you join our team, and we look forward to a beneficial and
fruitful relationship. Nevertheless, you should be aware that your employment with the Company is for no specified period and constitutes at-will employment. As a result, you are free to resign at any time, for any reason or for no reason.
Similarly, the Company is free to conclude its employment relationship with you at any time, with or without cause, and with or without advance notice. We request that, in the event of resignation, you give the Company at least two-week’s
notice. 
 Due to requirements under its DEA application the company conducts background checks on all of its potential
employees. Your job offer, therefore, in contingent upon a clearance of such a background investigation. 
 For purposes of
federal immigration law, you will be required to provide to the Company documentary evidence of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3) business days of your
date of hire, or our employment relationship with you may be terminated. 
 We also ask that, if you have not already done so,
you disclose to the Company any and all agreements relating to your prior employment that may affect your eligibility to be employed by the Company or limit the manner in which you may be employed. It is the Company’s understanding that any
such agreements will not prevent you from performing the duties of your position and you represent that such is the case. Moreover, you agree that, during the term of your employment with the Company, you will not engage in any other employment,
occupation, consulting or other business activity directly related to the business in which the Company is now involved or becomes involved during the term of your employment, nor will you engage in any other activities that conflict with your
obligations to the Company, subject to the below. Similarly, you agree not to bring any third-party confidential information to the Company, including that of your former employer(s), and that in performing your duties for the Company, you will not
in any way utilize any such information. 
 As you know, Transcept is involved in an industry that is highly competitive and
that changes quickly. Thus, although the position we are offering is as its Chief Financial Officer, Transcept may change your position and/or your duties at any time, with or without cause or advance notice. As with all of our employees, your
employment is also subject to our general employment policies, many of which are described in our Employee Handbook. As a Company employee, you will be expected to abide by company rules and standards. You will be specifically required to sign an
acknowledgment that you have read and that you understand the Company’s rules of conduct, which are included in the Company Handbook. 
 As a condition of your employment, you will also be required to sign and comply with an At-Will Employment, Confidential Information, Invention Assignment, and Arbitration Agreement which requires,
among other provisions, the assignment of patent rights to any invention made during your employment at the Company, and non-disclosure of proprietary information. In the event of any dispute or claim relating to or arising out of this agreement or
our employment relationship, you and the Company agree to an arbitration in which (i) you are waiving any and all rights to a jury trial but all court remedies will be available in arbitration,
(ii)

 
we agree that all disputes between you and the Company shall be fully and finally resolved by binding arbitration, (iii) all disputes shall be resolved by a single neutral arbitrator who
shall issue a written opinion, (iv) the arbitration proceeding shall provide for adequate discovery, and (v) the Company shall pay all arbitration fees in excess of any court fees which you would be required to pay if the dispute were
decided in a court of law. Any such arbitration shall be conducted in the San Francisco Bay Area by Judicial Arbitration and Mediation Services (JAMS) under the JAMS Employment Arbitration Rules and Procedures. 

To indicate your acceptance of the Company’s offer, please sign and date this letter in the space provided below. A duplicate
original is enclosed for your records. If you accept our offer, your first day of employment shall be subject to mutual agreement, but in no event be later than June 25, 2012. This letter, along with your At-Will Employment, Confidential
Information, Invention Assignment, and Arbitration Agreement and the Severance Agreement, sets forth the entire terms of your employment with the Company and supersede any prior representations or agreements including, but not limited to any
representations made during your interviews or relocation negotiations, whether written or oral. This letter, including, but not limited to, its at-will employment provision, may not be modified or amended except by a written agreement signed by the
Company President and you. This offer of employment will terminate if it is not accepted, signed and returned by May 25, 2012. 
 We look forward to your favorable reply and to working with you at Transcept. 
  

	
	Sincerely,
	Transcept Pharmaceuticals, Inc.
	
	 /s/ Thomas Soloway

	Thomas Soloway
	Executive Vice President & COO

  

			
	Agreed to and accepted:
		
	Signature:	 	 /s/ Leone Patterson

		 	Leone Patterson
		
	Date:	 	5/22/12

 Enclosures: 
  

	 	•	 	 Duplicate Original Letter 

  

	 	•	 	 At-Will Employment, Confidential Information, Invention Assignment and Arbitration Agreement 

 

	 	•	 	 Severance Agreement

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00205-of-00352.parquet"}]]